EP4705343A1 - Anticorps anti-m-cadhérine humaine (cdh15), conjugués et leurs utilisations pour l'administration de charges utiles génétiques à des cellules musculaires - Google Patents

Anticorps anti-m-cadhérine humaine (cdh15), conjugués et leurs utilisations pour l'administration de charges utiles génétiques à des cellules musculaires

Info

Publication number
EP4705343A1
EP4705343A1 EP24728805.3A EP24728805A EP4705343A1 EP 4705343 A1 EP4705343 A1 EP 4705343A1 EP 24728805 A EP24728805 A EP 24728805A EP 4705343 A1 EP4705343 A1 EP 4705343A1
Authority
EP
European Patent Office
Prior art keywords
protein
binding
antigen
capsid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24728805.3A
Other languages
German (de)
English (en)
Inventor
Trevor Stitt
Michael Stec
Mark W. Sleeman
Leah SABIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of EP4705343A1 publication Critical patent/EP4705343A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • This application is generally directed to human antibodies and antigen-binding fragments of human antibodies that bind human Cadherin 15 (hM-Cadherin, hCDH15), and methods of use thereof, e.g., in methods of treating a disorder in a patient in need thereof.
  • the application also relates to antigen-binding molecules comprising at least an antigen-binding fragment of an anti-hCDH15 antibody, wherein complexation of the antigen-binding molecule to CDH15 mediates internalization of the antigen-binding molecule/CDH15 complex, and/or blocks activity of CDH15.
  • the application further relates to conjugates comprising an anti-hCDH15 antibody (or antigen-binding molecules comprising an antigen-binding fragment of an anti- hCDH15 antibody) and a therapeutic agent, which conjugates may be useful in treating diseases.
  • the disclosure further relates to methods of making and using recombinant viral particles, e.g., recombinant AAV particles, comprising capsid proteins retargeted to Cadherin 15 (CDH15), useful for modification of muscle cells, such as muscle stem cells, in vitro or in vivo.
  • a gene delivery vehicle is able to stably introduce genetic material into desired cells and avoid introducing genetic material into non-target cells.
  • Viral particles particularly those based on adeno-associated virus (AAV), as gene delivery vehicles have been the focus of much research since AAVs are capable of transducing a wide range of primate species and tissues in vivo.
  • AAV safely transduces postmitotic tissues.
  • the virus can occasionally integrate into host chromosomes, it does so very infrequently into a safe-harbor locus in human chromosome 19, and only when the replication (Rep) proteins are supplied in trans.
  • Rep replication
  • a targeting ligand is directly inserted into, or coupled to, a viral capsid, i.e., protein viral capsid genes are modified to express capsid proteins comprising a heterologous targeting ligand.
  • the targeting ligand then redirects, e.g., binds, a receptor or marker preferentially or exclusively expressed on a target cell.
  • a viral capsid is modified with a heterologous “scaffold”, which then links to an adaptor that includes a targeting ligand.
  • the adaptor binds to the scaffold and the target cell.
  • Fc binding molecules e.g, Fc receptors, Protein A, etc.
  • (strept)avidin which binds to biotinylated adaptors
  • biotin which binds to adaptors fused with (strept)avidin
  • a detectable label which is useful for detection and/or isolation of viral particles, bound by a bispecific adaptor able to non-covalently bind the detectable label and target molecule
  • protein protein binding pairs that form isopeptide bonds have been described for a variety of viral particles. (See, e.g., Gigout et al.
  • Skeletal muscle is the largest organ in the body, comprising -40% of total body mass, and is one of the three significant muscle tissues in the human body.
  • Muscle stem cells MuSCs
  • MuSC-mediated muscle regeneration is delayed in aging subjects, which may be related, in part, to changes in muscle stem cell-specific markers.
  • anti -human antibodies capable of binding to muscle stem cellspecific markers could be helpful for therapy, e.g., stimulating muscle repair, particularly in aging subjects, and/or treating muscle-related cancers.
  • the anti-human antibodies as described herein may be used in conjunction with recombinant viral, e.g., AAV, particles for the targeted introduction of nucleic acids of interest into cells expressing muscle stem cell-specific markers.
  • recombinant viral e.g., AAV
  • some muscle-related cancers including rhabdomyosarcomas, may also benefit from therapeutics, e.g., antibody-drug conjugates, retargeted viral particles, etc., as described herein that target muscle stem cell-specific markers thereby.
  • the antigen-binding protein comprises a set of three heavy chain complementary determining region (HCDR1, HCDR2, and HCDR3) amino acid sequences selected from Table 1 below. In some embodiments, the antigen-binding protein comprises a set of three light chain complementary determining region (LCDR1, LCDR2 and LCDR3) amino acid sequences selected from Table 1 below. In some embodiments, the antigen-binding protein comprises a set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequences selected from Table 1 below.
  • the antigen-binding protein comprises a set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequences selected from the group consisting of SEQ ID NOs: 4-6-8-12-14-16, 24-26-28-32-34-36, 44-46-48-52-34-54, 62- 64-66-52-34-54, 72-74-76-52-34-54, 82-84-86-52-34-54, 92-94-96-100-34-102, 82-111-113- 117-34-119, 127-129-131-135-137-139, 147-149-151-155-157-159, 167-169-171-175-177-179, 187-189-191-52-34-196, 204-206-208-212-137-214, 222-224-226-52-34-54, 232-234-236-52- 34-54, 242-244-246-52-34-54, 82-253-255-52-34-54, 261-263-265-269
  • Table 1 sets forth the amino acid and nucleic acid sequence identifiers of the HCVRs and LCVRs, as well as HCDR1, HCDR2 and HCDR3 within each HCVR, and LCDR1, LCDR2 and LCDR3 within each LCVR of each of the example anti-hCDH15 antibodies of the present disclosure.
  • the antigen-binding protein comprises a heavy chain variable region (HCVR or VH).
  • the HCVR comprises a set of HCDR1- HCDR2-HCDR3 amino acid sequences selected from Table 1.
  • the HCVR comprises an amino acid sequence selected from any of the HCVR amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
  • the antigen-binding protein comprises a light chain variable region (LCVR or VL).
  • the LCVR comprises a set of LCDR1- LCDR2-LCDR3 amino acid sequences selected from Table 1 below.
  • the LCVR comprises an amino acid sequence selected from any of the LCVR amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
  • the antigen-binding protein comprises an anti-hCDH15 antibody or antigen-binding fragment thereof.
  • the anti-hCDH15 antibody or antigen-binding fragment thereof comprises a human or humanized antibody or antigen binding fragment thereof, a monovalent Fab’, a divalent Fab2, a F(ab)’3 fragment, a single-chain fragment variable (scFv), a bis-scFv, a (scFv)2, a diabody, a minibody, a nanobody, a triabody, a tetrabody, a disulfide stabilized Fv protein (dsFv), a single-domain antibody (sdAb), an Ig NAR, a bispecific antibody or binding fragment thereof, a bi-specific T-cell engager (BiTE), a trispecific antibody, or a chemically modified derivative thereof.
  • the scFv comprises variable regions arranged in the following orientation from N-terminus to C-terminus: HCVR-LCVR. In some embodiments, the scFv comprises variable regions arranged in the following orientation from N-terminus to C-terminus: LCVR-HCVR. In some embodiments, the scFv variable regions are connected by a linker. In some embodiments, the linker is a peptide linker. In some embodiments, the peptide linker is -(GGGGS)n- (SEQ ID NO: 789), wherein n is 1-10.
  • the antigen-binding protein binds to hCDH15 with a KD of about 1X10’ 7 M or a stronger affinity. In some embodiments, the antigen-binding protein binds to hCDH15 with a KD of about 10X10’ 8 to about 1X10' 10 . In some embodiments, the antigen-binding protein binds to hCDH15 with a KD of about 5X1 O’ 9 to about 1X1 O’ 10 .
  • the antigen-binding protein e.g, antibody or antigenbinding fragment thereof, comprises an HCVR and an LCVR amino acid sequence pair (HCVR/LCVR) comprising any of the HCVR amino acid sequences listed in Table 1 paired with any of the LCVR amino acid sequences listed in Table 1.
  • the antigenbinding protein e.g., antibody or antigen-binding fragment thereof, as described herein comprises an HCVR/LCVR amino acid sequence pair contained within any of the example anti- hCDH15 antibodies listed in Table 1.
  • the HCVR/LCVR amino acid sequence pair is selected from the group consisting of SEQ ID NOs: 2 and 10, 22 and 30, 42 and 50, 60 and 50, 70 and 50, 80 and 50, 90 and 98, 108 and 115, 125 and 133, 145 and 153, 165 and 173, 185 and 193, 202 and 210, 220 and 50, 230 and 50, 240 and 50, 250 and 50, 259 and 267, 279 and 287, 299 and 307, 319 and 327, 339 and 347, 358 and 366, 378 and 50, 386 and 394,
  • nucleic acid molecules i.e., polynucleotides, encoding the antigen-binding protein, e.g., anti-hCDH15 antibodies or antigen-binding fragments thereof, described herein.
  • the nucleic acid molecule as described herein comprises a nucleic acid sequence encoding a set of HCDR1-HCDR2-HCDR3 amino acid sequences listed in Table 1.
  • a nucleic acid molecule as described herein comprises a nucleic acid sequence encoding any of the HCVR amino acid sequences listed in Table 1.
  • the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCVR nucleic acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
  • the nucleic acid molecule as described herein comprises a nucleic acid sequence encoding a set of LCDR1-LCDR2-LCDR3 amino acid sequences listed in Table 1.
  • a nucleic acid molecule as described herein comprises a nucleic acid sequence encoding any of the LCVR amino acid sequences listed in Table 1.
  • the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCVR nucleic acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
  • nucleic acid molecules encoding an HCVR wherein the HCVR comprises a set of three CDRs (i.e., HCDR1-HCDR2-HCDR3), wherein the HCDR1- HCDR2-HCDR3 amino acid sequence set is as defined by any of the example anti-hCDH15 antibodies listed in Table 1.
  • nucleic acid molecules encoding an LCVR wherein the LCVR comprises a set of three CDRs i.e., LCDR1-LCDR2-LCDR3), wherein the LCDR1- LCDR2-LCDR3 amino acid sequence set is as defined by any of the example anti- hCDH15 antibodies listed in Table 1.
  • nucleic acid molecules encoding both an HCVR and an LCVR, wherein the HCVR comprises an amino acid sequence of any of the HCVR amino acid sequences listed in Table 1, and wherein the LCVR comprises an amino acid sequence of any of the LCVR amino acid sequences listed in Table 1.
  • the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCVR nucleic acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto, and a polynucleotide sequence selected from any of the LCVR nucleic acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
  • the nucleic acid molecule encodes an HCVR and LCVR, wherein the HCVR and LCVR are both derived from the same anti-hCDH15 antibody listed in Table 1.
  • a pharmaceutical composition comprising the antigenbinding protein described herein, e.g., a recombinant human antibody or fragment thereof which binds human CDH15, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition as described herein comprises a combination of an anti-hCDH15 antibody and a second therapeutic agent.
  • the second therapeutic agent is any agent that is advantageously combined with an anti-hCDH15 antibody. Additional combination therapies and co-formulations involving the anti-hCDH15 antibodies are described herein.
  • Also described herein is a method of inhibiting the activity of CDH15 in a cell, e.g., in vivo, in vitro, or ex vivo, comprising contacting the cell expressing CDH15 with the antigen-binding protein that binds human CDH15, or the pharmaceutical composition thereof as described herein.
  • the cell expressing CDH15 is a muscle stem cell, a myoblast, or a myocyte.
  • Also described herein is a method of accelerating the transition from quiescence to activation of a muscle stem cell, e.g., in vivo, in vitro, or ex vivo, comprising contacting the muscle stem cell with the antigen-binding protein that binds human CDH15 or the pharmaceutical composition thereof as described herein.
  • a method of treating a condition in a subject in need thereof comprises administering a therapeutically effective amount of a pharmaceutical composition comprising the antigen-binding protein that binds human CDH15 as described herein to the subject.
  • the condition is muscle injury.
  • the condition is cancer, e.g., rhabdomyosarcoma.
  • the antigen-binding protein is conjugated to a therapeutic agent, e.g., an antibody-drug conjugate (ADC).
  • the therapeutic agent comprises a cytotoxic chemotherapeutic agent.
  • the therapeutic agent is Aflibercept, Amsacrine, Azacitidine, Azathioprine, Belantamab mafodotin, Bendamustine, Bleomycin, Bortezomib, Brentuximab vedotin, Busulfan, Cabazitaxel, Capecitabine, Carboplatin, Carfilzomib, Carmustine, Chlorambucil, Cisplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Cytarabine liposomal, dacarbazine, Dactinomycin (actinomycin D), Daunorubicin, Docetaxel, Doxorubicin, Doxorubicin liposomal, Epirubicin, Eribulin, Etoposide, Etoposide phosphate, Fludarabine, Fluorouracil, Fotemustine, Ganciclovir, Gemcitabine, Gemtuzumab ozo
  • the antigen binding protein is conjugated to the therapeutic agent via a valine-citrulline (VC). In some embodiments, the antigen binding protein is conjugated to the therapeutic agent via a para-aminobenzyl (PAB) linker. In some embodiments, the pharmaceutical composition is administered to the subject intravenously or subcutaneously.
  • VC valine-citrulline
  • PAB para-aminobenzyl
  • Also described herein is a method of restoring the muscle regenerative capacity of a subject, wherein the method comprises administering a therapeutically effective amount of a pharmaceutical composition comprising the antigen-binding protein that binds human CDH15 as described herein to the subject.
  • the subject is an aged subject.
  • the muscle regenerative capacity of the aged subject is restored to a functional state at or near that of a control subject.
  • the pharmaceutical composition is administered to the subject intravenously or subcutaneously.
  • a method of imaging a muscle cell in a subject in need thereof comprises administering a pharmaceutical composition comprising the antigen-binding protein that binds human CDH15 as described herein to the subject, wherein the antigen binding protein is conjugated to a detectable moiety.
  • the muscle cell comprises one or more selected from the group consisting of a muscle stem cell, a myoblast, and a myocyte.
  • the detectable moiety comprises a radionuclide.
  • the pharmaceutical composition is administered to the subject intravenously or subcutaneously.
  • antigen-binding protein that binds human CDH15 or a pharmaceutical composition thereof in the manufacture of a medicament, e.g., for the treatment of a condition as described herein.
  • an antigen-binding protein that binds human CDH15 or a pharmaceutical composition thereof for use in therapy, e.g., for treating a condition as described herein, and/or for use in restoring the muscle regenerative capacity of a subject.
  • an antibody or antigen-binding fragment that competes for binding to human CDH15 with a reference antibody comprising an HCVR/LCVR amino acid sequence pair as set forth in Table 1.
  • an antibody or antigen-binding fragment as described herein competes for binding to human CDH15 with a reference antibody comprising an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 and 10, 22 and 30, 42 and 50, 60 and 50, 70 and 50, 80 and 50, 90 and 98, 108 and 115, 125 and 133, 145 and 153, 165 and 173, 185 and 193, 202 and 210, 220 and 50, 230 and 50, 240 and 50, 250 and 50, 259 and 267, 279 and 287, 299 and 307, 319 and 327, 339 and 347, 358 and 366, 378 and 50, 386 and 394, 404 and 412, 420 and 428, 436 and 444,
  • an antibody or antigen-binding fragment wherein the antibody or antigen-binding fragment thereof binds to the same epitope on human CDH15 as a reference antibody comprising an HCVR/LCVR amino acid sequence pair as set forth in Table 1.
  • an antibody or antigen-binding fragment as described herein binds to the same epitope on human CDH15 as a reference antibody comprising an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 and 10, 22 and 30, 42 and 50, 60 and 50, 70 and 50, 80 and 50, 90 and 98, 108 and 115, 125 and 133, 145 and 153, 165 and 173, 185 and 193, 202 and 210, 220 and 50, 230 and 50, 240 and 50, 250 and 50, 259 and 267, 279 and 287, 299 and 307, 319 and 327, 339 and 347, 358 and 366, 378 and 50, 386 and 394,
  • an isolated antibody or antigen-binding fragment thereof that binds human CDH15 wherein the antibody or antigen-binding fragment comprises: the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) having an amino acid sequence as set forth in Table 1; and the CDRs of a light chain variable region (LCVR) having an amino acid sequence as set forth in Table 1.
  • CDRs complementarity determining regions
  • HCVR heavy chain variable region
  • LCVR light chain variable region
  • the isolated antibody or antigen-binding fragment comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 and 10, 22 and 30, 42 and 50, 60 and 50, 70 and 50, 80 and 50, 90 and 98, 108 and 115, 125 and 133, 145 and 153, 165 and 173, 185 and 193, 202 and 210, 220 and 50, 230 and 50, 240 and 50, 250 and 50, 259 and 267, 279 and 287, 299 and 307, 319 and 327, 339 and 347, 358 and 366, 378 and 50, 386 and 394, 404 and 412, 420 and 428, 436 and 444, 452 and 460, 468 and 476, 484 and 492, 500 and 508, 516 and 524, 532 and 540, 548 and 556, 564 and 572, 580 and 588, 596 and 604, 612 and
  • the isolated antibody or antigen-binding fragment comprises HCDR1-HCDR2-HCDR3-LCDR1- LCDR2-LCDR3 domains, respectively, selected from the group consisting SEQ ID NOs: 4-6-8- 12-14-16, 24-26-28-32-34-36, 44-46-48-52-34-54, 62-64-66-52-34-54, 72-74-76-52-34-54, 82- 84-86-52-34-54, 92-94-96-100-34-102, 82-111-113-117-34-119, 127-129-131-135-137-139, 147-149-151-155-157-159, 167-169-171-175-177-179, 187-189-191-52-34-196, 204-206-208- 212-137-214, 222-224-226-52-34-54, 232-234-236-52-34-54, 242-244-246-52-34-54, 82-253- 255-52-34-54, 261-263-265-269
  • an isolated antibody or antigen-binding fragment thereof that binds human CDH15 wherein the antibody or antigen-binding fragment comprises: (a) a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 22, 42, 60, 70, 80, 90, 108, 125, 145, 165, 185, 202, 220, 230, 240, 250, 259, 279, 299, 319, 339, 358, 378, 386, 404, 420, 436, 452, 468, 484,
  • HCVR heavy chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 22, 42, 60, 70, 80, 90, 108, 125, 145, 165, 185, 202, 220, 230, 240, 250, 259, 279, 299, 319, 339, 358, 378, 386, 404, 420, 436, 452, 468, 484,
  • LCVR light chain variable region
  • the isolated antibody or antigen-binding fragment comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 and 10, 22 and 30, 42 and 50, 60 and 50, 70 and 50, 80 and 50, 90 and 98, 108 and 115, 125 and 133, 145 and 153, 165 and 173, 185 and 193, 202 and 210, 220 and 50, 230 and 50, 240 and 50, 250 and 50, 259 and 267, 279 and 287, 299 and 307, 319 and 327, 339 and 347, 358 and 366, 378 and 50, 386 and 394, 404 and 412, 420 and 428, 436 and 444, 452 and 460, 468 and 476, 484 and 492,
  • viral particles that are particularly suited for the targeted introduction of a nucleotide of interest specifically to a muscle cell (e.g, a muscle stem cell) since the viral capsid or viral capsid protein(s) described herein comprise a targeting ligand that binds a muscle-cell specific surface protein (e.g, an antigen -binding protein as described herein that binds to human CDH15).
  • a targeting ligand that binds a muscle-cell specific surface protein (e.g, an antigen -binding protein as described herein that binds to human CDH15).
  • the viral capsid or viral capsid protein(s) described herein comprise(s) a direct insertion of the targeting ligand (e.g., the targeting ligand is directly coupled to, fused to, etc., optionally via a linker to the viral capsid or viral capsid proteins), e.g., viral capsid genes are modified to express capsid proteins comprising the targeting ligand.
  • a viral capsid or viral capsid protein comprises the targeting ligand via a scaffold or an adaptor, e.g., a first member of a protein: protein binding pair, which may be associated with its cognate second member of the protein: protein binding pair, wherein the second member is linked (e.g, fused to) a targeting ligand that binds a musclecell specific surface protein (e.g., an antigen-binding protein as described herein that binds to human CDH15).
  • the targeting ligand is operably linked to the second member, e.g, fused to the second member, optionally via a linker.
  • the targeting ligand may be a binding moiety, e.g, a natural ligand, antibody, a multispecific binding molecule, etc.
  • the targeting ligand is an antibody or portion thereof.
  • the targeting ligand is an antibody comprising a variable domain that binds a surface protein (e.g, a variable domain of an antigen-binding protein as described herein that binds to human CDH15) on a non-terminally differentiated muscle cell (e.g, a muscle stem cell, a myoblast, myocyte, any combination thereof, etc.) and a heavy chain constant domain.
  • a surface protein e.g, a variable domain of an antigen-binding protein as described herein that binds to human CDH15
  • a non-terminally differentiated muscle cell e.g, a muscle stem cell, a myoblast, myocyte, any combination thereof, etc.
  • the targeting ligand is an antibody comprising a variable domain that binds a non-terminally differentiated muscle cell surface protein (e.g, a variable domain of an antigenbinding protein as described herein that binds to human CDH15) on a target cell (e.g., a muscle stem cell, myoblast, myocyte, any combination thereof, e/c.), and optionally an IgG heavy chain constant domain.
  • a non-terminally differentiated muscle cell surface protein e.g, a variable domain of an antigenbinding protein as described herein that binds to human CDH15
  • a target cell e.g., a muscle stem cell, myoblast, myocyte, any combination thereof, e/c.
  • the targeting ligand is an antibody comprising a variable domain that binds a non-terminally differentiated muscle cell surface protein (e.g, a variable domain of an antigen-binding protein as described herein that binds to human CDH15) on a target cell (e.g, a muscle stem cell, myoblast, myocyte, any combination thereof, etc.) and an IgG heavy chain constant domain, wherein the IgG heavy chain constant domain is operably linked, e.g., directly or via a linker, to a capsid protein.
  • a non-terminally differentiated muscle cell surface protein e.g, a variable domain of an antigen-binding protein as described herein that binds to human CDH15
  • a target cell e.g, a muscle stem cell, myoblast, myocyte, any combination thereof, etc.
  • IgG heavy chain constant domain operably linked, e.g., directly or via a linker, to a capsid protein.
  • the targeting ligand is an antibody comprising (i) a variable domain that binds a non-terminally differentiated muscle cell surface protein (e.g., a variable domain of an antigen-binding protein as described herein that binds to human CDH15), and (ii) an IgG heavy chain constant domain, wherein the IgG heavy chain constant domain is operably linked (optionally via a linker) to a protein (e.g., second member of a protein: protein binding pair) that forms an isopeptide covalent bond with the cognate first member of the proteimprotein binding pair.
  • a non-terminally differentiated muscle cell surface protein e.g., a variable domain of an antigen-binding protein as described herein that binds to human CDH15
  • an IgG heavy chain constant domain wherein the IgG heavy chain constant domain is operably linked (optionally via a linker) to a protein (e.g., second member of a protein: protein binding pair) that forms an isopeptide co
  • a capsid protein described herein comprises a first member of the protein: protein binding pair, comprising, e.g., SpyTag (SEQ ID NO: 815) or a biologically equivalent variant thereof, operably linked to the viral capsid protein, wherein SpyTag or a biologically equivalent variant thereof is covalently linked (e.g., via an isopeptide bond) to the SpyTag to its second cognate protein: protein binding member, e.g., SpyCatcher (SEQ ID NO: 816) or a biologically equivalent variant thereof, which in turn may be linked to a targeting ligand comprising an antibody variable domain and an IgG heavy chain domain, wherein SpyCatcher and the IgG heavy chain domain are linked via an amino acid linker, e.g., GSGESG (SEQ ID NO: 828).
  • protein binding pair comprising, e.g., SpyTag (SEQ ID NO: 815) or a biologically equivalent variant thereof, operably linked to the viral capsid protein
  • the non-terminally differentiated muscle cell surface protein comprises CDH15.
  • the targeting ligand binds CDH15, e.g., human CDH15.
  • the targeting ligand comprises a variable domain of an antigen-binding protein as described herein that binds to human CDH15.
  • the targeting ligand comprises an antibody variable domain comprising a CDR, e.g., an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and/or an LCDR3, of an HCVR and/or LCVR sequence as set forth in Table 1.
  • the targeting ligand comprises an antibody variable domain comprising a CDR, e.g., an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and/or an LCDR3, as set forth in Table 1.
  • the targeting ligand comprises an antibody variable domain comprising a set of three CDRs, e.g., an HCDR1, an HCDR2, and an HCDR3, and/or an LCDR1, an LCDR2, and an LCDR3, of an HCVR and/or LCVR sequence as set forth in Table 1.
  • the targeting ligand comprises an antibody variable domain comprising a set of three CDRs, e.g., an HCDR1, an HCDR2, and an HCDR3, and/or an LCDR1, an LCDR2, and an LCDR3, as set forth in Table 1.
  • the targeting ligand comprises an antibody variable domain comprising an HCVR and/or LCVR as set forth in Table 1.
  • FIG. 1 depicts a schematic illustration of myogenesis of non-terminally differentiated muscle cells.
  • Muscle stem cells also known as satellite cells
  • MuSCs are mitotically quiescent and non-proliferative under steady-state conditions in adult muscle tissue.
  • MuSCs begin to actively divide, producing daughter cells. While some daughter cells become quiescent once more to replenish the pool of MuSCs, others continue to proliferate as myoblasts, which align and fuse together during differentiation into mature myotubes/myofibers that make up muscle fibers.
  • Quiescent muscle stem cells can be characterized by Pax7 expression
  • proliferating myoblasts can be characterized by Pax7 and myogenic differentiation factor 1 (MyoD) expression
  • myoblasts committing to terminal differentiation i.e., myocytes
  • myotubes can be characterized by myosin heavy chain (MyHC) expression.
  • MyoD myogenic differentiation factor 1
  • MyHC myosin heavy chain
  • FIGs 2A-2D demonstrate accelerated muscular regeneration in mice with CDH15 expression abolished.
  • Figure 2A depicts a schematic illustration of the example experiments. Wild-type (WT) or homozygous CDH15 knockout mice (CDH15-/-) were injected intramuscularly with cardiotoxin (CTX) at day 0 to induce muscle damage. Histology was then performed on samples of muscle retrieved 5-, 15-, and 25-days post-injury (dpi).
  • WT Wild-type
  • CDH15-/- homozygous CDH15 knockout mice
  • CTX cardiotoxin
  • Figure 2B depicts an example of immunohistochemical cross-sections of WT and CDH15-/- muscle samples stained with DAPI (blue; light grey in greyscale), laminin (white), and embryonic myosin heavy chain (eMyHC; green; dark grey in greyscale), which is transiently upregulated in immature myofibers but downregulated as myofibers mature (Rodgers, Growth Hormone & IGF Research, 2005, 15(6): 377-383). Cross-sections were visualized by fluorescence microscopy.
  • Figure 2C depicts the myofiber cross-section area (CSA) for WT and CDH15-/- mice at the indicated time points post-injury, as quantified from histological images, see, e.g., Figure 2B.
  • Figure 2D depicts the percentage of centrally nucleated myofibers for WT and CDH15-/- mice at 15 days post-injury, as quantified from histological images, see, e.g., Figure 2B. Data are reported as means +/- SEM, *p ⁇ 0.05, **p ⁇ 0.01.
  • Figures 3A-3B demonstrate improved functional recovery from injury in mice with CDH15 expression abolished.
  • Figure 3A depicts a schematic illustration of the example experiments. WT or CDH15-/- mice were injected with CTX into the extensor digitorum longus (EDL) muscle at day 0. At 15 dpi, the contractile force of the EDL muscle was measured ex vivo.
  • Figure 3B depicts the maximal tetanic force loss in WT or CDH15-/- muscle as compared to muscle isolated from uninjured EDL. Data are reported as means +/- SEM, *p ⁇ 0.05.
  • Figures 4A-4B demonstrate accelerated exit from quiescence ex vivo in MuSCs with CDH15 expression abolished.
  • Figure 4A depicts an example of immunohistochemical images of WT and CDH15-/- MuSCs following 48 hours of culture on single myofibers. Arrows in the Pax7 and Merge columns denote individual cells in a multi-cell cluster.
  • Figure 4B depicts the percentage of Pax7+ single-cell and multi-cell clusters (top) and the number of Pax7+ cells per cluster (bottom) for WT and CDH15-/- MuSCs, as quantified from histological images, see, e g., Figure 4A . Data are reported as means +/- SEM, **p ⁇ 0.01.
  • Figures 5A-5B demonstrate the upregulation of early response genes containing serum response factor (SRF) motifs.
  • Figure 5A depicts a volcano plot of genes that are downregulated or upregulated in FACS-isolated CDH15-/- MuSCs as compared to WT MuSCs.
  • Figure 5B depicts a transcription factor motif analysis, with several relevant transcription factors highlighted in red.
  • FIGs 6A-6D demonstrate that abolishing expression of CDH15 in aged mice rescues age-related declines in muscle regeneration.
  • Figure 6A depicts a schematic illustration of the example experiments. Aged (23 -month-old) wild-type (WT) or homozygous CDH15 knockout mice (CDH15-/-) were injected with cardiotoxin (CTX) at day 0 to induce muscle damage of the tibialis anterior muscle. Histology was then performed on samples of muscle retrieved 15 days post-injury (dpi).
  • CTR cardiotoxin
  • Figure 6B depicts an example of immunohistochemical cross-sections of aged WT and CDH15-/- muscle samples stained for nuclei (DAPI; blue; grey in greyscale) and laminin (white) and visualized by fluorescence microscopy.
  • Figure 6C depicts the myofiber cross-section area (CSA) for aged WT and CDH15-/- mice at 15 dpi, as quantified from histological images, see, e.g., Figure 6B.
  • the dotted line depicts the average CSA for young mice at 15 dpi.
  • Figure 6D depicts the percentage of centrally nucleated myofibers containing 3 or more central nuclei for aged WT and CDH15-/- mice at 15 dpi, as quantified from histological images, see, e.g., Figure 6B. Data are reported as means +/- SEM, *p ⁇ 0.05.
  • Figures 7A-7C demonstrate that CDH15 protein is focalized to the apical surface of the majority of wild-type (WT) muscle stem cells (MuSCs) and is undetectable in CDH15-/- MuSCs.
  • Figure 7A depicts an immunohistochemical cross-section of a WT single myofiber with an associated WT MuSC, with CDH15 protein present at the apical surface of the MuSC.
  • Anti- CDH15 staining is depicted as red and denoted with an arrow and dotted outline and DAPI staining is depicted as blue and denoted with an arrowhead and a dashed outline.
  • Figure 7B depicts an immunohistochemical cross-section of WT mouse muscle, with Pax7-positive MuSCs observed on the periphery of myofibers, again with CDH15 present at the apical surface of the MuSC.
  • Anti-CDH15 is depicted as red and denoted with an arrow and a dotted outline in the magnified inset image, DAPI-stained nuclei are depicted as blue, Pax7 is depicted as green, and laminin is depicted as white.
  • FIG. 7C depicts the proportion of Pax7-positive MuSCs that are also CDH15-positive in WT and CDH15-/- mouse muscle, as quantified from histological images, see, e.g., Figure 7A and 7B. While CDH15 protein is detected in the majority (-95%) of WT Pax7-positive muscle cells, CDH15 is undetectable in CDH15-/- Pax7- positive cells, as expected.
  • Figure 8 demonstrates the specific binding of anti-hCDH15 antibodies to human rhabdomyosarcoma cells, but not glioblastoma cells.
  • Alveolar, embryonal, and glioblastoma cells were live-stained with the indicated anti-hCDH15 antibodies (REGN8787 and REGN9295) for 30 minutes, washed, stained with anti-human IgG Alexa FluorTM 647-conjugated secondary antibody (red), washed again, fixed, and then stained for myogenin (green) and nuclei (DAPI; blue) prior to visualization by fluorescence microscopy.
  • Cells incubated with murine IgG2a and human IgG4 were also used as controls. The last row depicts a merge of the three markers.
  • Figure 9 demonstrates the specific binding of anti-hCDH15 antibodies to human rhabdospheres grown in 3D culture.
  • Embryonal rhabdomyosarcoma tumorspheres z.e., rhabdospheres
  • anti-hCDH15 or human IgG4 as a negative control for 30 minutes, washed, stained with anti-human IgG Alexa FluorTM 647-conjugated secondary antibody (white), washed again, fixed and stained for myogenin (red) and nuclei (DAPI; blue).
  • the last column depicts a merge of the three markers.
  • Figure 10 demonstrates anti-CDH15 antigen-binding domain-mediated retargeting of AAV9 to C2C12 mouse myoblasts. Depicted are representative immunofluorescence images demonstrating the transduction efficiency via GFP fluorescence of C2C12 myoblasts transduced with 2.5 x 10 5 vg/cell of AAV9 expressing eGFP +/- plasmids encoding anti-CDH15 antigen-binding domains or control antigen-binding domains (anti- ASGR1) and varying mosaic capsid ratios. DAPI-stained nuclei are depicted in blue (top row) and eGFP is depicted in green (bottom row).
  • the ratio provided indicates the ratio of quantities of transfected plasmid encoding SpyTag-conjugated AAV9 capsid versus non-conjugated N272A de-targeted AAV9 capsid.
  • an antigen-binding domain is indicated e.g., a mAb or a Fab
  • the AAV9 capsid comprises SpyTag inserted at position 453 and attached via a 10 amino acid linker
  • the antigen-binding domain comprises SpyCatcher fused to the C-terminus of the heavy chain construct.
  • Figure 11 demonstrates anti-CDH15 antigen-binding domain-mediated retargeting of AAV9 to human skeletal myoblasts. Depicted are representative immunofluorescence images demonstrating the transduction efficiency via GFP fluorescence of human skeletal myoblasts transduced with 2.5 x 10 5 vg/cell of AAV9 expressing eGFP +/- plasmids encoding anti-CDH15 antigen-binding domains or control antigen-binding domains (anti-ASGRl) and varying mosaic capsid ratios. DAPI-stained nuclei are depicted in blue (top row) and eGFP is depicted in green (bottom row).
  • the ratio provided indicates the ratio of quantities of transfected plasmid encoding SpyTag-conjugated AAV9 capsid versus nonconjugated N272A de-targeted AAV9 capsid.
  • an antigen-binding domain is indicated e.g., a mAb or a Fab
  • the AAV9 capsid comprises SpyTag inserted at position 453 and attached via a 10 amino acid linker
  • the antigen -binding domain comprises SpyCatcher fused to the C-terminus of the heavy chain construct.
  • Each individual skeletal muscle consists of thousands of muscle fibers wrapped together by connective tissue sheaths.
  • the individual bundles of muscle fibers in a skeletal muscle are known as fasciculi.
  • the outermost connective tissue sheath surrounding the entire muscle is known as epimysium.
  • the connective tissue sheath covering each fasciculus is known as perimysium, and the innermost sheath surrounding individual muscle fiber is known as endomysium.
  • Each muscle fiber comprises myofibrils containing multiple myofilaments.
  • the primary functions of the skeletal muscle take place via its intrinsic excitationcontraction coupling process. As the muscle is attached to the bone tendons, the contraction of the muscle leads to movement of that bone that allows for the performance of specific movements.
  • the skeletal muscle also provides structural support and helps in maintaining the posture of the body.
  • the skeletal muscle also acts as a storage source for amino acids that can be used by different organs of the body for synthesizing organ-specific proteins.
  • the skeletal muscle also acts as a site of glucose disposal in the form of muscle glycogen.
  • the skeletal muscle also plays a central role in maintaining thermostasis and acts as an energy source during starvation. Thus, skeletal muscle plays key roles in locomotion, thermoregulation, and in controlling whole body metabolism.
  • Treatments for muscle wasting and genetic muscle diseases typically consist of broad-acting therapies, such as testosterone therapy for muscle wasting, glucocorticoids for muscular dystrophies, and systemic AAV delivery for treatment of muscle diseases (e.g., X- linked myotubular myopathy (XLMTM), Duchenne muscular dystrophy (DMD), myotonic dystrophy (DM1), Facioscapulohumeral muscular dystrophy Type 1 (FSHD), congenital muscular dystrophy type 1A (MDC1A), Limb girdle muscular dystrophy, and dystroglycanopathy, etc.).
  • XLMTM X- linked myotubular myopathy
  • DMD Duchenne muscular dystrophy
  • DM1 myotonic dystrophy
  • FSHD Facioscapulohumeral muscular dystrophy Type 1
  • MDC1A congenital muscular dystrophy type 1A
  • Limb girdle muscular dystrophy and dystroglycanopathy, etc.
  • Muscle stem cells are important for skeletal muscle regeneration. While MuSCs are normally quiescent in adult muscle, upon injury, they activate, proliferate, and differentiate into functional myofibers. However, MuSCs in aging subjects display delayed activation and reduced motility in vitro, which translates to impaired MuSC mediated repair in vivo.
  • Mitotically quiescent muscle stem cells also called satellite cells
  • proliferating myoblasts are the embryonic precursors of myocytes (also called muscle cells) which have not yet fused together to form myotubes or myofibers that later become the muscle fibers.
  • Muscle stem cells and myoblasts differentiate into muscle cells through a process called myogenesis depicted schematically (not to scale) in Figure 1.
  • muscle stem cells In general, once exposed to signals from the damaged environment, muscle stem cells will leave their quiescent state, reenter the cell cycle, and start proliferating as myoblasts. Some daughter cells continue to differentiate, while others return to quiescence to replenish the reserve population of muscle stem cells. During the differentiation stage, certain genes (e.g., striated alpha-actin genes) are expressed and the myoblasts align with one another. The myoblasts then fuse to form myofibers with the recruitment of actin to the plasma membrane.
  • Muscle stem cells can be characterized by a combination of several genetic markers, such Pax7 and muscle regulatory proteins. Pax7 is a paired homeobox transcription factor, which specifies the myogenic properties of precursor muscle cells.
  • muscle stem cells whether quiescent or proliferating, may be characterized as Pax7+. See, e.g, Figure 1.
  • myogenic cellular lineage characterization is possible since myogenesis depends on the precise and dynamic integration of multiple muscle regulatory factors, such as myogenic factor 5 (MYF5), myogenic differentiation factor 1 (MYOD), myogenin (MYOG), and embryonic myosin heavy chain (MyHC).
  • MYOD myogenic factor 5
  • MYOD myogenic differentiation factor 1
  • MYOG myogenin
  • MyHC embryonic myosin heavy chain
  • MYOD is expressed in myogenic cells, but not expressed in stationary quiescent muscle stem cells, and thus, may be used to identify proliferating muscle stem cells, myoblasts, or other differentiating myocytes. See, e.g., Figure 1.
  • Myogenin appears to be expressed by myoblasts committed to differentiating into myofibers. See, e.g., Figure 1.
  • An additional marker that may be used to identify which stage of myogenesis a cell is undergoing includes, but is not limited to embryonic myosin heavy chain (eMyHC), which is transiently upregulated in immature myofibers but downregulated as myofibers mature. See, e.g., Figure 1.
  • eMyHC embryonic myosin heavy chain
  • Myoblasts may be classified as skeletal muscle myoblasts, smooth muscle myoblasts, and cardiac muscle myoblasts depending on the type of muscle cell that they will differentiate into. Thus, muscle stem cells, myoblasts, myocytes, and undifferentiated myotubes or myofibers may all be considered a non-terminally differentiated muscle cell.
  • Cadherin 15 An example cell surface protein found on non-terminally differentiated muscle cells Cadherin 15 (CDH15).
  • Cadherins are a class of calcium-dependent transmembrane proteins involved in cell-cell adhesion.
  • Classical cadherins consist of an extracellular domain comprising five repeats of an immunoglobulin-like cadherin domain, a single transmembrane region, and a cytoplasmic domain.
  • Cadherin 15 (also known as M-cadherin) is expressed at the apical surface of muscle stem cells and is believed to regulate adhesion of muscle stem cells to muscle myofibers.
  • Cadherin 15 is encoded by the CDH15 gene, located on the long arm of chromosome 16 (16q24.3).
  • CDH15 comprises 14 exons and is approximately 23,745 bases in length.
  • An exemplary sequence for human CDH15 gene is assigned NCBI Accession Number NM_004933.3 (SEQ ID NO: 787).
  • An exemplary human CDH15 protein is assigned NCBI Accession Number NP_004924.1 and/or UniProt Accession Number P55291 (SEQ ID NO: 788).
  • Genetically modified animal models may prove to be particularly useful for studying the function of CDH15 in muscle.
  • antagonistic antibodies, or CDH15 blocking antibodies may be useful in enhancing muscle regeneration in both young subjects and older adults following a damage stimulus (e.g., joint arthroplasty).
  • Rhabdomyosarcomas are characterized by the expression of myogenic genes, but multiple subtypes exist. For example, embryonal RMS is the most prevalent subtype, typically has a more favorable prognosis, and is believed to be driven by loss of tumor suppressor genes or gain-of-function of proto-oncogenes. Alveolar RMS is less common but has generally carries a much poorer prognosis. Alveolar RMS is believed to be caused by chromosomal translocation of Pax3 or Pax7 gene, or alternative gene fusions.
  • Rhabdomyosarcomas make up -3% of all childhood cancers, with -400-500 new cases per year in the U.S (American Cancer Society, 2021).
  • the prognosis is generally good in children (e.g., -70% survival), but depends on risk category. For example, 1/3 of patients with localized RMS and 2/3 of patients with metastatic RMS experience relapsed disease. If RMS is relapsed, the majority of patients have an estimated 5-year survival of -10%. Moreover, the prognosis is generally much poorer in adults (20-50% overall survival).
  • anti-CDH15 antibodies may be useful to deliver a therapeutic agent (e.g., a cytotoxic agent) to RMS tumors.
  • a therapeutic agent e.g., a cytotoxic agent
  • antigen-binding proteins e.g., antibodies and antigenbinding fragments thereof that bind to human CDH15.
  • the antibodies described herein may be useful, inter alia, for specifically directing the internalization of an agent, e.g., a drug conjugate, etc., to a muscle cell and/or a muscle-related cancer cell, for blocking activity of CDH15, and/or for specifically stimulating muscle regeneration.
  • antibodies, or antigen-binding fragments thereof, that bind human CDH15 include antibody-protein fusion constructs comprising an antibody, or antigen-binding fragment thereof, that bind human CDH15; and antibody drug conjugates comprising an antibody, or antigen-binding fragment thereof, that bind human CDH15.
  • viral particles e.g., AAV viral particles, that can target non-terminally differentiated muscle cell surface proteins, such as mammalian CDH15.
  • the “percent (%) identity” or the like may be readily determined for amino acid or nucleotide sequences, over the full-length of a protein, or a portion thereof. A portion may be at least about 5 amino acids or 24 nucleotides, respectively, in length, and may be up to about 700 amino acids or 2100 nucleotides, respectively. Generally, when referring to “identity”, “homology”, or “similarity” between two different adeno-associated viruses, “identity”, “homology” or “similarity” is determined in reference to “aligned” sequences. “Aligned” sequences or “alignments” refer to multiple nucleic acid sequences or protein (amino acids) sequences, often containing corrections for missing or additional bases or amino acids as compared to a reference sequence.
  • Alignments may be performed using any of a variety of publicly or commercially available Multiple Sequence Alignment Programs. Sequence alignment programs are available for amino acid sequences, e.g., the “Clustal X”, “MAP”, “PIMA”, “MSA”, “BLOCKMAKER”, “MEME”, and “Match-Box” programs. Generally, any of these programs are used at default settings, although one of skill in the art can alter these settings as needed. Alternatively, one of skill in the art can utilize another algorithm or computer program which provides at least the level of identity or alignment as that provided by the referenced algorithms and programs. See, e.g., J. D. Thomson et al, Nucl. Acids. Res., “A comprehensive comparison of multiple sequence alignments”, 27(13):2682-2690 (1999).
  • nucleic acid sequences are also available for nucleic acid sequences. Examples of such programs include, “Clustal W”, “CAP Sequence Assembly”, “MAP”, and “MEME”, which are accessible through Web Servers on the internet. Other sources for such programs are known to those of skill in the art. Alternatively, Vector NTI utilities are also used. There are also a number of algorithms known in the art that can be used to measure nucleotide sequence identity, including those contained in the programs described above. As another example, polynucleotide sequences can be compared using FASTATM, a program in GCG Version 6.1. FASTATM provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences. For instance, percent sequence identity between nucleic acid sequences can be determined using FASTATM with its default parameters (a word size of 6 and the NOPAM factor for the scoring matrix) as provided in GCG Version 6.1, herein incorporated by reference.
  • FASTATM provides alignments and percent sequence identity of the regions of the best overlap between the
  • “Significant identity” encompasses amino acid or nucleic acid sequences alignments that are at least 90%, e.g., at least 93%, e.g., at least 95%, e.g., at least 96%, e.g., at least 97%, e.g., at least 98%, e.g., at least 99%, or e.g., at least 100% identical.
  • chimeric encompasses a functional gene or polypeptide comprising nucleic acid sequences or amino acid sequences, respectively, from at least two different AAV serotype, e.g., portions of a gene or polypeptide of at least a first and second AAV, wherein the at least first and second portions are operably linked to form a functional chimeric AAV nucleic acid that encodes a functional amino acid.
  • nucleotide sequences, genes, polypeptides, and amino acids are considered non-chimeric in that the nucleotide sequences, genes, polypeptides, and amino acids comprise a nucleic acid sequence or amino acid sequence having significant identity to a nucleic acid sequence or amino acid sequence, respectively, of a single AAV serotype.
  • operably linked includes a physical juxtaposition (e.g., in three-dimensional space) of components or elements that interact, directly or indirectly with one another, or otherwise coordinate with each other to participate in a biological event, which juxtaposition achieves or permits such interaction and/or coordination.
  • a regulatory element e.g., an expression control sequence
  • a regulatory element in a nucleic acid is said to be “operably linked” to a coding sequence when it is located relative to the coding sequence such that its presence or absence impacts expression and/or activity of the coding sequence.
  • operable linkage involves covalent linkage of relevant components or elements with one another.
  • covalent linkage is not required to achieve effective operable linkage.
  • proteins operably linked together may be associated with each other, e.g., via a covalent bond or a non- covalent bond.
  • a capsid protein as described herein may be operably linked to a targeting ligand, where the capsid protein is non-covalently bound to the targeting ligand, or covalently bound to the targeting ligand, optionally with or without a scaffold and/or adaptor between the capsid protein and the targeting ligand.
  • nucleic acid regulatory elements that are operably linked with coding sequences that they control are contiguous with the nucleotide of interest.
  • one or more such regulatory elements acts in trans or at a distance to control a coding sequence of interest.
  • regulatory element refers to polynucleotide sequences which are necessary and/or sufficient to effect the expression and processing of coding sequences to which they are ligated.
  • a regulatory element may be or comprise appropriate transcription initiation, termination, promoter and/or enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., Kozak consensus sequence); sequences that enhance protein stability; and/or, in some embodiments, sequences that enhance protein secretion.
  • one or more regulatory elements are preferentially or exclusively active in a particular host cell or organism, or type thereof.
  • regulatory elements may typically include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes, in many embodiments, regulatory elements may typically include promoters, enhancers, and/or transcription termination sequences.
  • regulatory elements refers to components whose presence is essential for expression and processing, and in some embodiments includes components whose presence is advantageous for expression (including, for example, leader sequences, targeting sequences, and/or fusion partner sequences).
  • an antibody that binds CDH15 includes an antibody and antigen-binding fragment thereof that specifically recognizes a single CDH15 molecule.
  • An antibody and antigen-binding fragment thereof as described herein may bind soluble CDH15 and/or cell surface expressed CDH15.
  • Soluble CDH15 includes natural CDH15 proteins as well as recombinant CDH15 protein variants that lack a transmembrane domain or are otherwise unassociated with a cell membrane.
  • cell surface-expressed CDH15 refers to one or more CDH15 protein(s) that is/are expressed on the surface of a cell in vitro or in vivo, such that at least a portion of a CDH15 protein is exposed to the extracellular side of the cell membrane and is accessible to an antigen-binding portion of an antibody.
  • a “cell surface-expressed CDH15” can comprise or consist of a CDH15 protein expressed on the surface of a cell which normally expresses CDH15 protein.
  • “cell surface-expressed CDH15” can comprise or consist of a CDH15 protein expressed on the surface of a cell that normally does not express human CDH15 on its surface but has been artificially engineered to express CDH15 on its surface.
  • antigen -binding molecule includes an antibody and an antigenbinding fragment of an antibody.
  • antibody refers to any antigen-binding molecule or molecular complex comprising at least one complementarity determining region (CDR) that specifically binds to or interacts with a particular antigen (e.g., CDH15).
  • CDR complementarity determining region
  • Each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region.
  • the heavy chain constant region comprises three domains, CHI, CH2 and CH3.
  • Each light chain comprises a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region.
  • the light chain constant region comprises one domain, CL.
  • the VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).
  • CDR complementarity determining regions
  • FR framework regions
  • Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy -terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (heavy chain CDRs may be abbreviated as HCDR1, HCDR2 and HCDR3; light chain CDRs may be abbreviated as LCDR1, LCDR2 and LCDR3.
  • the term “high affinity” antibody refers to those antibodies having a binding affinity to their target of at least 10' 9 M, at least IO' 10 M; at least 10' 11 M; or at least 10' 12 M, as measured by surface plasmon resonance, e.g., BIACORETM or solution-affinity ELISA.
  • antibody may encompass any type of antibody, such as e.g., monoclonal or polyclonal. Moreover, the antibody may be or any origin, such as e.g, mammalian or nonmammalian. In one embodiment, the antibody may be mammalian or avian. In a further embodiment, the antibody may be of human origin and may further be a human monoclonal antibody.
  • antibody also includes antigen-binding fragments of full antibody molecules.
  • antigen-binding portion of an antibody, “antigen-binding fragment” of an antibody, and the like include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds an antigen to form a complex.
  • Antigen-binding fragments of an antibody may be derived, e.g., from full antibody molecules using any suitable standard techniques such as proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable and optionally constant domains.
  • DNA is known and/or is readily available from, e.g., commercial sources, DNA libraries (including, e.g., phage-antibody libraries), or can be synthesized.
  • the DNA may be sequenced and manipulated chemically or by using molecular biology techniques, for example, to arrange one or more variable and/or constant domains into a suitable configuration, or to introduce codons, create cysteine residues, modify, add or delete amino acids, etc.
  • Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab’)2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of the amino acid residues that mimic the hypervariable region of an antibody (e.g, an isolated complementarity determining region (CDR) such as a CDR3 peptide), or a constrained FR3- CDR3-FR4 peptide.
  • CDR complementarity determining region
  • engineered molecules such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g. monovalent nanobodies, bivalent nanobodies, efc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains, are also encompassed within the expression “antigen-binding fragment”.
  • SMIPs small modular immunopharmaceuticals
  • shark variable IgNAR domains are also encompassed within the expression “antigen-binding fragment”.
  • An antigen-binding fragment of an antibody will typically comprise at least one variable domain.
  • the variable domain may be of any size or amino acid composition and will generally comprise at least one CDR which is adjacent to or in frame with one or more framework sequences.
  • the VH and VL domains may be situated relative to one another in any suitable arrangement.
  • the variable region may be dimeric and contain VH-VH, VH-VL or VL-VL dimers.
  • the antigen-binding fragment of an antibody may contain a monomeric VH or VL domain.
  • an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain.
  • variable and constant domains that may be found within an antigenbinding fragment of an antibody as described herein include: (i) VH-CH1; (ii) VH-CH2; (iii) VH- CH3; (iv) VH-CH1-CH2; (V) VH-CH1-CH2-CH3; (vi) VH-CH2-CH3; (vii) VH-CL; (viii) VL-CH1; (ix) VL-CH2; (X) VL-CH3; (xi) VL-C H 1-CH2; (xii) VL-CH1-C H 2-CH3; (xiii) VL-C H 2-CH3; and (xiv) V L - CL.
  • variable and constant domains may be either directly linked to one another or may be linked by a full or partial hinge or linker region.
  • a hinge region may consist of at least 2 (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids which result in a flexible or semi -flexible linkage between adjacent variable and/or constant domains in a single polypeptide molecule.
  • an antigen-binding fragment of an antibody as described herein may comprise a homo-dimer or hetero-dimer (or other multimer) of any of the variable and constant domain configurations listed above in non-covalent association with one another and/or with one or more monomeric VH or VL domain (e.g., by disulfide bond(s)).
  • antigen-binding fragments may be monospecific or multispecific (e.g., bispecific).
  • a multispecific antigen-binding fragment of an antibody will typically comprise at least two different variable domains, wherein each variable domain is capable of specifically binding to a separate antigen or to a different epitope on the same antigen.
  • Any multispecific antibody format including the example bispecific antibody formats disclosed herein, may be adapted for use in the context of an antigen-binding fragment of an antibody as described herein using routine techniques available in the art.
  • the anti-hCDH15 antibodies as described herein are human antibodies.
  • the term “human antibody” refers to antibodies having variable and constant regions derived from human germline immunoglobulin sequences.
  • the human antibodies as described herein may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in particular CDR3.
  • the term “human antibody” is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
  • the antibodies as described herein may, in some embodiments, be recombinant human antibodies.
  • the term “recombinant human antibody” is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described further below), antibodies isolated from a recombinant, combinatorial human antibody library (described further below), antibodies isolated from an animal e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor et al. (1992) Nucl. Acids Res.
  • Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo.
  • Human antibodies may exist in two general forms that are associated with hinge heterogeneity.
  • an immunoglobulin molecule comprises a stable four chain construct of approximately 150-160 kDa in which the dimers are held together by an interchain heavy chain disulfide bond.
  • the dimers are not linked via inter-chain disulfide bonds and a molecule of about 75-80 kDa is formed composed of a covalently coupled light and heavy chain (half-antibody). These forms have been extremely difficult to separate, even after affinity purification.
  • the frequency of appearance of the second form in various intact IgG isotypes is due to, but not limited to, structural differences associated with the hinge region isotype of the antibody.
  • a single amino acid substitution in the hinge region of the human IgG4 hinge can significantly reduce the appearance of the second form (Angal et al. (1993) Molecular Immunology 30: 105) to levels typically observed using a human IgGl hinge.
  • the antibodies as described herein may have one or more mutations in the hinge, CH2 or CH3 region which may be desirable, for example, in production, to improve the yield of the desired antibody form.
  • the antibodies as described herein may be isolated antibodies.
  • An “isolated antibody” refers to an antibody that has been identified and separated and/or recovered from at least one component of its natural environment. For example, an antibody that has been separated or removed from at least one component of an organism, or from a tissue or cell in which the antibody naturally exists or is naturally produced, may be considered an “isolated antibody.”
  • An isolated antibody also includes an antibody in situ within a recombinant cell. Isolated antibodies are antibodies that have been subjected to at least one purification or isolation step. According to certain embodiments, an isolated antibody may be substantially free of other cellular material and/or chemicals.
  • one-arm antibodies that bind CDH15.
  • the term “one- arm antibody” refers to an antigen-binding molecule comprising a single antibody heavy chain and a single antibody light chain.
  • the one-arm antibodies as described herein may comprise any of the HCVR/LCVR or CDR amino acid sequences as set forth in Table 1.
  • the anti-hCDH15 antibodies disclosed herein may comprise one or more amino acid substitutions, insertions and/or deletions in the framework and/or CDR regions of the heavy and light chain variable domains as compared to the corresponding germline sequences from which the antibodies were derived. Such mutations can be readily ascertained by comparing the amino acid sequences disclosed herein to germline sequences available from, for example, public antibody sequence databases.
  • antibodies, and antigen-binding fragments thereof which are derived from any of the amino acid sequences disclosed herein, wherein one or more amino acids within one or more framework and/or CDR regions are mutated to the corresponding residue(s) of the germline sequence from which the antibody was derived, or to the corresponding residue(s) of another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue(s) (such sequence changes are referred to herein collectively as “germline mutations”).
  • Germline mutations such sequence changes are referred to herein collectively as “germline mutations”.
  • all of the framework and/or CDR residues within the VH and/or VL domains are mutated back to the residues found in the original germline sequence from which the antibody was derived.
  • only certain residues are mutated back to the original germline sequence, e.g., only the mutated residues found within the first 8 amino acids of FR1 or within the last 8 amino acids of FR4, or only the mutated residues found within CDR1, CDR2 or CDR3.
  • one or more of the framework and/or CDR residue(s) are mutated to the corresponding residue(s) of a different germline sequence (z.e., a germline sequence that is different from the germline sequence from which the antibody was originally derived).
  • the antibodies as described herein may contain any combination of two or more germline mutations within the framework and/or CDR regions, e.g., wherein certain individual residues are mutated to the corresponding residue of a particular germline sequence while certain other residues that differ from the original germline sequence are maintained or are mutated to the corresponding residue of a different germline sequence.
  • an antibody and an antigen-binding fragment that contains one or more germline mutations can be easily tested for one or more desired property such as, improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as the case may be), reduced immunogenicity, etc.
  • an antibody or an antigen-binding fragment as described herein is obtained in this general manner.
  • anti-hCDH15 antibodies comprising variants of any of the HCVR, LCVR, and/or CDR amino acid sequences disclosed herein having one or more conservative substitutions.
  • some embodiments include anti-hCDH15 antibodies having HCVR, LCVR, and/or CDR amino acid sequences with, e.g, 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc. conservative amino acid substitutions relative to any of the HCVR, LCVR, and/or CDR amino acid sequences set forth in Table 1 herein.
  • bispecific antibody includes an antibody capable of selectively binding two or more epitopes.
  • Bispecific antibodies generally comprise two different heavy chains, with each heavy chain specifically binding a different epitope — either on two different molecules (e.g., antigens) or on the same molecule (e.g., on the same antigen). If a bispecific antibody is capable of selectively binding two different epitopes (a first epitope and a second epitope), the affinity of the first heavy chain for the first epitope will generally be at least one to two or three or four orders of magnitude lower than the affinity of the first heavy chain for the second epitope, and vice versa.
  • the epitopes recognized by the bispecific antibody can be on the same or a different target (e.g., on the same or a different protein).
  • Bispecific antibodies can be made, for example, by combining heavy chains that recognize different epitopes of the same antigen.
  • nucleic acid sequences encoding heavy chain variable sequences that recognize different epitopes of the same antigen can be fused to nucleic acid sequences encoding different heavy chain constant regions, and such sequences can be expressed in a cell that expresses an immunoglobulin light chain.
  • a typical bispecific antibody has two heavy chains each having three heavy chain CDRs, followed by (N-terminal to C-terminal) a CHI domain, a hinge, a CH2 domain, and a CH3 domain, and an immunoglobulin light chain that either may not confer antigen-binding specificity but that can associate with each heavy chain, or that can associate with each heavy chain and that can bind one or more of the epitopes bound by the heavy chain antigen-binding regions, or that can associate with each heavy chain and participate in binding of one or both of the heavy chains to one or both epitopes.
  • heavy chain or “immunoglobulin heavy chain” includes an immunoglobulin heavy chain constant region sequence from any organism, and unless otherwise specified includes a heavy chain variable domain.
  • Heavy chain variable domains include three heavy chain CDRs and four FR regions, unless otherwise specified. Fragments of heavy chains include CDRs, CDRs and FRs, and combinations thereof.
  • a typical heavy chain has, following the variable domain (from N-terminal to C-terminal), a CHI domain, a hinge, a CH2 domain, and a CH3 domain.
  • a functional fragment of a heavy chain includes a fragment that is capable of specifically recognizing an antigen (e.g., recognizing the antigen with a KD in the micromolar, nanomolar, or picomolar range), that is capable of expressing and secreting from a cell, and that comprises at least one CDR.
  • an antigen e.g., recognizing the antigen with a KD in the micromolar, nanomolar, or picomolar range
  • the term “heavy chain only antibody,” “heavy chain only antigen binding protein,” “single domain antigen binding protein,” “single domain binding protein” or the like refers to a monomeric or homodimeric immunoglobulin molecule comprising an immunoglobulin-like chain comprising a variable domain operably linked to a heavy chain constant region, that is unable to associate with a light chain because the heavy chain constant region typically lacks a functional CHI domain.
  • the term “heavy chain only antibody,” “heavy chain only antigen binding protein,” “single domain antigen binding protein,” “single domain binding protein” or the like encompasses a both (i) a monomeric single domain antigen binding protein comprising one of the immunoglobulin-like chain comprising a variable domain operably linked to a heavy chain constant region lacking a functional CHI domain, or (ii) a homodimeric single domain antigen binding protein comprising two immunoglobulin-like chains, each of which comprising a variable domain operably linked to a heavy chain constant region lacking a functional CHI domain.
  • a homodimeric single domain antigen binding protein comprises two identical immunoglobulin-like chains, each of which comprising an identical variable domain operably linked to an identical heavy chain constant region lacking a functional CHI domain.
  • each immunoglobulin-like chain of a single domain antigen binding protein comprises a variable domain, which may be derived from heavy chain variable region gene segments (e.g., VH, DH, JH), light chain gene segments (e.g, VL, JL), or a combination thereof, linked to a heavy chain constant region (CH) gene sequence comprising a deletion or inactivating mutation in a CHI encoding sequence (and, optionally, a hinge region) of a heavy chain constant region gene, e.g., IgG, IgA, IgE, IgD, or a combination thereof.
  • CH heavy chain constant region
  • a single domain antigen binding protein comprising a variable domain derived from heavy chain gene segments may be referred to as a “VH- single domain antibody” or “Vn-single domain antigen binding protein”, see, e.g., U.S. Patent No. 8,754,287; U.S. Patent Publication Nos. 20140289876; 20150197553; 20150197554; 20150197555; 20150196015; 20150197556 and 20150197557, each of which is incorporated in its entirety by reference.
  • a single domain antigen binding protein comprising a variable domain derived from light chain gene segments may be referred to as a or “V -single domain antigen binding protein,” see, e.g., U.S. Publication No. 20150289489, incorporated in its entirety by reference.
  • light chain includes an immunoglobulin light chain constant region sequence from any organism, and unless otherwise specified includes human kappa and lambda light chains.
  • Light chain variable (VL) domains typically include three light chain CDRs and four framework (FR) regions, unless otherwise specified.
  • FR framework
  • a full-length light chain includes, from amino terminus to carboxyl terminus, a VL domain that includes FR1-CDR1- FR2-CDR2-FR3-CDR3-FR4, and a light chain constant domain.
  • Light chains that may be useful include e.g., those, that do not selectively bind either the first or second antigen selectively bound by the antigen-binding protein.
  • Suitable light chains include those that can be identified by screening for the most commonly employed light chains in existing antibody libraries (wet libraries or in silico), where the light chains do not substantially interfere with the affinity and/or selectivity of the antigen-binding domains of the antigen-binding proteins. Suitable light chains include those that can bind one or both epitopes that are bound by the antigen-binding regions of the antigen-binding protein.
  • variable domain includes an amino acid sequence of an immunoglobulin light or heavy chain (modified as desired) that comprises the following amino acid regions, in sequence from N-terminal to C-terminal (unless otherwise indicated): FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • a “variable domain” includes an amino acid sequence capable of folding into a canonical domain (VH or VL) having a dual beta sheet structure wherein the beta sheets are connected by a disulfide bond between a residue of a first beta sheet and a second beta sheet.
  • CDR complementarity determining region
  • a CDR includes an amino acid sequence encoded by a nucleic acid sequence of an organism’s immunoglobulin genes that normally (i.e., in a wildtype animal) appears between two framework regions in a variable region of a light or a heavy chain of an immunoglobulin molecule (e.g., an antibody or a T cell receptor).
  • a CDR can be encoded by, for example, a germline sequence or a rearranged or unrearranged sequence, and, for example, by a naive or a mature B cell or a T cell.
  • CDRs can be encoded by two or more sequences (e.g., germline sequences) that are not contiguous (e.g., in an unrearranged nucleic acid sequence) but are contiguous in a B cell nucleic acid sequence, e.g., as the result of splicing or connecting the sequences (e.g, V-D-J recombination to form a heavy chain CDR3).
  • sequences e.g., germline sequences
  • a B cell nucleic acid sequence e.g., as the result of splicing or connecting the sequences (e.g, V-D-J recombination to form a heavy chain CDR3).
  • Methods and techniques for identifying CDRs within HCVR and LCVR amino acid sequences are well known in the art and can be used to identify CDRs within the specified HCVR and/or LCVR amino acid sequences disclosed herein.
  • Examples of conventions that can be used to identify the boundaries of CDRs include, e.g., the Kabat definition, the Chothia definition, and the AbM definition.
  • the Kabat definition is based on sequence variability
  • the Chothia definition is based on the location of the structural loop regions
  • the AbM definition is a compromise between the Kabat and Chothia approaches.
  • antibody fragment refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen.
  • binding fragments encompassed within the term “antibody fragment” include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab’)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHI domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al.
  • antibody forms of single chain antibodies, such as diabodies are also encompassed under the term “antibody” (see e.g., Holliger el al. (1993) PNAS USA 90:6444-6448; Poljak et al. (1994) Structure 2: 1121-1123).
  • Fc-containing protein includes antibodies, bispecific antibodies, immunoadhesins, and other binding proteins that comprise at least a functional portion of an immunoglobulin CH2 and CH3 region.
  • a “functional portion” refers to a CH2 and CH3 region that can bind a Fc receptor (e.g., an FcyR; or an FcRn, i.e., a neonatal Fc receptor), and/or that can participate in the activation of complement. If the CH2 and CH3 region contains deletions, substitutions, and/or insertions or other modifications that render it unable to bind any Fc receptor and also unable to activate complement, the CH2 and CH3 region is not functional.
  • Fc-containing proteins can comprise modifications in immunoglobulin domains, including where the modifications affect one or more effector function of the binding protein (e.g, modifications that affect FcyR binding, FcRn binding and thus half-life, and/or CDC activity).
  • modifications include, but are not limited to, the following modifications and combinations thereof, with reference to EU numbering of an immunoglobulin constant region: 238, 239, 248, 249, 250, 252, 254, 255, 256, 258, 265, 267, 268, 269, 270, 272, 276, 278, 280,
  • the binding protein is an Fc-containing protein and exhibits enhanced serum half-life (as compared with the same Fc-containing protein without the recited modification(s)) and have a modification at position 250 (e.g., E or Q); 250 and 428 (e.g., L or F); 252 (e.g., L/Y/F/W or T), 254 (e.g, S or T), and 256 (e.g., S/R/Q/E/D or T); or a modification at 428 and/or 433 (e.g., L/R/SI/P/Q or K) and/or 434 (e.g, H/F or Y); or a modification at 250 and/or 428; or a modification at 307 or 308 (e.g., 308F, V308F), and 434.
  • 250 and 428 e.g., L or F
  • 252 e.g., L/Y/F/W or T
  • 254 e.g
  • the modification can comprise a 428L (e.g., M428L) and 434S (e.g., N434S) modification; a 428L, 2591 (e.g., V259I), and a 308F (e.g., V308F) modification; a 433K (e.g., H433K) and a 434 (e.g., 434Y) modification; a 252, 254, and 256 (e.g., 252Y, 254T, and 256E) modification; a 250Q and 428L modification (e.g, T250Q and M428L); a 307 and/or 308 modification (e.g., 308F or 308P).
  • a 428L e.g., M428L
  • 434S e.g., N434S
  • a 428L, 2591 e.g., V259I
  • a 308F e.g., V308F
  • antigen-binding protein refers to a polypeptide or protein (one or more polypeptides complexed in a functional unit) that specifically recognizes an epitope on an antigen, such as a cell-specific antigen and/or a target antigen as described herein.
  • An antigen-binding protein may be multi-specific.
  • multi-specific with reference to an antigen-binding protein means that the protein recognizes different epitopes, either on the same antigen or on different antigens.
  • a multi-specific antigen-binding protein as described herein can be a single multifunctional polypeptide, or it can be a multimeric complex of two or more polypeptides that are covalently or non-covalently associated with one another.
  • the term “antigen-binding protein” includes antibodies or fragments thereof as described herein that may be linked to or co-expressed with another functional molecule, e.g, another peptide or protein.
  • an antibody or fragment thereof can be functionally linked (e.g., by chemical coupling, genetic fusion, non-covalent association or otherwise) to one or more other molecular entities, such as a protein or fragment thereof to produce a bispecific or a multi-specific antigenbinding molecule with a second binding specificity.
  • protein means any amino acid polymer having multiple amino acids covalently linked via amide bonds. Proteins contain one or more amino acid polymer chains, generally known in the art as “polypeptides”. Thus, a polypeptide may be a protein, and a protein may contain multiple polypeptides to form a single functioning biomolecule. Disulfide bridges (i.e., between cysteine residues to form cystine) may be present in some proteins. These covalent links may be within a single polypeptide chain, or between two individual polypeptide chains. For example, disulfide bridges are essential to proper structure and function of insulin, immunoglobulins, protamine, and the like. For a recent review of disulfide bond formation, see Oka and Bulleid, “Forming disulfides in the endoplasmic reticulum,” 1833(11) Biochim Biophys Acta 2425-9 (2013).
  • protein includes biotherapeutic proteins, recombinant proteins used in research or therapy, trap proteins and other Fc-fusion proteins, chimeric proteins, antibodies, monoclonal antibodies, human antibodies, bispecific antibodies, antibody fragments, nanobodies, recombinant antibody chimeras, scFv fusion proteins, cytokines, chemokines, peptide hormones, and the like. Proteins may be produced using recombinant cell-based production systems, such as the insect bacculovirus system, yeast systems (e.g., Pichia sp.), mammalian systems (e.g., CHO cells and CHO derivatives like CHO-K1 cells).
  • yeast systems e.g., Pichia sp.
  • mammalian systems e.g., CHO cells and CHO derivatives like CHO-K1 cells.
  • epitope refers to the portion of the antigen which is recognized by the multi-specific antigen-binding polypeptide.
  • a single antigen such as an antigenic polypeptide may have more than one epitope.
  • Epitopes may be defined as structural or functional. Functional epitopes are generally a subset of structural epitopes and are defined as those residues that directly contribute to the affinity of the interaction between the antigen- binding polypeptide and the antigen. Epitopes may also be conformational, that is, composed of non-linear amino acids.
  • epitopes may include determinants that are chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and, in certain embodiments, may have specific three- dimensional structural characteristics, and/or specific charge characteristics. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents.
  • domain refers to any part of a protein or polypeptide having a particular function or structure.
  • domains as described herein bind to cell-specific or target antigens.
  • Cell-specific antigen- or target antigen-binding domains, and the like, as used herein, include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds an antigen.
  • half-body or “half-antibody”, which are used interchangeably, refers to half of an antibody, which essentially contains one heavy chain and one light chain. Antibody heavy chains can form dimers, thus the heavy chain of one half-body can associate with heavy chain associated with a different molecule (e.g., another half-body) or another Fc-containing polypeptide. Two slightly different Fc-domains may “heterodimerize” as in the formation of bispecific antibodies or other heterodimers, -trimers, -tetramers, and the like. See Vincent and Murini, “Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates,” 7 Biotechnol. J. 1444-1450 (20912); and Shimamoto et al., “Peptibodies: A flexible alternative format to antibodies,” 4(5) MAbs 586-91 (2012).
  • single-chain variable fragment or “scFv” includes a single chain fusion polypeptide containing an immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL).
  • VH and VL are connected by a linker sequence of 10 to 25 amino acids.
  • ScFv polypeptides may also include other amino acid sequences, such as CL or CHI regions.
  • ScFv molecules can be manufactured by phage display or made by directly subcloning the heavy and light chains from a hybridoma or B-cell.
  • the term “muscle-related cancer” refers to any cancerous cell defined by the expression of myogenic genes e.g, expression of CDH15. “Muscle-related cancers” include, but are not limited to, rhabdomyosarcoma e.g., embryonal, alveolar, spindle cell/scl erosing, pleomorphic, etc.
  • target cells includes any cells in which expression of a nucleotide of interest is desired.
  • target cells exhibit a receptor on their surface that allows the cell to be targeted with a targeting ligand, as described below.
  • a target cell is a muscle cell.
  • a “muscle cell”, as used herein, refers to any cell expressing myogenic markers and/or involved in skeletal muscle regeneration, e.g., muscle stem cells (“MuSC”, also known as satellite cells) and which express Pax7 and thus are considered Pax7 + cells, e.g., Pax7 + /MyoD' when quiescent and Pax7 + /MyoD + when proliferating), myoblasts (e.g., MyoD + Myogenin + cells), myocytes, myotubes (also known as myofibers, e.g., MyHC + cells), etc.
  • Muscle cell refers to any cell expressing myogenic markers and/or involved in skeletal muscle regeneration, e.g., muscle stem cells (“MuSC”, also known as satellite cells) and which express Pax7 and thus are considered Pax7 + cells, e.g., Pax7 + /MyoD' when quiescent and Pax7 + /MyoD + when proliferating), myoblasts
  • “Retargeting” or “redirecting” may include a scenario in which the wildtype particle targets several cells within a tissue and/or several organs within an organism, and general targeting of the tissue or organs is reduced or abolished by insertion of the heterologous amino acid, and retargeting to more a specific cell in the tissue or a specific organ in the organism is achieved with the targeting ligand (e.g., via a targeting ligand) that binds a marker expressed by the specific cell.
  • the targeting ligand e.g., via a targeting ligand
  • Such retargeting or redirecting may also include a scenario in which the wildtype particle targets a tissue, and targeting of the tissue is reduced to or abolished by insertion of the heterologous amino acid, and retargeting to a completely different tissue is achieved with the targeting ligand.
  • “Specific binding pair,” “binding pair,” “protein:protein binding pair” and the like includes two members (e.g., a first member (e.g., a first polypeptide) and a second cognate member (e.g., a second polypeptide)) that interact to form a bond (e.g., a non-covalent bond between a first member epitope and a second member antigen-binding portion of an antibody that recognizes the epitope; a covalent bond between e.g., proteins capable of forming isopeptide bonds; split inteins that recognize each other and, through the process of protein trans-splicing, mediate ligation of the flanking proteins and their own removal).
  • a bond e.g., a non-covalent bond between a first member epitope and a second member antigen-binding portion of an antibody that recognizes the epitope
  • a covalent bond between e.g., proteins capable of forming isopeptide bonds e.g
  • cognate refers to components that function together.
  • Epitopes and cognate antibodies thereto, particularly epitopes that may also act as a detectable label (e.g., c-myc) are well-known in the art.
  • Specific proteimprotein binding pairs capable of interacting to form a covalent isopeptide bond are reviewed in Veggiani et al. (2014) Trends Biotechnol.
  • a first member of a protein: protein binding pair refers to member of a protein: protein binding pair, which is generally less than 30 amino acids in length, and which forms a spontaneous covalent isopeptide bond with the second cognate protein, wherein the second cognate protein is generally larger, but may also be less than 30 amino acids in length such as in the SpyTag:KTag system.
  • isopeptide bond refers to an amide bond between a carboxyl or carboxamide group and an amino group at least one of which is not derived from a protein main chain or alternatively viewed is not part of the protein backbone.
  • An isopeptide bond may form within a single protein or may occur between two peptides or a peptide and a protein.
  • an isopeptide bond may form intramolecularly within a single protein or intermolecularly i.e. between two peptide/protein molecules, e.g. between two peptide linkers.
  • an isopeptide bond may occur between a lysine residue and an asparagine, aspartic acid, glutamine, or glutamic acid residue or the terminal carboxyl group of the protein or peptide chain or may occur between the alpha-amino terminus of the protein or peptide chain and an asparagine, aspartic acid, glutamine or glutamic acid.
  • Each residue of the pair involved in the isopeptide bond is referred to herein as a reactive residue.
  • an isopeptide bond may form between a lysine residue and an asparagine residue or between a lysine residue and an aspartic acid residue.
  • isopeptide bonds can occur between the side chain amine of lysine and carboxamide group of asparagine or carboxyl group of an aspartate.
  • the SpyTag: SpyCatcher system is described in U.S. Patent No. 9,547,003 and Zaveri et al. (2012) PNAS 109:E690-E697, each of which is incorporated herein in its entirety by reference, and is derived from the CnaB2 domain of the Streptococcus pyogenes fibronectin- binding protein FbaB.
  • Zakeri et al. obtained a peptide “SpyTag” having the sequence AHIVMVDAYKPTK (SEQ ID NO: 815) which forms an amide bond to its cognate protein “SpyCatcher,” an 112 amino acid polypeptide having the amino acid sequence set forth in SEQ ID NO: 816.
  • SpyTag:KTag An additional specific binding pair derived from CnaB2 domain is SpyTag:KTag, which forms an isopeptide bond in the presence of SpyLigase.
  • SpyLigase was engineered by excising the P strand from SpyCatcher that contains a reactive lysine, resulting in KTag, a 10-residue first member of a protein: protein binding pair having the amino acid sequence ATHIKFSKRD (SEQ ID NO: 817).
  • SpyTag002 has the amino acid sequence VPTIVMVDAYKRYK, set forth as SEQ ID NO: 821, and binds SpyCatcher002.
  • SpyTag003 has the amino acid sequence RGVPHIVMVDAYKRYK, set forth as SEQ ID NO: 822, and binds SpyCatcher003.
  • SnoopTag SnoopCatcher system is described in Veggiani (2016) PNAS 113: 1202-07.
  • the D4 Ig-like domain of RrgA an adhesion from Streptococcus pneumoniae, was split to form SnoopTag (residues 734-745) and SnoopCatcher (residues 749-860).
  • the isopeptag:pilin-C specific binding pair was derived from the major pilin protein Spy0128 from Streptococcus pyogenes. (Zakeir and Howarth (2010) J. Am. Chem. Soc. 132:4526-27). Isopeptag has the amino acid sequence TDKDMTITFTNKKDAE, set forth as SEQ ID NO: 820, and binds pilin-C (residues 18-299 of SpyO 128). Incubation of isopeptag and pilin-C results in a spontaneous isopeptide bond that is specific between the complementary proteins. Zakeir and Howarth (2010), supra.
  • transduction or “infection” or the like refers to the introduction of a nucleic acid into a target cell e.g., a muscle stem cell, myoblast, myocyte, any combination thereof, etc.) nucleus by a viral particle.
  • efficiency in relation to transduction or the like e.g., “transduction efficiency” refers to the fraction e.g., percentage) of cells expressing a nucleotide of interest after incubation with a set number of viral particles comprising the nucleotide of interest.
  • Well-known methods of determining transduction efficiency include flow cytometry of cells transduced with a fluorescent reporter gene, RT-PCR for expression of the nucleotide of interest, etc.
  • “reference” viral capsid protein/capsid/particle are identical to test viral capsid protein/capsid/particle but for the change for which the effect is to be tested. For example, to determine the effect, e.g., on transduction efficiency, of inserting a first member of a specific binding pair into a test viral particle, the transduction efficiencies of the test viral particle (in the absence or presence of an appropriate targeting ligand) can be compared to the transduction efficiencies of a reference viral particle (in the absence or presence of an appropriate targeting ligand if necessary) which is identical to the test viral particle in every instance (e.g., additional point mutations, nucleotide of interest, numbers of viral particles and target cells, etc.) except for the presence of a first member of a specific binding pair.
  • a reference viral capsid protein is one that is able to form a capsid with a second viral capsid protein modified to comprise at least a first member of a proteimprotein binding pair, where the reference viral capsid protein does not comprise the first member of a protein: protein binding pair, preferably wherein the capsid formed by the reference viral capsid protein and the modified viral capsid protein is a mosaic capsid.
  • antigen-binding proteins e.g., antibodies, or antigen-binding fragments thereof, comprising an amino acid of an HCVR, HCDR1, HCDR2, HCDR3, LCVR, LCV1, LCVR2, and/or LCVR3 as set forth in Table 1.
  • an antigen-binding protein e.g., an antibody, or an antigen-binding fragment thereof, as described herein comprises a heavy chain CDR1 (HCDR1) comprising an amino acid sequence selected from any of the HCDR1 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.
  • HCDR1 heavy chain CDR1
  • an antigen-binding protein e.g., an antibody, or an antigen-binding fragment thereof, as described herein comprises a heavy chain CDR2 (HCDR2) comprising an amino acid sequence selected from any of the HCDR2 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
  • HCDR2 heavy chain CDR2
  • an antigen-binding protein e.g., an antibody, or an antigen-binding fragment thereof, as described herein comprises a heavy chain CDR3 (HCDR3) comprising an amino acid sequence selected from any of the HCDR3 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
  • HCDR3 heavy chain CDR3
  • an antigen-binding protein e.g., an antibody, or an antigen-binding fragment thereof, as described herein comprises a light chain CDR1 (LCDR1) comprising an amino acid sequence selected from any of the LCDR1 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
  • LCDR1 light chain CDR1
  • an antigen-binding protein e.g., an antibody, or an antigen-binding fragment thereof, as described herein comprises a light chain CDR2 (LCDR2) comprising an amino acid sequence selected from any of the LCDR2 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
  • LCDR2 light chain CDR2
  • an antigen-binding protein e.g., an antibody, or an antigen-binding fragment thereof, as described herein comprises a light chain CDR3 (LCDR3) comprising an amino acid sequence selected from any of the LCDR3 amino acid sequences listed in Table lor a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
  • LCDR3 light chain CDR3
  • an antibody, or an antigen-binding fragment thereof, as described herein comprises an HCDR3 and an LCDR3 amino acid sequence pair (HCDR3/LCDR3) comprising any of the HCDR3 amino acid sequences listed in Table 1 paired with any of the LCDR3 amino acid sequences listed in Table 1.
  • an antibody, or antigen-binding fragments thereof, as described herein comprises an HCDR3/LCDR3 amino acid sequence pair contained within any of the example anti-hCDH15 antibodies listed in Table 1.
  • the HCDR3/LCDR3 amino acid sequence pair is selected from the group consisting of SEQ ID NOs: 8 and 16, 28 and 36, 48 and 54, 66 and 54, 76 and 54, 86 and 54, 96 and 102, 113 and 119, 131 and 139, 151 and 159, 171 and 179, 191 and 196, 208 and 214, 226 and 54, 236 and 54, 246 and 54, 255 and 54, 265 and 273, 285 and 293, 305 and 313, 325 and 333, 345 and 352, 364 and 372, 382 and 54, 392 and 398, 410 and 414, 426 and 434, 442 and 450, 458 and 466, 474 and 482, 490 and 498, 506 and 514, 522 and 530, 538 and 546, 554 and 562, 570 and 578, 586 and 594, 602 and 610, 618 and 626, 634 and 642, 650 and 658, 6
  • antigen-binding proteins e.g., an antibody, or an antigenbinding fragment thereof, comprising a set of six CDRs (i.e., HCDR1-HCDR2-HCDR3-LCDR1- LCDR2-LCDR3) contained within any of the example anti-hCDH15 antibodies listed in Table 1.
  • the HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequences set is selected from the group consisting of SEQ ID NOs: 4-6-8-12-14-16, 24-26-28- 32-34-36, 44-46-48-52-34-54, 62-64-66-52-34-54, 72-74-76-52-34-54, 82-84-86-52-34-54, 92- 94-96-100-34-102, 82-111-113-117-34-119, 127-129-131-135-137-139, 147-149-151-155-157- 159, 167-169-171-175-177-179, 187-189-191-52-34-196, 204-206-208-212-137-214, 222-224- 226-52-34-54, 232-234-236-52-34-54, 242-244-246-52-34-54, 82-253-255-52-34-54, 261-263- 265-269-271-273, 281-283-
  • antibodies, or antigen-binding fragments thereof comprising a set of six CDRs (z.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained within an HCVR/LCVR amino acid sequence pair as defined by any of the example anti-hCDH15 antibodies listed in Table 1.
  • an antibody, or antigenbinding fragments thereof, as described herein comprises the HCDR1-HCDR2-HCDR3-LCDR1- LCDR2-LCDR3 amino acid sequences set contained within an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 and 10, 22 and 30, 42 and 50, 60 and 50, 70 and 50, 80 and 50, 90 and 98, 108 and 115, 125 and 133, 145 and 153, 165 and 173, 185 and 193, 202 and 210, 220 and 50, 230 and 50, 240 and 50, 250 and 50, 259 and 267, 279 and 287, 299 and 307, 319 and 327, 339 and 347, 358 and 366, 378 and 50, 386 and 394,
  • the antigen-binding protein comprises a heavy chain variable region (HCVR or VH).
  • the HCVR comprises a set of HCDR1- HCDR2-HCDR3 amino acid sequences selected from Table 1.
  • the HCVR comprises an amino acid sequence selected from any of the HCVR amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
  • the antigen-binding protein comprises a light chain variable region (LCVR or VL).
  • the LCVR comprises a set of LCDR1- LCDR2-LCDR3 amino acid sequences selected from Table 1 below.
  • the LCVR comprises an amino acid sequence selected from any of the LCVR amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
  • the antigen-binding protein e.g, antibody or antigenbinding fragment thereof, comprises an HCVR and an LCVR amino acid sequence pair (HCVR/LCVR) comprising any of the HCVR amino acid sequences listed in Table 1 paired with any of the LCVR amino acid sequences listed in Table 1.
  • the antigenbinding protein e.g., antibody or antigen-binding fragment thereof, as described herein comprises an HCVR/LCVR amino acid sequence pair contained within any of the example anti- hCDH15 antibodies listed in Table 1.
  • the HCVR/LCVR amino acid sequence pair is selected from the group consisting of SEQ ID NOs: 2 and 10, 22 and 30, 42 and 50, 60 and 50, 70 and 50, 80 and 50, 90 and 98, 108 and 115, 125 and 133, 145 and 153, 165 and 173, 185 and 193, 202 and 210, 220 and 50, 230 and 50, 240 and 50, 250 and 50, 259 and 267, 279 and 287, 299 and 307, 319 and 327, 339 and 347, 358 and 366, 378 and 50, 386 and 394,
  • nucleic acid molecules e.g., polynucleotides, encoding the antigen-binding proteins, e.g., antibodies or antigen-binding fragments thereof, as described herein.
  • nucleic acid molecules encoding any of the HCDR1 amino acid sequences listed in Table 1; in some embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR1 nucleic acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
  • nucleic acid molecules encoding any of the HCDR2 amino acid sequences listed in Table 1; in some embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR2 nucleic acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
  • nucleic acid molecules encoding any of the HCDR3 amino acid sequences listed in Table 1; in some embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR3 nucleic acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
  • nucleic acid molecules encoding any of the LCDR1 amino acid sequences listed in Table 1; in some embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR1 nucleic acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
  • nucleic acid molecules encoding any of the LCDR2 amino acid sequences listed in Table 1; in some embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR2 nucleic acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
  • nucleic acid molecules encoding any of the LCDR3 amino acid sequences listed in Table 1; in some embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR3 nucleic acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto. Also described herein are nucleic acid molecules encoding both an HCVR and an LCVR, wherein the HCVR comprises an amino acid sequence of any of the HCVR amino acid sequences listed in Table 1, and wherein the LCVR comprises an amino acid sequence of any of the LCVR amino acid sequences listed in Table 1.
  • the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCVR nucleic acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto, and a polynucleotide sequence selected from any of the LCVR nucleic acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
  • the nucleic acid molecule encodes an HCVR and LCVR, wherein the HCVR and LCVR are both derived from the same anti-hCDH15 antibody listed in Table 1.
  • a recombinant expression vector capable of expressing a polypeptide comprising a heavy and/or light chain variable region of an anti-hCDH15 antibody.
  • a recombinant expression vector comprises any of the nucleic acid molecules mentioned above, i.e., nucleic acid molecules encoding any of the HCVR, LCVR, and/or CDR sequences as set forth in Table 1.
  • host cells into which such vectors have been introduced as well as methods of producing the antibodies or portions thereof by culturing the host cells under conditions permitting production of the antibodies or antibody fragments, and recovering the antibodies or antibody fragments so produced.
  • An anti-hCDH15 antibody and antigen-binding fragment thereof as described herein may be monospecific, bi-specific, or multispecific. Multispecific antibodies may be specific for different epitopes of one target polypeptide or may contain antigen-binding domains specific for more than one target polypeptide. See, e.g., Tutt et al., 1991, J. Immunol. 147:60-69; Kufer etal., 2004, Trends Biotechnol. 22:238-244.
  • An anti-hCDH15 antibody and antigenbinding fragment thereof as described herein can be linked to or co-expressed with another functional molecule, e.g, another peptide or protein.
  • an antibody or fragment thereof can be functionally linked e.g., by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody or antibody fragment to produce a bi-specific or a multispecific antibody with a second or additional binding specificity.
  • Use of the expression “anti-hCDH15 antibody” herein is intended to include both monospecific anti-hCDH15 antibodies as well as bispecific antibodies comprising a CDH15- binding arm and a “target’ ’-binding arm.
  • the CDH15-binding arm can comprise any of the HCVR/LCVR or CDR amino acid sequences as set forth in Table 1 herein.
  • the CDH15-binding arm binds to human CDH15 and induces internalization of the CDH15 and antibody bound thereto. In certain embodiments, the CDH15-binding arm binds weakly to human CDH15 and induces internalization of CDH15 and antibody bound thereto. In certain embodiments, the CDH15-binding arm binds to human CDH15 and blocks the activity of CDH15.
  • the bispecific antigen-binding molecule is a bispecific antibody.
  • Each antigen-binding domain of a bispecific antibody comprises a heavy chain variable domain (HCVR) and a light chain variable domain (LCVR).
  • HCVR heavy chain variable domain
  • LCVR light chain variable domain
  • the CDRs of the first antigen-binding domain may be designated with the prefix “Al” and the CDRs of the second antigen-binding domain may be designated with the prefix “A2”.
  • the CDRs of the first antigen-binding domain may be referred to herein as A1-HCDR1, A1-HCDR2, and A1-HCDR3; and the CDRs of the second antigenbinding domain may be referred to herein as A2-HCDR1, A2-HCDR2, and A2-HCDR3.
  • the first antigen-binding domain and the second antigen-binding domain may be directly or indirectly connected to one another to form a bispecific antigen-binding molecule as described herein.
  • the first antigen-binding domain and the second antigen-binding domain may each be connected to a separate multimerizing domain.
  • the association of one multimerizing domain with another multimerizing domain facilitates the association between the two antigen-binding domains, thereby forming a bispecific antigen-binding molecule.
  • a “multimerizing domain” is any macromolecule, protein, polypeptide, peptide, or amino acid that has the ability to associate with a second multimerizing domain of the same or similar structure or constitution.
  • a multimerizing domain may be a polypeptide comprising an immunoglobulin CH3 domain.
  • a non-limiting example of a multimerizing component is an Fc portion of an immunoglobulin (comprising a CH2-CH3 domain), e.g., an Fc domain of an IgG selected from the isotypes IgGl, IgG2, IgG3, and IgG4, as well as any allotype within each isotype group.
  • Bispecific antigen-binding molecules as described herein will typically comprise two multimerizing domains, e.g, two Fc domains that are each individually part of a separate antibody heavy chain.
  • the first and second multimerizing domains may be of the same IgG isotype such as, e.g., IgGl/IgGl, IgG2/IgG2, IgG4/IgG4.
  • the first and second multimerizing domains may be of different IgG isotypes such as, e.g., IgGl/IgG2, IgGl/IgG4, IgG2/IgG4, etc.
  • the multimerizing domain is an Fc fragment or an amino acid sequence of from 1 to about 200 amino acids in length containing at least one cysteine residue. In other embodiments, the multimerizing domain is a cysteine residue, or a short cysteine-containing peptide.
  • Other multimerizing domains include peptides or polypeptides comprising or consisting of a leucine zipper, a helix-loop motif, or a coiled-coil motif.
  • any bispecific antibody format or technology may be used to make the bispecific antigen-binding molecules as described herein.
  • an antibody or fragment thereof having a first antigen binding specificity can be functionally linked (e.g., by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody or antibody fragment having a second antigen-binding specificity to produce a bispecific antigen-binding molecule.
  • bispecific formats include, without limitation, e.g., scFv-based or diabody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-Ig, Quadroma, knobs-into-holes, common light chain (e.g., common light chain with knobs-into-holes, etc.), CrossMab, CrossFab, (SEED)body, leucine zipper, Duobody, IgGl/IgG2, dual acting Fab (DAF)-IgG, and Mab 2 bispecific formats (see, e.g., Klein et al. 2012, mAbs 4:6, 1-11, and references cited therein, for a review of the foregoing formats).
  • the multimerizing domains e.g, Fc domains
  • the multimerizing domains may comprise one or more amino acid changes (e.g., insertions, deletions or substitutions) as compared to the wild-type, naturally occurring version of the Fc domain.
  • bispecific antigen-binding molecules may comprise one or more modifications in the Fc domain that results in a modified Fc domain having a modified binding interaction (e.g., enhanced or diminished) between Fc and FcRn.
  • the bispecific antigen-binding molecule comprises a modification in a CH2 or a CH3 region, wherein the modification increases the affinity of the Fc domain to FcRn in an acidic environment (e.g., in an endosome where pH ranges from about 5.5 to about 6.0).
  • Non-limiting examples of such Fc modifications include, e.g., a modification at position 250 e.g., E or Q); 250 and 428 (e.g., L or F); 252 (e.g., L/Y/F/W or T), 254 (e.g., S or T), and 256 (e.g, S/R/Q/E/D or T); or a modification at position 428 and/or 433 (e.g., L/R/S/P/Q or K) and/or 434 (e.g., H/F or Y); or a modification at position 250 and/or 428; or a modification at position 307 or 308 (e.g., 308F, V308F), and 434.
  • a modification at position 250 e.g., E or Q e.g., E or Q
  • 250 and 428 e.g., L or F
  • 252 e.g., L/Y/F/W or T
  • 254
  • the modification comprises a 428L (e.g., M428L) and 434S (e.g., N434S) modification; a 428L, 2591 (e.g., V259I), and 308F (e.g., V308F) modification; a 433K (e.g., H433K) and a 434 (e.g, 434Y) modification; a 252, 254, and 256 (e.g., 252Y, 254T, and 256E) modification; a 250Q and 428L modification (e.g., T250Q and M428L); and a 307 and/or 308 modification (e.g., 308F or 308P).
  • a 428L e.g., M428L
  • 434S e.g., N434S
  • 428L, 2591 e.g., V259I
  • 308F e.g., V308F
  • 433K
  • bispecific antigen-binding molecules comprising a first CH3 domain and a second Ig CH3 domain, wherein the first and second Ig CH3 domains differ from one another by at least one amino acid, and wherein at least one amino acid difference reduces binding of the bi specific antibody to Protein A as compared to a bi-specific antibody lacking the amino acid difference.
  • the first Ig CH3 domain binds Protein A and the second Ig CH3 domain contains a mutation that reduces or abolishes Protein A binding such as an H95R modification (by IMGT exon numbering; H435R by EU numbering).
  • the second CH3 may further comprise a Y96F modification (by IMGT; Y436F by EU).
  • the Fc domain may be chimeric, combining Fc sequences derived from more than one immunoglobulin isotype.
  • a chimeric Fc domain can comprise part or all of a CH2 sequence derived from a human IgGl, human IgG2 or human IgG4 CH2 region, and part or all of a CH3 sequence derived from a human IgGl, human IgG2 or human IgG4.
  • a chimeric Fc domain can also contain a chimeric hinge region.
  • a chimeric hinge may comprise an “upper hinge” sequence, derived from a human IgGl, a human IgG2 or a human IgG4 hinge region, combined with a “lower hinge” sequence, derived from a human IgGl, a human IgG2 or a human IgG4 hinge region.
  • a particular example of a chimeric Fc domain that can be included in any of the antigen-binding molecules set forth herein comprises, from N- to C-terminus: [IgG4 CHI] - [IgG4 upper hinge] - [IgG2 lower hinge] - [IgG4 CH2] - [IgG4 CH3],
  • Another example of a chimeric Fc domain that can be included in any of the antigen-binding molecules set forth herein comprises, from N- to C-terminus: [IgGl CHI] - [IgGl upper hinge] - [IgG2 lower hinge] - [IgG4 CH2] - [IgGl CH3]
  • These and other examples of chimeric Fc domains that can be included in any of the antigen -binding molecules as described herein are described in US Publication 2014/0243504, published August 28, 2014, which is herein incorporated in its entirety. Chimeric Fc domains having these general structural arrangements, and variants
  • an antibody heavy chain as described herein comprises a heavy chain constant (CH) region that comprises an amino acid sequence at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to any one of SEQ ID NOs: 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, or 802.
  • the heavy chain constant region (CH) region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, or 802.
  • an antibody heavy chain as described herein comprises an Fc domain that comprises an amino acid sequence at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to any one of SEQ ID NOs: 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, or 814.
  • the Fc domain comprises an amino acid sequence selected form the group consisting SEQ ID NOs: 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, or 814.
  • the anti-hCDH15 antibodies disclosed herein may comprise one or more amino acid substitutions, insertions and/or deletions in the framework and/or CDR regions of the heavy chain variable domains as compared to the corresponding germline sequences from which the antibodies were derived.
  • An anti-hCDH15 antibody and antigen-binding fragment thereof as disclosed herein may be derived from any of the amino acid sequences disclosed herein, wherein one or more amino acids within one or more framework and/or CDR regions are mutated to the corresponding residue(s) of the germline sequence from which the antibody was derived, or to the corresponding residue(s) of another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue(s) (such sequence changes are referred to herein collectively as “germline mutations”), and having weak or no detectable binding to a CDH15 antigen.
  • Germline mutations such sequence changes are referred to herein collectively as “germline mutations”
  • an anti-hCDH15 antibody and antigen-binding fragment thereof as disclosed herein may contain any combination of two or more germline mutations within the framework and/or CDR regions, e.g., wherein certain individual residues are mutated to the corresponding residue of a particular germline sequence while certain other residues that differ from the original germline sequence are maintained or are mutated to the corresponding residue of a different germline sequence.
  • an antibody or antigen-binding fragment that contains one or more germline mutations can be tested for one or more desired properties such as, improved binding specificity, weak or reduced binding affinity, improved or enhanced pharmacokinetic properties, reduced immunogenicity, etc.
  • an antibody or antigen-binding fragment as described herein is obtained in this general manner.
  • anti-hCDH15 antibodies and antigen-binding fragments thereof comprising variants of any of the HCVR, LCVR, and/or CDR amino acid sequences disclosed herein having one or more conservative substitutions.
  • an anti-hCDH15 antibody or antigen-binding fragment thereof as described herein may comprise HCVR, LCVR, and/or CDR amino acid sequences with, e.g., 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc. conservative amino acid substitutions relative to any of the HCVR, LCVR, and/or CDR amino acid sequences set forth in Table 1 herein.
  • An antibody and antigen-binding fragment thereof as described herein may comprise one or more amino acid substitutions, insertions and/or deletions in the framework and/or CDR regions of the heavy and light chain variable domains as compared to the corresponding germline sequences from which the individual antigen-binding domains were derived, while maintaining or improving the desired weak-to-no detectable binding to, e.g., CDH15.
  • a “conservative amino acid substitution” is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (e.g, charge or hydrophobicity).
  • a conservative amino acid substitution will not substantially change the functional properties of a protein, i.e., the amino acid substitution maintains or improves the desired weak to no detectable binding affinity in the case of anti-hCDH15 binding molecules.
  • groups of amino acids that have side chains with similar chemical properties include (1) aliphatic side chains: glycine, alanine, valine, leucine and isoleucine; (2) aliphatic-hydroxyl side chains: serine and threonine; (3) amide- containing side chains: asparagine and glutamine; (4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; (5) basic side chains: lysine, arginine, and histidine; (6) acidic side chains: aspartate and glutamate, and (7) sulfur-containing side chains are cysteine and methionine.
  • Preferred conservative amino acids substitution groups are: valine-leucine- isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamate-aspartate, and asparagine-glutamine.
  • a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) Science 256: 1443- 1445.
  • a “moderately conservative” replacement is any change having a nonnegative value in the PAM250 log-likelihood matrix.
  • anti-hCDH15 antibodies and antigen-binding fragments thereof comprising an antigen-binding domain with an HCVR and/or CDR amino acid sequence that is substantially identical to any of the HCVR and/or CDR amino acid sequences disclosed herein, while maintaining or improving the desired weak affinity to CDH15 antigen.
  • substantially identical when referring to an amino acid sequence means that two amino acid sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 95% sequence identity, even more preferably at least 98% or 99% sequence identity.
  • residue positions which are not identical differ by conservative amino acid substitutions.
  • the percent sequence identity or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well-known to those of skill in the art. See, e.g., Pearson (1994) Methods Mol. Biol. 24: 307-331.
  • Sequence similarity for polypeptides is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions.
  • GCG software contains programs such as Gap and Bestfit which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms or between a wild type protein and a mutein thereof. See, e.g, GCG Version 6.1. Polypeptide sequences also can be compared using FASTA using default or recommended parameters, a program in GCG Version 6.1.
  • FASTA e.g., FASTA2 and FASTA3
  • FASTA2 and FASTA3 provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson (2000) supra).
  • Another preferred algorithm when comparing a sequence as described herein to a database containing a large number of sequences from different organisms is the computer program BLAST, especially BLASTP or TBLASTN, using default parameters. See, e.g., Altschul et al. (1990) J. Mol. Biol. 215:403-410 and Altschul et al. (1997) Nucleic Acids Res. 25:3389-402.
  • antigen-binding domains that contain one or more germline mutations were tested for decreased binding affinity utilizing one or more in vitro assays.
  • antibodies that recognize a particular antigen are typically screened for their purpose by testing for high (i.e. strong) binding affinity to the antigen.
  • binding in the context of the binding of an antibody, immunoglobulin, antibody-binding fragment, or Fc-containing protein to either, e.g., a predetermined antigen, such as a cell surface protein or fragment thereof, typically refers to an interaction or association between a minimum of two entities or molecular structures, such as an antibody-antigen interaction.
  • binding affinity typically corresponds to a KD value of about 10' 7 M or less, such as about 10' 8 M or less, such as about 10' 9 M or less when determined by, for instance, surface plasmon resonance (SPR) technology in a BIAcore 3000 instrument using the antigen as the ligand and the antibody, Ig, antibody -binding fragment, or Fc-containing protein as the analyte (or antiligand).
  • SPR surface plasmon resonance
  • FACS fluorescent-activated cell sorting
  • an anti-hCDH15 antibody and antigen-binding fragment thereof as described herein bind to the predetermined antigen or cell surface molecule (receptor) having an affinity corresponding to a KD value that is at least ten-fold lower than its affinity for binding to a non-specific antigen (e.g., BSA, casein).
  • a non-specific antigen e.g., BSA, casein.
  • the affinity of an antibody corresponding to a KD value that is equal to or less than ten-fold lower than a non-specific antigen may be considered non- detectable binding, however such an antibody may be paired with a second antigen binding arm for the production of a bispecific antibody as described herein.
  • KD KD in molar
  • M the dissociation equilibrium constant of a particular antibody-antigen interaction, or the dissociation equilibrium constant of an antibody or antibody-binding fragment binding to an antigen.
  • KD KD
  • binding affinity There is an inverse relationship between KD and binding affinity, therefore the smaller the KD value, the higher, i.e. stronger, the affinity.
  • higher affinity or “stronger affinity” relate to a higher ability to form an interaction and therefore a smaller KD value
  • lower affinity or “weaker affinity” relate to a lower ability to form an interaction and therefore a larger KD value.
  • a higher binding affinity (or KD) of a particular molecule (e.g. antibody) to its interactive partner molecule (e.g. antigen X) compared to the binding affinity of the molecule (e.g. antibody) to another interactive partner molecule (e.g. antigen Y) may be expressed as a binding ratio determined by dividing the larger KD value (lower, or weaker, affinity) by the smaller KD (higher, or stronger, affinity), for example expressed as 5-fold or 10- fold greater binding affinity, as the case may be.
  • kd (sec -1 or 1/s) refers to the dissociation rate constant of a particular antibody-antigen interaction, or the dissociation rate constant of an antibody or antibody -binding fragment. Said value is also referred to as the k o ff value.
  • k a (M-l x sec-1 or 1/M) refers to the association rate constant of a particular antibody-antigen interaction, or the association rate constant of an antibody or antibody-binding fragment.
  • KA (M-l or 1/M) refers to the association equilibrium constant of a particular antibody-antigen interaction, or the association equilibrium constant of an antibody or antibody-binding fragment. The association equilibrium constant is obtained by dividing the k a by the ka.
  • EC50 refers to the half maximal effective concentration, which includes the concentration of an antibody which induces a response halfway between the baseline and maximum after a specified exposure time.
  • the EC50 essentially represents the concentration of an antibody where 50% of its maximal effect is observed.
  • the EC50 value equals the concentration of an antibody as described herein that gives half-maximal binding to cells expressing CDH15, as determined by e.g. a FACS binding assay or an androgen receptor activation luciferase assay. Thus, reduced or weaker binding is observed with an increased EC50, or half maximal effective concentration value.
  • decreased binding can be defined as an increased EC50 antibody concentration which may result in binding to the half-maximal amount of target cells.
  • an antigen-binding protein e.g., an antibody or antigenbinding fragment thereof, that binds CDH15-expressing cells with a single digit nM or triple digit pM KD, as measured by surface plasmon resonance, or equivalent assay.
  • an antigen-binding protein e.g., antibody or antigen-binding fragment thereof, that binds CDH15-expressing cells with an EC50 of greater than 100 nM as measured by FACS analysis.
  • an antigen-binding protein e.g., antibody or antigen-binding fragment thereof, that binds and is internalized into CDH15-expressing cells upon binding to CDH15.
  • an antigen-binding protein e.g., antibody or antigen-binding fragment thereof, that binds to and blocks the activity of CDH15.
  • An anti-hCACNGl antibody and antigen-binding fragment as described herein may comprise one or more amino acid substitutions, insertions and/or deletions in the framework and/or CDR regions of the heavy and light chain variable domains as compared to the corresponding germline sequences from which the individual antigen-binding domains were derived.
  • Such mutations can be readily ascertained by comparing the amino acid sequences disclosed herein to germline sequences available from, for example, public antibody sequence databases.
  • the antigen-binding molecules as described herein may comprise antigen-binding domains which are derived from any of the example amino acid sequences disclosed herein, wherein one or more amino acids within one or more framework and/or CDR regions are mutated to the corresponding residue(s) of the germline sequence from which the antibody was derived, or to the corresponding residue(s) of another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue(s) (such sequence changes are referred to herein collectively as “germline mutations”).
  • germline mutations such sequence changes are referred to herein collectively as “germline mutations”.
  • all of the framework and/or CDR residues within the VH and/or VL domains are mutated back to the residues found in the original germline sequence from which the antigen-binding domain was originally derived.
  • only certain residues are mutated back to the original germline sequence, e.g., only the mutated residues found within the first 8 amino acids of FR1 or within the last 8 amino acids of FR4, or only the mutated residues found within CDR1, CDR2 or CDR3.
  • one or more of the framework and/or CDR residue(s) are mutated to the corresponding residue(s) of a different germline sequence (z.e., a germline sequence that is different from the germline sequence from which the antigen-binding domain was originally derived).
  • the antigen-binding domains may contain any combination of two or more germline mutations within the framework and/or CDR regions, e.g., wherein certain individual residues are mutated to the corresponding residue of a particular germline sequence while certain other residues that differ from the original germline sequence are maintained or are mutated to the corresponding residue of a different germline sequence.
  • antigenbinding domains that contain one or more germline mutations can be easily tested for one or more desired property such as, improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as the case may be), reduced immunogenicity, etc.
  • desired property such as, improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as the case may be), reduced immunogenicity, etc.
  • antigen-binding molecules comprising one or more antigen-binding domains obtained in this general manner.
  • antigen-binding molecules wherein one or both antigenbinding domains comprise variants of any of the HCVR, LCVR, and/or CDR amino acid sequences disclosed herein having one or more conservative substitutions.
  • antigenbinding molecules as described herein may comprise an antigen-binding domain having HCVR, LCVR, and/or CDR amino acid sequences with, e.g., 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc. conservative amino acid substitutions relative to any of the HCVR, LCVR, and/or CDR amino acid sequences disclosed herein.
  • a “conservative amino acid substitution” is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein.
  • Examples of groups of amino acids that have side chains with similar chemical properties include (1) aliphatic side chains: glycine, alanine, valine, leucine and isoleucine; (2) aliphatic-hydroxyl side chains: serine and threonine; (3) amide-containing side chains: asparagine and glutamine; (4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; (5) basic side chains: lysine, arginine, and histidine; (6) acidic side chains: aspartate and glutamate, and (7) sulfur-containing side chains are cysteine and methionine.
  • Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamate-aspartate, and asparagine-glutamine.
  • a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) Science 256: 1443-1445, herein incorporated by reference.
  • a “moderately conservative” replacement is any change having a nonnegative value in the PAM250 log-likelihood matrix.
  • Antigen-binding molecules as described herein may comprise an antigen-binding domain with an HCVR, LCVR, and/or CDR amino acid sequence that is substantially identical to any of the HCVR, LCVR, and/or CDR amino acid sequences disclosed herein.
  • the term “substantial identity” or “substantially identical,” when referring to an amino acid sequence means that two amino acid sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 95% sequence identity, even more preferably at least 98% or 99% sequence identity.
  • residue positions which are not identical differ by conservative amino acid substitutions.
  • sequence identity or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well-known to those of skill in the art. See, e.g., Pearson (1994) Methods Mol. Biol. 24: 307-331, herein incorporated by reference.
  • Sequence similarity for polypeptides which is also referred to as sequence identity, is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions.
  • GCG software contains programs such as Gap and Bestfit which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms or between a wild type protein and a mutein thereof. See, e.g, GCG Version 6.1. Polypeptide sequences also can be compared using FASTA using default or recommended parameters, a program in GCG Version 6.1. FASTA (e.g, FASTA2 and FASTA3) provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson (2000) supra).
  • BLAST Altschul et al. (1990) J. Mol. Biol. 215:403-410 and Altschul et al. (1997) Nucleic Acids Res. 25:3389-402, each herein incorporated by reference. pH-Dependent Binding
  • anti-hCDH15 antibodies and antigen-binding fragments thereof with pH-dependent binding characteristics may exhibit reduced binding to CDH15 at acidic pH as compared to neutral pH.
  • anti-hCDH15 antibodies as described herein may exhibit enhanced binding to CDH15 at acidic pH as compared to neutral pH.
  • the expression “acidic pH” includes pH values less than about 6.2, e.g., about 6.0, 5.95, 5,9, 5.85, 5.8, 5.75, 5.7, 5.65, 5.6, 5.55, 5.5, 5.45, 5.4, 5.35, 5.3, 5.25, 5.2, 5.15, 5.1, 5.05, 5.0, or less.
  • neutral pH means a pH of about 7.0 to about 7.4.
  • neutral pH includes pH values of about 7.0, 7.05, 7.1, 7.15, 7.2, 7.25, 7.3, 7.35, and 7.4.
  • “reduced binding ... at acidic pH as compared to neutral pH” is expressed in terms of a ratio of the KD value of the antibody binding to its antigen at acidic pH to the KD value of the antibody binding to its antigen at neutral pH (or vice versa).
  • an antibody or antigen-binding fragment thereof may be regarded as exhibiting “reduced binding to CACNG1 at acidic pH as compared to neutral pH” for purposes of the description herein if the antibody or antigen-binding fragment thereof exhibits an acidic/neutral KD ratio of about 3.0 or greater.
  • the acidic/neutral KD ratio for an antibody or antigen-binding fragment as described herein can be about 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 20.0. 25.0, 30.0, 40.0, 50.0, 60.0, 70.0, 100.0 or greater.
  • Antibodies with pH-dependent binding characteristics may be obtained, e.g. , by screening a population of antibodies for reduced (or enhanced) binding to a particular antigen at acidic pH as compared to neutral pH. Additionally, modifications of the antigen-binding domain at the amino acid level may yield antibodies with pH-dependent characteristics. For example, by substituting one or more amino acids of an antigen-binding domain (e.g., within a CDR) with a histidine residue, an antibody with reduced antigen-binding at acidic pH relative to neutral pH may be obtained.
  • an anti-hCDH15 antibody and antigen-binding fragment thereof comprising an Fc domain comprising one or more mutations which enhance or diminish antibody binding to the FcRn receptor, e.g., at acidic pH as compared to neutral pH.
  • antibodies as described herein may comprise a mutation in the CH2 or a CH3 region of the Fc domain, wherein the mutation(s) increases the affinity of the Fc domain to FcRn in an acidic environment (e.g., in an endosome where pH ranges from about 5.5 to about 6.0).
  • Such mutations may result in an increase in serum half-life of the antibody when administered to an animal.
  • Fc modifications include, e.g., a modification at position 250 (e.g., E or Q); 250 and 428 (e.g., L or F); 252 (e.g., L/Y/F/W or T), 254 (e.g., S or T), and 256 (e.g., S/R/Q/E/D or T); or a modification at position 428 and/or 433 (e.g., H/L/R/S/P/Q or K) and/or 434 (e.g., H/F or Y); or a modification at position 250 and/or 428; or a modification at position 307 or 308 (e.g., 308F, V308F), and 434.
  • a modification at position 250 e.g., E or Q
  • 250 and 428 e.g., L or F
  • 252 e.g., L/
  • the modification comprises a 428L (e.g., M428L) and 434S (e.g., N434S) modification; a 428L, 2591 (e.g., V259I), and 308F (e.g, V308F) modification; a 433K (e.g., H433K) and a 434 (e.g., 434Y) modification; a 252, 254, and 256 (e.g., 252Y, 254T, and 256E) modification; a 250Q and 428L modification (e.g., T250Q and M428L); and a 307 and/or 308 modification (e.g, 308F or 308P).
  • a 428L e.g., M428L
  • 434S e.g., N434S
  • 428L, 2591 e.g., V259I
  • 308F e.g, V308F
  • 433K e.
  • an anti-hCDH15 antibody and antigen-binding fragment as described herein may comprise an Fc domain comprising one or more pairs or groups of mutations selected from the group consisting of: 250Q and 248L (e.g., T250Q and M248L);
  • 252Y, 254T and 256E e.g., M252Y, S254T and T256E
  • 428L and 434S e.g., M428L and N434S
  • 433K and 434F e.g, H433K and N434F
  • an antibody and antigen-binding fragment thereof that binds human CDH15 with high, medium or low affinity, depending on the therapeutic context and particular targeting properties that are desired.
  • a target antigen e.g., a tumor associated antigen
  • preferential targeting of the antigen-binding molecule to cells expressing the target antigen may be achieved while avoiding general/untargeted CDH15 binding and the consequent adverse side effects associated therewith.
  • antibodies, antigen-binding fragments, and bispecific antibodies thereof that bind human CDH15 with weak (i.e. low) or even no detectable affinity.
  • an antibody and antigen-binding fragment thereof as described herein binds human CDH15 (e.g., at 37°C) with a KD of greater than about 100 nM as measured by surface plasmon resonance.
  • an antibody or antigen-binding fragment as described herein binds CDH15 with a KD of greater than about greater than about 110 nM, at least 120 nM, greater than about 130 nM, greater than about 140 nM, greater than about 150 nM, at least 160 nM, greater than about 170 nM, greater than about 180 nM, greater than about 190 nM, greater than about 200 nM, greater than about 250 nM, greater than about 300 nM, greater than about 400 nM, greater than about 500 nM, greater than about 600 nM, greater than about 700 nM, greater than about 800 nM, greater than about 900 nM, or greater than about 1 pM, or with no detectable affinity, as measured by surface plasmon resonance (e.g., mAb-capture or antigencapture format), or a substantially similar assay.
  • surface plasmon resonance e.g., mAb-capture or antigencapture format
  • the epitope on CDH15 to which an anti-hCDH15 antibody and antigen-binding fragment thereof as described herein may consist of a single contiguous sequence of 3 or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more) amino acids of a CDH15 protein.
  • the epitope may consist of a plurality of non-contiguous amino acids (or amino acid sequences) of CDH15.
  • epitope refers to an antigenic determinant that interacts with a specific antigen binding site in the variable region of an antibody molecule known as a paratope.
  • a single antigen may have more than one epitope.
  • Epitopes may be either conformational or linear.
  • a conformational epitope is produced by spatially juxtaposed amino acids from different segments of the linear polypeptide chain.
  • a linear epitope is one produced by adjacent amino acid residues in a polypeptide chain.
  • an epitope may include moieties of saccharides, phosphoryl groups, or sulfonyl groups on the antigen.
  • Another method that can be used to identify the amino acids within a polypeptide with which an antigen-binding domain of an antibody interacts is hydrogen/deuterium exchange detected by mass spectrometry.
  • the hydrogen/deuterium exchange method involves deuterium-labeling the protein of interest, followed by binding the antibody to the deuterium-labeled protein. Next, the protein/antibody complex is transferred to water to allow hydrogen-deuterium exchange to occur at all residues except for the residues protected by the antibody (which remain deuterium- labeled).
  • the target protein After dissociation of the antibody, the target protein is subjected to protease cleavage and mass spectrometry analysis, thereby revealing the deuterium-labeled residues which correspond to the specific amino acids with which the antibody interacts. See, e.g., Ehring (1999) Analytical Biochemistry 262(2y.252-25 Engen and Smith (2001) Anal. Chem. 73:256A- 265A. X-ray crystallography of the antigen/antibody complex may also be used for epitope mapping purposes.
  • anti-hCDHl 5 antibodies that bind to the same epitope as any of the specific example antibodies described herein (e.g., antibodies comprising any of the amino acid sequences as set forth in Table 1 herein).
  • anti-hCDH15 antibodies that compete for binding to CDH15 with any of the specific example antibodies described herein (e.g., antibodies comprising any of the amino acid sequences as set forth in Table 1 herein).
  • One can easily determine whether a particular antigen-binding molecule e.g., antibody
  • antigen-binding domain thereof binds to the same epitope as, or competes for binding with, a reference antigen-binding molecule as described herein by using routine methods known in the art. For example, to determine if a test antibody binds to the same epitope on CDH15 as a reference bispecific antigen-binding molecule as described herein, the reference bispecific molecule is first allowed to bind to a CDH15 protein. Next, the ability of a test antibody to bind to the CDH15 molecule is assessed.
  • a particular antigen-binding molecule e.g., antibody
  • antigen-binding domain thereof binds to the same epitope as, or competes for binding with, a reference antigen-binding molecule as described herein by using routine methods known in the art. For example, to determine if a test antibody binds to the same epitope on CDH15 as a reference bi
  • test antibody If the test antibody is able to bind to CDH15 following saturation binding with the reference bispecific antigen-binding molecule, it can be concluded that the test antibody binds to a different epitope of CDH15 than the reference bispecific antigen-binding molecule. On the other hand, if the test antibody is not able to bind to the CDH15 molecule following saturation binding with the reference bispecific antigen-binding molecule, then the test antibody may bind to the same epitope of CDH15 as the epitope bound by the reference bispecific antigen-binding molecule as described herein.
  • Additional routine experimentation e.g., peptide mutation and binding analyses
  • peptide mutation and binding analyses can then be carried out to confirm whether the observed lack of binding of the test antibody is in fact due to binding to the same epitope as the reference bispecific antigen-binding molecule or if steric blocking (or another phenomenon) is responsible for the lack of observed binding.
  • steric blocking or another phenomenon
  • this sort can be performed using ELISA, RIA, Biacore, flow cytometry or any other quantitative or qualitative antibody-binding assay available in the art.
  • two antigen-binding proteins bind to the same (or overlapping) epitope if, e.g., a 1-, 5-, 10-, 20- or 100-fold excess of one antigen-binding protein inhibits binding of the other by at least 50% but preferably 75%, 90% or even 99% as measured in a competitive binding assay (see, e.g., Junghans et al., Cancer Res. 1990:50: 1495-1502).
  • two antigen-binding proteins are deemed to bind to the same epitope if essentially all amino acid mutations in the antigen that reduce or eliminate binding of one antigen-binding protein reduce or eliminate binding of the other.
  • Two antigen-binding proteins are deemed to have “overlapping epitopes” if only a subset of the amino acid mutations that reduce or eliminate binding of one antigenbinding protein reduce or eliminate binding of the other.
  • an antibody or antigen-binding domain thereof competes for binding with a reference antigen-binding molecule
  • the above-described binding methodology is performed in two orientations: In a first orientation, the reference antigen-binding molecule is allowed to bind to a CDH15 protein under saturating conditions followed by assessment of binding of the test antibody to the CDH15 molecule. In a second orientation, the test antibody is allowed to bind to a CDH15 molecule under saturating conditions followed by assessment of binding of the reference antigen-binding molecule to the CDH15 molecule.
  • an antibody that competes for binding with a reference antigen-binding molecule may not necessarily bind to the same epitope as the reference antibody, but may sterically block binding of the reference antibody by binding an overlapping or adjacent epitope.
  • Antigen-binding domains specific for particular antigens can be prepared by any antibody generating technology known in the art. Once obtained, two different antigen-binding domains, specific for two different antigens (e.g., CDH15 and a target antigen), can be appropriately arranged relative to one another to produce a bispecific antigen-binding molecule as described herein using routine methods. (A discussion of example bispecific antibody formats that can be used to construct the bispecific antigen-binding molecules as described herein is provided elsewhere herein).
  • one or more of the individual components (e.g., heavy and light chains) of the antigen-binding molecules as described herein are derived from chimeric, humanized or fully human antibodies. Methods for making such antibodies are well known in the art.
  • one or more of the heavy and/or light chains of the antigenbinding molecules as described herein can be prepared using VELOCIMMUNETM technology. Using VELOCIMMUNETM technology (or any other human antibody generating technology), high affinity chimeric antibodies to a particular antigen (e.g., CDH15) are initially isolated having a human variable region and a mouse constant region. The antibodies are characterized and selected for desirable characteristics, including affinity, selectivity, epitope, etc. The mouse constant regions are replaced with a desired human constant region to generate fully human heavy and/or light chains that can be incorporated into the antigen-binding molecules as described herein.
  • Genetically engineered animals may be used to make human bispecific antigenbinding molecules.
  • a genetically modified mouse can be used which is incapable of rearranging and expressing an endogenous mouse immunoglobulin light chain variable sequence, wherein the mouse expresses only one or two human light chain variable domains encoded by human immunoglobulin sequences operably linked to the mouse kappa constant gene at the endogenous mouse kappa locus.
  • Such genetically modified mice can be used to isolate heavy chain and light chain variable regions to produce fully human bispecific antigen-binding molecules.
  • the fully human bispecific antigen-binding molecules comprise two different heavy chains that associate with the same light chain. See, e.g., US 2011/0195454).
  • Fully human refers to an antibody, or antigen-binding fragment or immunoglobulin domain thereof, comprising an amino acid sequence encoded by a DNA derived from a human sequence over the entire length of each polypeptide of the antibody or antigen-binding fragment or immunoglobulin domain thereof.
  • the fully human sequence is derived from a protein endogenous to a human.
  • the fully human protein or protein sequence comprises a chimeric sequence wherein each component sequence is derived from human sequence. While not being bound by any one theory, chimeric proteins or chimeric sequences are generally designed to minimize the creation of immunogenic epitopes in the junctions of component sequences, e.g. compared to any wild-type human immunoglobulin regions or domains.
  • Bispecific antigen-binding molecules may be constructed with one heavy chain having a modified Fc domain that abrogates its binding to Protein A, thus enabling a purification method that yields a heterodimeric protein. See, for example, US Patent No. 8,586,713.
  • the bispecific antigen-binding molecules comprise a first CH3 domain and a second Ig CH3 domain, wherein the first and second Ig CH3 domains differ from one another by at least one amino acid, and wherein at least one amino acid difference reduces binding of the bispecific antibody to Protein A as compared to a bi-specific antibody lacking the amino acid difference.
  • the first Ig CH3 domain binds Protein A and the second Ig CH3 domain contains a mutation/modification that reduces or abolishes Protein A binding such as an H95R modification (by IMGT exon numbering; H435R by EU numbering).
  • the second CH3 may further comprise a Y96F modification (by IMGT; Y436F by EU).
  • Antigen-binding molecules having amino acid sequences that vary from those of the example molecules disclosed herein but that retain the ability to bind CDH15 are also described herein. Such variant molecules may comprise one or more additions, deletions, or substitutions of amino acids when compared to parent sequence, but exhibit biological activity that is essentially equivalent to that of the described bispecific antigen-binding molecules.
  • Antigen-binding molecules that are bioequivalent to any of the example antigenbinding molecules set forth herein are also described. Two antigen-binding proteins, or antibodies, are considered bioequivalent if, for example, they are pharmaceutical equivalents or pharmaceutical alternatives whose rate and extent of absorption do not show a significant difference when administered at the same molar dose under similar experimental conditions, either single dose or multiple doses.
  • antigen-binding proteins will be considered equivalents or pharmaceutical alternatives if they are equivalent in the extent of their absorption but not in their rate of absorption and yet may be considered bioequivalent because such differences in the rate of absorption are intentional and are reflected in the labeling, are not essential to the attainment of effective body drug concentrations on, e.g., chronic use, and are considered medically insignificant for the particular drug product studied.
  • two antigen-binding proteins are bioequivalent if there are no clinically meaningful differences in their safety, purity, and potency. [00191] In one embodiment, two antigen-binding proteins are bioequivalent if a patient can be switched one or more times between the reference product and the biological product without an expected increase in the risk of adverse effects, including a clinically significant change in immunogenicity, or diminished effectiveness, as compared to continued therapy without such switching.
  • two antigen-binding proteins are bioequivalent if they both act by a common mechanism or mechanisms of action for the condition or conditions of use, to the extent that such mechanisms are known.
  • Bioequivalence may be demonstrated by in vivo and in vitro methods.
  • Bioequivalence measures include, e.g., (a) an in vivo test in humans or other mammals, in which the concentration of the antibody or its metabolites is measured in blood, plasma, serum, or other biological fluid as a function of time; (b) an in vitro test that has been correlated with and is reasonably predictive of human in vivo bioavailability data; (c) an in vivo test in humans or other mammals in which the appropriate acute pharmacological effect of the antibody (or its target) is measured as a function of time; and (d) in a well-controlled clinical trial that establishes safety, efficacy, or bioavailability or bioequivalence of an antigen-binding protein.
  • Bioequivalent variants of the example bispecific antigen-binding molecules set forth herein may be constructed by, for example, making various substitutions of residues or sequences or deleting terminal or internal residues or sequences not needed for biological activity.
  • cysteine residues not essential for biological activity can be deleted or replaced with other amino acids to prevent formation of unnecessary or incorrect intramolecular disulfide bridges upon renaturation.
  • bioequivalent antigen-binding proteins may include variants of the example bispecific antigen-binding molecules set forth herein comprising amino acid changes which modify the glycosylation characteristics of the molecules, e.g., mutations which eliminate or remove glycosylation.
  • antigen-binding proteins e.g., antibodies or antigenbinding fragments thereof, such as anti-hCDH15 antibodies, comprising a modified glycosylation pattern.
  • modification to remove undesirable glycosylation sites may be useful, or an antibody lacking a fucose moiety present on the oligosaccharide chain, for example, to increase antibody dependent cellular cytotoxicity (ADCC) function (see Shields et al. (2002) JBC 277:26733), where cytotoxicity is desirable.
  • ADCC antibody dependent cellular cytotoxicity
  • modification of galactosylation can be made in order to modify complement dependent cytotoxicity (CDC).
  • antigen-binding molecules as described herein bind to human CDH15 but not to CDH15 from other species. Also described herein are antigen-binding molecules that bind to human CDH15 and to CDH15 from one or more non-human species.
  • antigen-binding molecules as described herein that bind to human CDH15 may bind, or not bind, as the case may be, to one or more of mouse, rat, guinea pig, hamster, gerbil, pig, cat, dog, rabbit, goat, sheep, cow, horse, camel, cynomolgus, marmoset, rhesus or chimpanzee CDH15.
  • ADCs Antibody-Drug Conjugates
  • ADCs antibody-drug conjugates
  • a payload e.g., a drug or molecular cargo, (e.g., a small molecule and/or therapeutic moiety, etc.).
  • ADCs comprise: A - [L - P] y , in which A is an antigen-binding molecule, e.g.
  • an anti-hCDH15 antibody or a fragment thereof (e.g., a fragment comprising at least a HCDR3 selected from any of the HCDR3 amino acid sequences listed in Table 1)
  • L is a linker
  • P is the payload or molecular cargo
  • y is an integer from 1 to 30.
  • the ADC comprises an anti-hCDH15 antibody or antigen-binding fragment thereof that comprises the CDRs of a HCVR or a LCVR having the amino acid sequences of the SEQ ID NOs set forth in Table 1 (e.g., SEQ ID NOs: 2, 22, 42, 60, 70, 80, 90, 108, 125, 145, 165, 185, 202, 220, 230, 240, 250, 259, 279, 299, 319, 339, 358, 378, 386, 404, 420, 436, 452, 468, 484, 500, 516, 532, 548, 564, 580, 596, 612, 628, 644, 660, 676, 692, 708, 724, 740, 748, 764, and 780; or 10, 30, 50, 50, 50, 50, 50, 98, 115, 133, 153, 173, 193, 210, 50, 50, 50, 50, 267, 2
  • the anti-hCDH15 antibody or fragment comprises CDRs with the amino acid sequences of the SEQ ID NOs set forth in Table 1 e.g., SEQ ID NOs: 4-6-8-12-14-16, 24-26-28-32-34-36, 44-46-48-52-34-54, 62- 64-66-52-34-54, 72-74-76-52-34-54, 82-84-86-52-34-54, 92-94-96-100-34-102, 82-111-113- 117-34-119, 127-129-131-135-137-139, 147-149-151-155-157-159, 167-169-171-175-177-179, 187-189-191-52-34-196, 204-206-208-212-137-214, 222-224-226-52-34-54, 232-234-236-52- 34-54, 242-244-246-52-34-54, 82-253-255-52-34-54, 261-263-265-269-271-273, 281-283
  • the anti-hCDH15 antibody or fragment comprises a HCVR and a LCVR having the amino acid sequences of the SEQ ID NOs set forth in Table 1 (e.g., SEQ ID NOs: : 2, 22, 42, 60, 70, 80, 90, 108, 125, 145, 165, 185, 202, 220, 230, 240, 250, 259, 279, 299, 319, 339, 358, 378, 386, 404, 420, 436, 452, 468, 484, 500, 516, 532, 548, 564, 580, 596, 612, 628, 644, 660, 676, 692, 708, 724, 740, 748, 764, and 780; and 10, 30, 50, 50, 50, 50, 50, 98, 115, 133, 153, 173, 193, 210, 50, 50, 50, 50, 267, 287, 307, 327, 347, 366, 50, 394,
  • the payload or molecular cargo comprises a small molecule as a therapeutic agent, e.g., a therapeutic agent that may be useful for treating muscle wasting or genetic muscle diseases and/or muscle-related cancer.
  • a small molecule can enter cells easily because it has a low molecular weight (typically, up to about 1 kDa). Once inside the cells, the small molecule can affect other molecules, such as proteins, and may, for example, cause cancer cells to die. This is different from many large molecular weight molecules such as antibodies.
  • An example, of a small molecule may be conjugated to an anti- CDH15 antigen-binding protein, to form an anti-CDH15:SM conjugate.
  • Therapeutic agents that may be useful for treating muscle wasting or genetic muscle diseases include testosterone and biologically active variants thereof, (e.g., dihydrotestosterone (DHT)), 02-adrenergic receptor agonists (e.g., clenbuterol), rapamycin or its analogs, MAPK inhibitors, or histone deacetylase inhibitors, etc.
  • DHT dihydrotestosterone
  • clenbuterol e.g., clenbuterol
  • rapamycin or its analogs e.g., clenbuterol
  • MAPK inhibitors e.g., rapamycin or its analogs
  • histone deacetylase inhibitors e.g., histone deacetylase inhibitors, etc.
  • the therapeutic payload is testosterone, or a biologically active derivative and/or portion thereof, e.g., dihydrotestosterone.
  • the therapeutic payload is rapamycin or analogs thereof, a MAPK inhibitor, a histone deacetylase inhibitor, or a Notch ligand.
  • the payload is a chemotherapeutic e.g., a cytotoxic drug.
  • Therapeutic agents that may be useful for treating muscle-related cancer include any chemotherapeutic agents known to delay, halt and/or destroy cancerous cells.
  • therapeutic agents include, but are not limited to, Aflibercept, Amsacrine, Azacitidine, Azathioprine, Belantamab mafodotin, Bendamustine, Bleomycin, Bortezomib, Brentuximab vedotin, Busulfan, Cabazitaxel, Capecitabine, Carboplatin, Carfilzomib, Carmustine, Chlorambucil, Cisplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Cytarabine liposomal, dacarbazine, Dactinomycin (actinomycin D), Daunorubicin, Docetaxel, Doxorubicin, Doxorubicin liposomal, Epirubicin,
  • Inotuzumab ozogamicin Irinotecan, Ixazomib, Lomustine, Melphalan, Mercaptopurine, Methotrexate, Mitomycin, Mitotane, Mitozantrone, Nab-paclitaxel, Oxaliplatin, Paclitaxel, Pemetrexed, Pegaspargase, Polatuzumab vedotin, Pralatrexate, Procarbazine, Raltitrexed, Romidepsin, Sacituzumab govitecan, Temozolomide, Teniposide, Thiotepa, Tioguanine, Topotecan, Trabectedin, Trastuzumab deruxtecan, Trastuzumab emtansine, Trifluridine/tipiracil, Valganciclovir, Vinblastine, Vincristine, Vindesine, Vinflunine, Vinorelbine, or Vismodegib.
  • ARCs antibody-radionuclide conjugates
  • radionuclides that can be used in the context of this aspect of the disclosure include, but are not limited to, e.g, 225 Ac, 212 Bi, 213 Bi, 131 I, 186 Re, 227 Th, 222 Rn, 223 Ra, 224 Ra, and 90 Y.
  • ADCs comprising, e.g, an anti-hCDH15 antigen-binding protein conjugated to a therapeutic agent e.g., any of the therapeutic agents disclosed above) via a linker molecule.
  • Linkers are any group or moiety that links, connects, or bonds the antibody or antigen-binding proteins described herein with a therapeutic moiety, e.g. cytotoxic agent. Suitable linkers may be found, for example, in Antibody-Drug Conjugates and Immunotoxins,' Phillips, G.
  • suitable binding agent linkers for the antibody conjugates described herein are those that are sufficiently stable to exploit the circulating half-life of the antibody and, at the same time, capable of releasing its payload after antigen-mediated internalization of the conjugate.
  • Linkers can be cleavable or non-cleavable.
  • Cleavable linkers include linkers that are cleaved by intracellular metabolism following internalization, e.g., cleavage via hydrolysis, reduction, or enzymatic reaction.
  • Non-cleavable linkers include linkers that release an attached payload via lysosomal degradation of the antibody following internalization.
  • Suitable linkers include, but are not limited to, acid-labile linkers, hydrolysis-labile linkers, enzymatically cleavable linkers, reduction labile linkers, self-immolative linkers, and non-cleavable linkers.
  • Suitable linkers also include, but are not limited to, those that are or comprise peptides, glucuronides, succinimide-thioethers, polyethylene glycol (PEG) units, hydrazones, mal-caproyl units, dipeptide units, valine-citrulline units, and para-aminobenzyl (PAB) units.
  • PEG polyethylene glycol
  • PAB para-aminobenzyl
  • linker molecule or linker technology known in the art can be used to create or construct an ADC of the present disclosure.
  • the linker is a cleavable linker.
  • the linker is a non-cleavable linker.
  • linkers that can be used in the context of the present disclosure are provided, e.g., in US 7,754,681 and in Ducry, Bioconjugate Chem., 2010, 27:5-13, and the references cited therein, the contents of which are incorporated by reference herein in their entireties.
  • the linkers are stable in physiological conditions.
  • the linkers are cleavable, for instance, able to release at least the payload portion in the presence of an enzyme or at a particular pH range or value.
  • a linker comprises an enzyme-cleavable moiety.
  • Illustrative enzyme-cleavable moieties include, but are not limited to, peptide bonds, ester linkages, hydrazones, and disulfide linkages.
  • the linker comprises a cathepsin-cleavable linker.
  • the linker comprises a non-cleavable moiety.
  • Suitable linkers also include, but are not limited to, those that are chemically bonded to two cysteine residues of a single binding agent, e.g., antibody. Such linkers can serve to mimic the antibody’s disulfide bonds that are disrupted as a result of the conjugation process.
  • the linker comprises one or more amino acids. Suitable amino acids include natural, non-natural, standard, non-standard, proteinogenic, non- proteinogenic, and L- or D- a-amino acids.
  • the linker comprises alanine, valine, glycine, leucine, isoleucine, methionine, tryptophan, phenylalanine, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, or citrulline, a derivative thereof, or combination thereof.
  • one or more side chains of the amino acids is linked to a side chain group, described below.
  • the linker comprises valine and citrulline.
  • the linker comprises lysine, valine, and citrulline.
  • the linker comprises lysine, valine, and alanine. In some embodiments, the linker comprises valine and alanine. [00211] In some embodiments, the linker comprises a self-immolative group.
  • the self- immolative group can be any such group known to those of skill.
  • the self-immolative group is ?-aminobenzyl (PAB), or a derivative thereof. Useful derivatives include /?-aminobenzyloxycarbonyl (PABC).
  • PAB ?-aminobenzyl
  • PABC /?-aminobenzyloxycarbonyl
  • the linker is: wherein is a bond to the antibody or antigen-binding protein (e.g., via lysine residue) and is a bond to the therapeutic payload (e.g., testosterone or a biologically equivalent variant thereof).
  • the linker is: wherein is a bond to the antibody or antigen-binding protein (e.g., via lysine residue) and _ ⁇ P 4 is a bond to a therapeutic payload (e.g. , testosterone or a biologically equivalent variant thereof).
  • the linker is:
  • the linker is:
  • the linker is derived from maleimidylmethyl-4-trans- cyclohexanecarboxy succinate:
  • the linker is: wherein is a bond to the antibody or antigen-binding protein (e.g., via lysine residue) and is a bond to therapeutic payload (e.g. , testosterone or a biologically equivalent variant thereof).
  • the linker is: wherein is a bond to the antibody or antigen-binding protein (e.g, via lysine residue) and
  • the present disclosure comprises ADCs in which a linker connects an anti- hCDH15 antigen-binding protein as described herein to therapeutic agent through an attachment at a particular amino acid within the antibody or antigen-binding molecule.
  • amino acid attachments that can be used in the context of this aspect, e.g., lysine (see, e.g., US 5,208,020; US 2010/0129314; Hollander et al., Bioconjugate Chem., 2008, 19:358-361; WO 2005/089808; US 5,714,586; and US 2013/0101546), cysteine (see, e.g., US 2007/0258987; WO 2013/055993; WO 2013/055990; WO 2013/053873; WO 2013/053872; WO 2011/130598; US 2013/0101546; and US 7,750,116), selenocysteine (see, e.g., WO 2008/12
  • Linkers can also be conjugated to an antigen-binding protein via attachment to carbohydrates (see, e.g., US 2008/0305497, WO 2014/065661, and Ryan et al., Food & Agriculture Immunol., 2001, 13: 127-130) and disulfide linkers (see, e.g., WO 2013/085925, WO 2010/010324, WO 2011/018611, and Shaunak etal., Nat. Chem. Biol., 2006, 2:312-313).
  • Site specific conjugation techniques can also be employed to direct conjugation to particular residues of the antibody or antigen binding protein (see, e.g., Schumacher et al.
  • Site specific conjugation techniques include, but are not limited to glutamine conjugation via transglutaminase (see e.g., Schibli, Angew Chemie Inter Ed. 2010, 49 ,9995).
  • a residue of an antibody as described herein e.g., a residue in a heavy chain constant region of the antibody, may be substituted with a glutamine to further facilitate glutamine conjugation via transglutaminase.
  • a human heavy chain constant region may be modified with the N180Q substitution found in the sequence of the human IgGl heavy chain constant region. Such substitution provides for a total of 4 glutamines for conjugation by transglutaminase.
  • an anti-hCDH15 antigen-binding protein drug conjugate is prepared by contacting an anti-hCDH15 antigen-binding protein as described herein with a compound comprising the desired linker and therapeutic agent, wherein said linker possesses a moiety that is reactive with the antibody or antigen-binding protein, e.g., at the desired residue of the antibody or antigen-binding protein.
  • AAV Adeno-associated viruses
  • AAV is an abbreviation for adeno-associated virus and may be used to refer to the virus itself or derivatives thereof.
  • AAVs are small, non-enveloped, single-stranded DNA viruses.
  • ITR inverted terminal repeats
  • ORFs open reading frames
  • Rep and cap The wildtype rep reading frame encodes four proteins of molecular weight 78 kD (“Rep78”), 68 kD (“Rep68”), 52 kD (“Rep52”) and 40 kD (“Rep 40”).
  • Rep78 and Rep68 are transcribed from the p5 promoter, and Rep52 and Rep40 are transcribed from the pl 9 promoter. These proteins function mainly in regulating the transcription and replication of the AAV genome.
  • the wildtype cap reading frame encodes three structural (capsid) viral proteins (VPs) having molecular weights of 83-85 kD (VP1), 72-73 kD (VP2) and 61-62 kD (VP3). More than 80% of total proteins in an AAV virion (capsid) comprise VP3; in mature virions VP1, VP2 and VP3 are found at relative abundance of approximately 1 : 1 : 10, although ratios of 1 : 1 :8 have been reported. Padron et al. (2005) J. Virology 79:5047-58.
  • AAV encompasses all subtypes and both naturally occurring and modified forms that are well-known in the art.
  • AAV includes primate AAV (e.g, AAV type 1 (AAV1), primate AAV type 2 (AAV2), primate AAV type 3 (AAV3B), primate AAV type 4 (AAV4), primate AAV type 5 (AAV5), primate AAV type 6 (AAV6), primate AAV type 7 (AAV7), primate AAV type 8 (AAV8), primate AAV type 9 (AAV9), AAV10, AAV11, AAV12, AAV13, AAVDJ, Anc80L65, AAV2G9, AAV-LK03, primate AAV type rhlO (AAV rhlO), AAV type hlO (AAV hlO), AAV type hul 1 (AAV hul l), AAV type rh32.33 (AAV rh32.33), AAV retro (A
  • Prime AAV refers to AAV generally isolated from primates.
  • non-primate animal AAV refers to AAV isolated from non-primate animals.
  • “of a [specified] AAV” in relation to a gene e.g., rep, cap, etc.
  • capsid protein e.g., a VP1 capsid protein, a VP2 capsid protein, a VP3 capsid protein, etc.
  • region of a capsid protein of a specified AAV e.g., PLA2 region, VPl-u region, VP1/VP2 common region, VP3 region
  • nucleotide sequence e.g., ITR sequence
  • a cap gene or capsid protein of AAV etc. encompasses, in addition to the gene or the polypeptide respectively comprising a nucleic acid sequence or amino acid sequence set forth herein for the specified AAV, also variants of the gene or polypeptide,
  • a variant gene or a variant polypeptide comprises a nucleic acid sequence or amino acid sequence that differs from the nucleic acid sequence or amino acid sequence set forth herein for the gene or polypeptide of a specified AAV, wherein the difference(s) does not generally alter at least one biological function of the gene or polypeptide, and/or the phylogenetic characterization of the gene or polypeptide, e.g., where the difference(s) may be due to degeneracy of the genetic code, isolate variations, length of the sequence, etc.
  • rep gene and the cap gene as used here may encompass rep and cap genes that differ from the wildtype gene in that the genes may encode one or more Rep proteins and Cap proteins, respectively.
  • a Rep gene encodes at least Rep78 and/or Rep68.
  • cap gene includes those may differ from the wildtype in that one or more alternative start codons or sequences between one or more alternative start codons are removed such that the cap gene encodes only a single Cap protein, e.g, wherein the VP2 and/or VP3 start codons are removed or substituted such that the cap gene encodes a functional VP1 capsid protein but not a VP2 capsid protein or a VP3 capsid protein.
  • a rep gene encompasses any sequence that encodes a functional Rep protein.
  • a cap gene encompasses any sequence that encodes at least one functional cap gene.
  • the wildtype cap gene expresses all three VP1, VP2, and VP3 capsid proteins from a single open reading frame of the cap gene under control of the p40 promoter found in the rep ORF.
  • the term “capsid protein,” “Cap protein” and the like includes a protein that is part of the capsid of the virus.
  • the capsid proteins are generally referred to as VP1, VP2 and/or VP3, and may be encoded by the single cap gene.
  • the three AAV capsid proteins are produced in nature an overlapping fashion from the cap ORF alternative translational start codon usage, although all three proteins use a common stop codon.
  • the ORF of a wildtype cap gene encodes from 5’ to 3’ three alternative start codons: “the VP1 start codon,” “the VP2 start codon,” and “the VP3 start codon”; and one “common stop codon”.
  • the largest viral protein, VP1 is generally encoded from the VP1 start codon to the “common stop codon.”
  • VP2 is generally encoded from the VP2 start codon to the common stop codon.
  • VP3 is generally encoded from the VP3 start codon to the common stop codon.
  • VP1 comprises at its N-terminus sequence that it does not share with the VP2 or VP3, referred to as the VPl-unique region (VPl-u).
  • the VPl-u region is generally encoded by the sequence of a wildtype cap gene starting from the VP1 start codon to the “VP2 start codon.”
  • VPl-u comprises a phospholipase A2 domain (PLA2), which may be important for infection, as well as nuclear localization signals which may aid the virus in targeting to the nucleus for uncoating and genome release.
  • PHA2 phospholipase A2 domain
  • the VP1, VP2, and VP3 capsid proteins share the same C-terminal sequence that makes up the entirety of VP3, which may also be referred to herein as the VP3 region.
  • the VP3 region is encoded from the VP3 start codon to the common stop codon.
  • VP2 has an additional ⁇ 60 amino acids that it shares with the VP 1. This region is called the VP1/VP2 common region.
  • one or more of the Cap proteins of the invention may be encoded by one or more cap genes having one or more ORFs.
  • the VP proteins of the invention may be expressed from more than one ORF comprising nucleotide sequence encoding any combination of VP1, VP2, and/or VP3 by use of separate nucleotide sequences operably linked to at least one expression control sequence for expression in packaging cell, each producing one or more of VP1, VP2, and/or VP3 capsid proteins of the invention.
  • a VP capsid protein of the invention may be expressed individually from an ORF comprising nucleotide sequence encoding any one of VP1, VP2, or VP3 by use of separate nucleotide sequences operably linked to one expression control sequence for expression in a viral replication cell, each producing only one of VP1, VP2, or VP3 capsid protein.
  • VP proteins may be expressed from one ORF comprising nucleotide sequences encoding VP1, VP2, and VP3 capsid proteins operably linked to at least one expression control sequence for expression in a viral replication cell, each producing VP1, VP2, and VP3 capsid protein.
  • amino acid positions provided herein may be provided in relation to the VP1 capsid protein of the referenced AAV, a skilled artisan would be able to respectively and readily determine the position of that same amino acid within the VP2 and/or VP3 capsid protein of the AAV, and the corresponding position of amino acids among different AAV.
  • ITR Inverted Terminal Repeat
  • the phrase “Inverted Terminal Repeat” or “ITR” includes symmetrical nucleic acid sequences in the genome of adeno-associated viruses required for efficient replication. ITR sequences are located at each end of the AAV DNA genome. The ITRs serve as the origins of replication for viral DNA synthesis and are essential cis components for generating AAV particles, e.g., packaging into AAV particles.
  • AAV ITRs comprise recognition sites for replication proteins Rep78 or Rep68.
  • a “D” region of the ITR comprises the DNA nick site where DNA replication initiates and provides directionality to the nucleic acid replication step.
  • An AAV replicating in a mammalian cell typically comprises two ITR sequences.
  • a single ITR may be engineered with Rep binding sites on both strands of the “A” regions and two symmetrical D regions on each side of the ITR palindrome.
  • Such an engineered construct on a double-stranded circular DNA template allows Rep78 or Rep68 initiated nucleic acid replication that proceeds in both directions.
  • a single ITR is sufficient for AAV replication of a circular particle.
  • the rep encoding sequence encodes a Rep protein or Rep protein equivalent that is capable of binding an ITR comprised on the transfer plasmid.
  • the Cap proteins of the invention when expressed with appropriate Rep proteins by a packaging cell, may encapsidate a transfer plasmid comprising a nucleotide of interest and an even number of two or more ITR sequences.
  • a transfer plasmid comprises one ITR sequence.
  • a transfer plasmid comprises two ITR sequences.
  • Rep proteins may be expressed from more than one ORF comprising nucleotide sequence encoding any combination of Rep78, Rep68, Rep 52 and/or Rep40 by use of separate nucleotide sequences operably linked to at least one expression control sequence for expression in a viral replication cell, each producing one or more of Rep78, Rep68, Rep 52 and/or Rep40 Rep proteins.
  • Rep proteins may be expressed individually from an ORF comprising a nucleotide sequence encoding any one of Rep78, Rep68, Rep 52, or Rep40 by use of separate nucleotide sequences operably linked to one expression control sequence for expression in a packaging cell, each producing only one Rep78, Rep68, Rep 52, or Rep40 Rep protein.
  • Rep proteins may be expressed from one ORF comprising nucleotide sequences encoding Rep78 and Rep52 Rep proteins operably linked to at least one expression control sequence for expression in a viral replication cell each producing Rep78 and Rep52 Rep protein.
  • a rep encoding sequence and a cap gene of the invention may be provided a single packaging plasmid.
  • proviso is not necessary.
  • viral particles may or may not include a genome.
  • a “chimeric AAV capsid protein” includes an AAV capsid protein that comprises amino acid sequences, e.g., portions, from two or more different AAV and that is capable of forming and/or forms an AAV viral capsid/viral particle.
  • a chimeric AAV capsid protein is encoded by a chimeric AAV capsid gene, e.g., a chimeric nucleotide comprising a plurality, e.g., at least two, nucleic acid sequences, each of which plurality is identical to a portion of a capsid gene encoding a capsid protein of distinct AAV, and which plurality together encodes a functional chimeric AAV capsid protein.
  • a chimeric capsid protein comprises one or more portions from a capsid protein of that AAV and one or more portions from a capsid protein of a different AAV.
  • a chimeric AAV2 capsid protein includes a capsid protein comprising one or more portions of a VP1, VP2, and/or VP3 capsid protein of AAV2 and one or more portions of a VP1, VP2, and/or VP3 capsid protein of a different AAV.
  • portion refers to at least 5 amino acids or at least 15 nucleotides, but less than the full-length polypeptide or nucleic acid molecule, with 100% identity to a sequence from which the portion is derived, see Penzes (2015) J. General Virol. 2769.
  • a “portion” encompasses any contiguous segment of amino acids or nucleotides sufficient to determine that the polypeptide or nucleic acid molecule form which the portion is derived is “of a [specified] AAV” or has “significant identity” to a particular AAV, e.g., a non-primate animal AAV or remote AAV.
  • a portion comprises at least 5 amino acids or 15 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 10 amino acids or 30 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 15 amino acids or 45 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 20 amino acids or 60 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 25 amino acids or 75 nucleotides with 100% identity to a sequence associated with the specified AAV.
  • a portion comprises at least 30 amino acids or 90 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 35 amino acids or 105 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 40 amino acids or 120 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 45 amino acids or 135 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 50 amino acids or 150 nucleotides with 100% identity to a sequence associated with the specified AAV.
  • a portion comprises at least 60 amino acids or 180 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 70 amino acids or 210 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 80 amino acids or 240 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 90 amino acids or 270 nucleotides with 100% identity to a sequence associated with the specified AAV. In some embodiments, a portion comprises at least 100 amino acids or 300 nucleotides with 100% identity to a sequence associated with the specified AAV.
  • a Cap protein e.g., a VP1 capsid protein as described herein, a VP2 capsid protein as described herein, and/or a VP3 capsid protein as described herein, is modified to comprise any one or combination of e.g., insertion of a targeting ligand, a chemical modification, a first member of a binding pair, a detectable label, point mutation, etc.
  • modification of gene or a polypeptide of a specified AAV results in nucleic acid sequence or an amino acid sequence that differs from the nucleic acid sequence or amino acid sequence set forth herein for the specified AAV, wherein the modification alters, confers, or removes one or more biological functions, but does not change the phylogenetic characterization of, the gene or polypeptide as an AAV gene or AAV polypeptide.
  • Modifications may include any one or a combination of: substitution of sequences of a first AAV serotype with sequences of a second AAV serotype to create chimerism; chemical modification; an insertion of: a first member of a binding pair, and/or a point mutation; etc., such that the natural tropism of the capsid protein is reduced to abolished, the tropism of the capsid protein may be more easily redirected, and/or such that the capsid protein comprises a detectable label.
  • Modifications as described herein generally do not alter and preferably decrease the low to no recognition of the modified capsid by pre-existing antibodies found in the general population that were produced during the course of infection with another AAV, e.g., infection with serotypes such as AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVDJ, Anc80L65, AAV2G9, AAV-LK03, virions based on such serotypes, virions from currently used AAV gene therapy modalities, or a combination thereof.
  • serotypes such as AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVDJ, Anc80L65, AAV2G9, AAV-LK03
  • Modifications described herein may pertain to the association (e.g., display, operable linkage, binding) of a targeting ligand to a modified capsid protein and/or capsid comprising a modified capsid protein.
  • a targeting ligand as described herein binds a surface protein expressed by a mammalian muscle cell, e.g., a protein that is expressed on the surface of a mammalian muscle cell, e.g, a mammalian non-terminally differentiated muscle cell specific surface protein.
  • a modified capsid protein and/or modified capsid comprises a targeting ligand that binds mammalian CDH15, e.g., a human CDH15.
  • Table 1 provides a summary of the SEQ ID NO for each binding portion (e.g., heavy chain variable domain (HCVR), light chain variable domain (LCVR), and CDR1, CDR2, and CDR3) of non-limiting and exemplary anti-human-CDH15 monoclonal antibodies (mAb ID) that may be used to redirect an AAV capsid as described herein.
  • HCVR heavy chain variable domain
  • LCVR light chain variable domain
  • CDR1, CDR2, and CDR3 CDR1, CDR2, and CDR3
  • mAb ID anti-human-CDH15 monoclonal antibodies
  • an AAV capsid as described herein comprises a targeting ligand that binds human CDH15, wherein the targeting ligand comprises heavy chain variable domain, light chain variable domain, heavy chain variable domain/light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and/or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence(s) at least 90% identical to, respectively, an amino acid sequence of a heavy chain variable domain, light chain variable domain, heavy chain variable domain/light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and/or set of HCDR1- HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 as set forth in any one of SEQ ID NOs: 1-786.
  • an AAV capsid as described herein comprises a targeting ligand that binds human CDH15, wherein the targeting ligand comprises a heavy chain variable domain, light chain variable domain, heavy chain variable domain/light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and/or set of HCDR1-HCDR2-HCDR3-LCDR1- LCDR2-LCDR3 amino acid sequence at least 95% identical to, respectively, amino acid sequence(s) of a heavy chain variable domain, light chain variable domain, heavy chain variable domain/light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and/or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 set forth in any one of SEQ ID NOs: 1-786.
  • an AAV capsid as described herein comprises a targeting ligand that binds human CDH15, wherein the targeting ligand comprises a heavy chain variable domain, light chain variable domain, heavy chain variable domain/light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and/or set of HCDR1-HCDR2- HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence at least 97% identical to amino acid sequence(s) of a heavy chain variable domain, light chain variable domain, heavy chain variable domain/light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and/or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 set forth in any one of SEQ ID NOs: 1-786.
  • an AAV capsid as described herein comprises a targeting ligand that binds human CDH15, wherein the targeting ligand comprises a heavy chain variable domain, light chain variable domain, heavy chain variable domain/light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and/or set of HCDR1-HCDR2- HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence(s) at least 98% identical to amino acid sequence(s) of a heavy chain variable domain, light chain variable domain, heavy chain variable domain/light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and/or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 set forth in any one of SEQ ID NOs: 1-786.
  • an AAV capsid as described herein comprises a targeting ligand that binds human CDH15, wherein the targeting ligand comprises a heavy chain variable domain, light chain variable domain, heavy chain variable domain/light chain variable domain pair, HCDR1, HCDR2, CDR3, LCDR1, LCDR2, LCDR3, and/or set of HCDR1-HCDR2- HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequences 99% identical to amino acid sequences of a heavy chain variable domain, light chain variable domain, heavy chain variable domain/light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and/or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 set forth in any one of SEQ ID NOs: 1-786.
  • antibodies, or antigen-binding fragments thereof comprising a set of six CDRs (z.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained within an HCVR/LCVR amino acid sequence pair as defined by any of the exemplary anti-hCDH15 antibodies listed in Table 1.
  • a targeting ligand as described herein comprises the HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequences set contained within an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2+10, 22+30, 42+50, 60+50, 70+50, 80+50, 90+98, 108+115, 125+133, 145+153, 165+173, 185+193, 202+210, 220+50, 230+50, 240+50, 250+50, 259+267, 279+287, 299+307, 319+327, 339+347, 358+366, 378+50, 386+394, 404+412, 420+428, 436+444, 452+460, 468+476, 484+492, 500+508, 516+524, 532+540, 548+556, 564+572, 580+588, 596+60
  • Non-limiting examples of targeting ligands that bind CDH15 include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of the amino acid residues that mimic the hypervariable region of an antibody (e.g., an isolated complementarity determining region (CDR) such as a CDR3 peptide), or a constrained FR3- CDR3-FR4 peptide.
  • CDR complementarity determining region
  • an anti-CDH15 targeting ligand that binds CDH15 useful for retargeting viral capsids as described herein comprises an scFv.
  • an scFv sequences in VL-(Gly4Ser)3-VH format useful for retargeting viral capsids as described herein may comprise a heavy chain variable domain, light chain variable domain, heavy chain variable domain/light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and/or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 that is 90%, 95%, 97%, 98%, 99% or 100% identical, respectively, to any one of the amino acid sequences of a heavy chain variable domain, light chain variable domain, heavy chain variable domain/light chain variable domain pair, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, and/or set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 as set forth in any one of SEQ ID NOs: 1- 786.
  • a targeting ligand that binds a mammalian non-terminally differentiated muscle cell surface protein may be associated with (e.g., displayed by, operably linked to, bound to) a modified AAV capsid protein and resulting AAV capsids according to well-known methods, e.g., a direct approach in which the targeting ligand is directly inserted into (e.g., using recombinatorial methods) according to well-known methods. See, e.g., Stachler et al. (2006), supra, White et al. (2004), supra, Girod et al. (1999), supra, Grifman et al. (2001), supra, Shi et al.
  • a targeting ligand that binds a mammalian non-terminally differentiated muscle cell specific surface protein may be coupled to a modified AAV capsid protein and resulting AAV capsids using well-known chemical linkers, e.g., wherein the AAV capsid protein may be chemically modified to comprise a dibenzocycootyne group or an azide group, and optionally wherein a targeting ligand as described herein is attached to the dibenzocycootyne group or the azide group, see, e.g, U.S.
  • a modified capsid as described herein comprises a targeting ligand, e.g., an anti- CDH15 antibody or binding portion thereof, directly inserted into or coupled to it according to well-known direct recombinatorial methods.
  • a targeting ligand that binds a mammalian non-terminally differentiated muscle cell surface protein may be associated with (e.g., displayed by, operably linked to, bound to) a modified AAV capsid protein and resulting AAV capsids according to indirect recombinatorial approaches, wherein the AAV capsid protein is modified to comprise a first member of a binding pair (e.g., a heterologous scaffold), and optionally wherein the first member of the binding pair is linked to (e.g., covalently or non-covalently bound to) a second cognate member of the binding pair (e.g., an adaptor), further optionally wherein the second cognate member of the binding pair is fused to the targeting ligand.
  • a binding pair e.g., a heterologous scaffold
  • the first member of the binding pair is linked to (e.g., covalently or non-covalently bound to) a second cognate member of the binding pair (e.g., an adapt
  • modifications of a capsid protein as described herein include those that generally result from modifications at the genetic level, e.g., via modification of a cap gene, such as modifications that insert first member of a binding pair (e.g., a protein: protein binding pair, a proteimnucleic acid binding pair), a detectable label, etc., for display by the Cap protein.
  • modifications that insert first member of a binding pair e.g., a protein: protein binding pair, a proteimnucleic acid binding pair
  • a detectable label e.g., a detectable label, etc.
  • the first member forms a binding pair with an immunoglobulin constant domain.
  • the first member forms a binding pair with a metal ion, e.g., Ni 2+ , Co 2+ , Cu 2+ , Zn 2+ , Fe 3+ , etc.
  • the first member is selected from the group consisting of Streptavidin, Strep II, HA, L14, 4C-RGD, LH, and Protein A.
  • the binding pair comprises an enzyme ucleic acid binding pair.
  • the first member comprises a HUH-endonuclease or HUH-tag and the second member comprises a nucleic acid binding domain.
  • the first member comprises a HUH tag. See, e.g., U.S. 2021/0180082, incorporated herein in its entirety by reference.
  • a capsid protein of the invention comprises at least a first member of a peptide:peptide binding pair.
  • each of a first member and a second member of a peptide:peptide binding pair comprises an intein. See, e.g., Wagner et al., (2021) Adv. Sci. 8: 2004018 (1 of 22); Muik et al. (2017) Biomaterials 144: 84, each of which is incorporated herein in its entirety by reference.
  • a first member is a B cell epitope, e.g., is between about 1 amino acid and about 35 amino acids in length, and forms a binding pair with an antibody paratope, e.g., an immunoglobulin variable domain.
  • a capsid protein of the invention may be modified to comprise a detectable label as a first member of a binding pair. Many detectable labels are known in the art. (See, e.g. Nilsson et al. (1997) “Affinity fusion strategies for detection, purification, and immobilization of modified proteins” Protein Expression and Purification 11 : 1-16, Terpe et al.
  • Detectable labels include, but are not limited to, a polyhistidine detectable labels (e.g., a His-6, His-8, or His-10) that binds immobilized divalent cations (e.g, Ni 2+ ), a biotin moiety (e.g., on an in vivo biotinylated polypeptide sequence) that binds immobilized avidin, a GST (glutathione S -transferase) sequence that binds immobilized glutathione, an S tag that binds immobilized S protein, an antigen that binds an immobilized antibody or domain or fragment thereof (including, e.g., T7, myc, FLAG, and B tags that bind corresponding antibodies), a FLASH Tag (a high detectable label that couples to specific arsenic based moi
  • a polyhistidine detectable labels e.g., a His-6, His-8, or His-10
  • immobilized divalent cations e.g,
  • a detectable label is a SNAP -tag, commercially available from Covalys (www.covalys.com).
  • a detectable label disclosed herein comprises a detectable label recognized by an antibody paratope, wherein the detectable label and the antibody paratope form a proteimprotein binding pair.
  • a capsid protein of the invention comprises a first member of a protein: protein binding pair comprising a detectable label, which may also be used for the detection and/or isolation of the Cap protein and/or as a first member of a protein: protein binding pair.
  • a detectable label acts as a first member of a proteimprotein binding pair for the binding of a targeting ligand comprising a multispecific binding protein that may bind both the detectable label and a target expressed by a cell of interest.
  • a Cap protein of the invention comprises a first member of a proteimprotein binding pair comprising c-myc (SEQ ID NO: 818).
  • the first member comprises a Bl epitope (SEQ ID NO: 819).
  • a capsid protein is modified to comprise a Bl epitope in the VP3 region.
  • the first member is selected from the group consisting of FLAG, HA and c-myc (SEQ ID NO: 818).
  • a capsid protein comprises a first member of a protein: protein binding pair, wherein the protein: protein binding pair forms a covalent isopeptide bond.
  • the first member of a peptide:peptide binding pair is covalently bound via an isopeptide bond to a cognate second member of the peptide:peptide binding pair, and optionally wherein the cognate second member of the peptide:peptide binding pair is fused with a targeting ligand, which targeting ligand binds a target expressed by a cell of interest.
  • the protein: protein binding pair may be selected from the group consisting of SpyTag: SpyCatcher, SpyTag002:SpyCatcher002, SpyTag003:SpyCatcher003, SpyTag:KTag, Isopeptag:pilin-C, and SnoopTag: SnoopCatcher.
  • the first member is SpyTag (or a biologically active portion or variant thereof) and the protein (second cognate member) is SpyCatcher (or a biologically active portion or variant thereof).
  • the first member is SpyTag (or a biologically active portion or variant thereof) and the protein (second cognate member) is KTag (or a biologically active portion or variant thereof).
  • the first member is KTag (or a biologically active portion or variant thereof) and the protein (second cognate member) is SpyTag (or a biologically active portion or variant thereof).
  • the first member is SnoopTag (or a biologically active portion or variant thereof) and the protein (second cognate member) is SnoopCatcher (or a biologically active portion or variant thereof).
  • the first member is Isopeptag (or a biologically active portion or variant thereof) and the protein (second cognate member) is Pilin-C (or a biologically active portion or variant thereof).
  • a Cap protein of the invention comprises a SpyTag, or a biologically active portion or variant thereof.
  • a first member of a proteimprotein binding pair and/or detectable label is operably linked to (translated in frame with, chemically attached to, and/or displayed by) a Cap protein of the invention via a first and/or second linker, e.g, an amino acid spacer that is at least one amino acid in length.
  • the first member of a protein: protein binding pair is flanked by a first and/or second linker, e.g, a first and/or second amino acid spacer, each of which spacer is at least one amino acid in length.
  • the first and/or second linkers are not identical. In some embodiments, the first and/or second linker is each independently one or two amino acids in length. In some embodiments, the first and/or second linker is each independently one, two or three amino acids in length. In some embodiments, the first and/or second linker is each independently one, two, three, or four amino acids in length. In some embodiments, the first and/or second linker is each independently one, two, three, four, or five amino acids in length. In some embodiments, the first and/or second linker are each independently one, two, three, four, or five amino acids in length.
  • the first and/or second linker is each independently one, two, three, four, five, or six amino acids in length. In some embodiments, the first and/or second linker is each independently one, two, three, four, five, six, or seven amino acids in length. In some embodiments, the first and/or second linker is each independently one, two, three, four, five, six, seven, or eight amino acids in length. In some embodiments, the first and/or second linker is each independently one, two, three, four, five, six, seven, eight or nine amino acids in length. In some embodiments, the first and or second linker is each independently one, two, three, four, five, six, seven, eight, nine, or ten amino acids in length. In some embodiments, the first and or second linker is each independently one, two, three, four, five, six, seven, eight, nine, or ten amino acids in length. In some embodiments, the first and or second linker is each independently one, two, three, four, five, six, seven, eight, nine,
  • the first and second linkers are identical in sequence and/or in length and are each one amino acid in length. In some embodiments, the first and second linkers are identical in length, and are each one amino acid in length. In some embodiments, the first and second linkers are identical in length, and are each two amino acids in length. In some embodiments, the first and second linkers are identical in length, and are each three amino acids in length. In some embodiments, the first and second linkers are identical in length, and are each four amino acids in length, e.g, the linker is GLSG (SEQ ID NO: 823). In some embodiments, the first and second linkers are identical in length, and are each five amino acids in length.
  • the first and second linkers are identical in length, and are each six amino acids in length, e.g., the first and second linkers each comprise a sequence of GLSGSG (SEQ ID NO: 824) or GSGESG (SEQ ID NO: 828).
  • the first and second linkers are identical in length, and are each seven amino acids in length.
  • the first and second linkers are identical in length, and are each eight amino acids in length, e.g., the first and second linkers each comprise a sequence of GLSGLSGS (SEQ ID NO: 825).
  • the first and second linkers are identical in length, and are each nine amino acids in length.
  • the first and second linkers are identical in length, and are each ten amino acids in length, e.g., the first and second linkers each comprise a sequence of GLSGLSGLSG (SEQ ID NO: 826) or GLSGGSGLSG (SEQ ID NO: 827). In some embodiments, the first and second linkers are identical in length, and are each more than ten amino acids in length.
  • a first member of a protein protein binding pair amino acid sequence as described herein, e.g., comprising a first member of a specific binding pair by itself or in combination with one or more linkers, is between about 5 amino acids to about 50 amino acids in length.
  • the first member of a protein: protein binding pair amino acid sequence is at least 5 amino acids in length.
  • the first member of a protein: protein binding pair amino acid sequence is 6 amino acids in length.
  • the first member of a protein: protein binding pair amino acid sequence is 7 amino acids in length.
  • the first member of a proteimprotein binding pair amino acid sequence is 8 amino acids in length.
  • the first member of a protein: protein binding pair amino acid sequence is 9 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 10 amino acids in length. In some embodiments, the first member of a protein :protein binding pair amino acid sequence is 11 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 12 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 13 amino acids in length. In some embodiments, the first member of a protein :protein binding pair amino acid sequence is 14 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 15 amino acids in length.
  • the first member of a protein: protein binding pair amino acid sequence is 16 amino acids in length. In some embodiments, the first member of a protein :protein binding pair amino acid sequence is 17 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 18 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 19 amino acids in length. In some embodiments, the first member of a protein :protein binding pair amino acid sequence is 20 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 21 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 22 amino acids in length.
  • the first member of a protein :protein binding pair amino acid sequence is 23 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 24 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 25 amino acids in length. In some embodiments, the first member of a protein :protein binding pair amino acid sequence is 26 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 27 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 28 amino acids in length. In some embodiments, the first member of a protein :protein binding pair amino acid sequence is 29 amino acids in length.
  • the first member of a protein: protein binding pair amino acid sequence is 30 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 31 amino acids in length. In some embodiments, the first member of a protein :protein binding pair amino acid sequence is 32 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 33 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 34 amino acids in length. In some embodiments, the first member of a protein :protein binding pair amino acid sequence is 35 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 36 amino acids in length.
  • the first member of a protein: protein binding pair amino acid sequence is 37 amino acids in length. In some embodiments, the first member of a proteimprotein binding pair amino acid sequence is 38 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 39 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 40 amino acids in length. In some embodiments, the first member of a proteimprotein binding pair amino acid sequence is 41 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 42 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 43 amino acids in length.
  • the first member of a protein :protein binding pair amino acid sequence is 44 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 45 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 46 amino acids in length. In some embodiments, the first member of a proteimprotein binding pair amino acid sequence is 47 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 48 amino acids in length. In some embodiments, the first member of a protein: protein binding pair amino acid sequence is 49 amino acids in length. In some embodiments, the first member of a proteimprotein binding pair amino acid sequence is 50 amino acids in length.
  • a targeting ligand comprises a multispecific binding molecule comprising (i) an antibody paratope that specifically binds the detectable label and (ii) a second binding domain that specifically binds a receptor, which may be conjugated to the surface of a bead (e.g, for purification) or expressed by a target cell (e.g., a muscle stem cell, myoblast, myocyte, any combination thereof, etc.).
  • a multispecific binding molecule comprising (i) an antibody paratope that specifically binds the detectable label and (ii) a second binding domain that specifically binds a receptor targets the viral particle.
  • Such “targeting” or “directing” may include a scenario in which the wildtype viral particle targets several cells within a tissue and/or several organs within an organism, which broad targeting of the tissue or organs is reduced to abolished by insertion of the detectable label, and which retargeting to more specific cells in the tissue or more specific organ in the organism is achieved with the multispecific binding molecule.
  • Such retargeting or redirecting may also include a scenario in which the wildtype viral particle targets a tissue, which targeting of the tissue is reduced to abolished by insertion of the detectable label, and which retargeting to a completely different tissue is achieved with the multispecific binding molecule.
  • An antibody paratope as described herein generally comprises at a minimum a complementarity determining region (CDR) that specifically recognizes the detectable label, e.g, a CDR3 region of a heavy and/or light chain variable domain.
  • a multispecific binding molecule comprises an antibody (or portion thereof) that comprises the antibody paratope that specifically binds the detectable label.
  • a multispecific binding molecule may comprise a single domain heavy chain variable region or a single domain light chain variable region, wherein the single domain heavy chain variable region or single domain light chain variable region comprises an antibody paratope that specifically binds the detectable label.
  • a multispecific binding molecule may comprise an Fv region, e.g., a multispecific binding molecule may comprise an scFv, that comprises an antibody paratope that specifically binds the detectable label.
  • a multispecific binding molecule as described herein comprises an antibody paratope that specifically binds c-myc (SEQ ID NO:818).
  • a viral capsid comprising a modified viral capsid protein as described herein is a mosaic capsid, e.g., comprises at least two sets of VP1, VP2, and/or VP3 proteins, each set of which is encoded by a different cap gene.
  • a mosaic capsid herein generally refers to a mosaic of a first viral capsid protein modified to comprise a first member of a binding pair and a second corresponding viral capsid protein lacking the first member of a binding pair.
  • the second viral capsid protein lacking the first member of a binding pair may be referred to as a reference capsid protein encoded by a reference cap gene.
  • a VP1, VP2, and/or VP3 reference capsid protein may comprise an amino acid sequence identical to that of the viral VP1, VP2, and/or VP3 capsid protein modified with a first member of a binding pair, except that the reference capsid protein lacks the first member of a binding pair.
  • a VP1, VP2, and/or VP3 reference capsid protein corresponds to the viral VP1, VP2, and/or VP3 capsid protein modified with a first member of a binding pair, except that the reference capsid protein lacks the first member of a binding pair.
  • a VP1 reference capsid protein corresponds to the viral VP1 capsid protein modified with a first member of a binding pair, except that the reference capsid protein lacks the first member of a binding pair.
  • a VP2 reference capsid protein corresponds to the viral VP2 capsid protein modified with a first member of a binding pair, except that the reference capsid protein lacks the first member of a binding pair.
  • a VP3 reference capsid protein corresponds to the viral VP3 capsid protein modified with a first member of a binding pair, except that the reference capsid protein lacks the first member of a binding pair.
  • a reference protein may be a corresponding capsid protein from which portions thereof form part of the chimeric capsid protein.
  • mosaic capsid comprising a chimeric AAV2/AAAV VP1 capsid protein modified to comprise a first member of a binding pair may further comprise as a reference capsid protein: an AAV2 VP1 capsid protein lacking the first member, an AAAV VP1 capsid protein lacking the first member, a chimeric AAV2/AAAV VP1 capsid protein lacking the first member.
  • a mosaic capsid comprising a chimeric AAV2/AAAV VP2 capsid protein modified to comprise a first member of a binding pair may further comprise as a reference capsid protein: an AAV2 VP2 capsid protein lacking the first member, an AAAV VP1 capsid protein lacking the first member, a chimeric AAV2/AAAV VP2 capsid protein lacking the first member.
  • a mosaic capsid comprising a chimeric AAV2/AAAV VP3 capsid protein modified to comprise a first member of a binding pair may further comprise as a reference capsid protein: an AAV2 VP2 capsid protein lacking the first member, an AAAV VP1 capsid protein lacking the first member, a chimeric AAV2/AAAV VP3 capsid protein lacking the first member.
  • a reference capsid protein may be any capsid protein so long as it that lacks the first member of the binding pair and is able to form a capsid with the first capsid protein modified with the first member of a binding pair.
  • mosaic particles may be generated by transfecting mixtures of the modified and reference Cap genes into production cells at the indicated ratios.
  • the protein subunit ratios e. , modified VP proteimunmodified VP protein ratios
  • the protein subunit ratios in the particle may, but do not necessarily, stoichiometrically reflect the ratios of the at least two species of the cap gene encoding the first capsid protein modified with a first member of a binding pair and the one or more reference cap genes, e.g., modified cap gene:reference cap gene(s) transfected into packaging cells.
  • the protein subunit ratios in the particle do not stoichiometrically reflect the modified cap gene reference cap gene(s) ratio transfected into packaging cells.
  • the protein subunit ratio ranges from about 1 :59 to about 59:1. In some mosaic viral particle embodiments, the protein subunit is at least about 1: 1 (e.g., the mosaic viral particle comprises about 30 modified capsid proteins and about 30 reference capsid protein). In some mosaic viral particle embodiments, the protein subunit ratio is at least about 1:2 e.g., the mosaic viral particle comprises about 20 modified capsid proteins and about 40 reference capsid proteins). In some mosaic viral particle embodiments, the protein subunit ratio is at least about 3:5. In some mosaic viral particle embodiments, the protein subunit ratio is at least about 1 :3 (e.g., the mosaic viral particle comprises about 15 modified capsid proteins and about 45 reference capsid proteins) .
  • the protein subunit ratio is at least about 1:4 (e.g., the mosaic viral particle comprises about 12 modified capsid proteins and 48 reference capsid proteins). In some mosaic viral particle embodiments, the protein subunit ratio is at least about 1:5 (e.g., the mosaic viral particle comprises 10 modified capsid proteins and 50 reference capsid proteins). In some mosaic viral particle embodiments, the protein subunit ratio is at least about 1:6. In some mosaic viral particle embodiments, the protein subunit ratio is at least about 1:7. In some mosaic viral particle embodiments, the protein subunit ratio is at least about 1 :8.
  • the protein subunit ratio is at least about 1 :9 (e.g., the mosaic viral particle comprises about 6 modified capsid proteins and about 54 reference capsid proteins). In some mosaic viral particle embodiments, the protein subunit ratio is at least about 1: 10. In some mosaic viral particle embodiments, the protein subunit ratio is at least about 1: 11 (e.g., the mosaic viral particle comprises about 5 modified capsid proteins and about 55 reference capsid proteins). In some mosaic viral particle embodiments, the protein subunit ratio is at least about 1 : 12. In some mosaic viral particle embodiments, the protein subunit ratio is at least about 1 : 13.
  • the protein subunit ratio is at least about 1 :14 (e.g., the mosaic viral particle comprises about 4 modified capsid proteins and about 56 reference capsid proteins). In some mosaic viral particle embodiments, the protein subunit ratio is at least about 1 : 15. In some mosaic viral particle embodiments, the protein subunit ratio is at least about 1 : 19 (e.g., the mosaic viral particle comprises about 3 modified capsid proteins and about 57 reference capsid proteins). In some mosaic viral particle embodiments, the protein subunit ratio is at least about 1 :29 (e.g, the mosaic viral particle comprises about 2 modified capsid proteins and about 58 reference capsid proteins). In some mosaic viral particle embodiments, the protein subunit ratio is at least about 1 :59.
  • the protein subunit ratio is at least about 2: 1 (e.g, the mosaic viral particle comprises about 40 modified capsid proteins and about 20 reference capsid proteins). In some mosaic viral particle embodiments, the protein subunit ratio is at least about 5:3. In some mosaic viral particle embodiments, the protein subunit ratio is at least about 3 : 1 (e.g, the mosaic viral particle comprises about 45 modified capsid proteins and about 15 reference capsid proteins). In some mosaic viral particle embodiments, the protein subunit ratio is at least about 4: 1 (e.g., the mosaic viral particle comprises about 48 modified capsid proteins and 12 reference capsid proteins).
  • the protein subunit ratio is at least about 5: 1 (e.g, the mosaic viral particle comprises 50 modified capsid proteins and 10 reference capsid proteins). In some mosaic viral particle embodiments, the protein subunit ratio is at least about 6: 1. In some mosaic viral particle embodiments, the protein subunit ratio is at least about 7: 1. In some mosaic viral particle embodiments, the protein subunit ratio is at least about 8:1. In some mosaic viral particle embodiments, the protein subunit ratio is at least about 9: 1 (e.g., the mosaic viral particle comprises about 54 modified capsid proteins and about 6 reference capsid proteins). In some mosaic viral particle embodiments, the protein subunit ratio is at least about 10:1.
  • the protein subunit ratio is at least about 11 :1 (e.g., the mosaic viral particle comprises about 55 modified capsid proteins and about 5 reference capsid proteins). In some mosaic viral particle embodiments, the protein subunit ratio is at least about 12:1. In some mosaic viral particle embodiments, the protein subunit ratio is at least about 13:1. In some mosaic viral particle embodiments, the protein subunit ratio is at least about 14: 1 (e.g., the mosaic viral particle comprises about 56 modified capsid proteins and about 4 reference capsid proteins). In some mosaic viral particle embodiments, the protein subunit ratio is at least about 15: 1.
  • the protein subunit ratio is at least about 19: 1 (e.g, the mosaic viral particle comprises about 57 modified capsid proteins and about 3 reference capsid proteins). In some mosaic viral particle embodiments, the protein subunit ratio is at least about 29: 1 (e.g, the mosaic viral particle comprises about 58 modified capsid proteins and about 2 reference capsid proteins). In some mosaic viral particle embodiments, the protein subunit ratio is at least about 59: 1.
  • the protein subunit ratio may be 1:0 wherein each capsid protein of the non-mosaic viral particle is modified with a first member of a binding pair. In some non-mosaic viral particle embodiments, the protein subunit ratio may be 0:1 wherein each capsid protein of the non-mosaic viral particle is not modified with a first member of a binding pair.
  • nucleic acids that encode a VP3 capsid protein of the invention may be, but are not necessarily, encoded by overlapping reading frames of the same gene with staggered start codons.
  • a nucleic acid that encodes a VP3 capsid protein of the invention does not also encode a VP2 capsid protein or VP1 capsid protein of the invention.
  • a nucleic acid that encodes a VP3 capsid protein of the invention may also encode a VP2 capsid protein of the invention but does not also encode a VP1 capsid of the invention.
  • a nucleic acid that encodes a VP3 capsid protein of the invention may also encode a VP2 capsid protein of the invention and a VP1 capsid of the invention.
  • One embodiment of the present invention is a multimeric structure comprising a modified viral capsid protein of the present invention.
  • a multimeric structure comprises at least 5, preferably at least 10, more preferably at least 30, most preferably at least 60 modified viral capsid proteins comprising a first member of a specific binding pair as described herein. They can form regular viral capsids (empty viral particles) or viral particles (capsids encapsidating a nucleotide of interest). The formation of viral particles comprising a viral genome is a highly preferred feature for use of the modified viral capsids described herein.
  • a further embodiment of the present invention is the use of at least one modified viral capsid protein and/or a nucleic acid encoding same, preferably at least one multimeric structure (e.g., viral particle) for the manufacture of and use in transfer of a nucleotide of interest to a target cell e.g., a muscle stem cell, myoblast, myocyte, any combination thereof, etc.). Insertion sites
  • variable regions VR I to VR IX provide an overlay of ribbons from different dependoparvovirus at Figure 7, depicting the variable regions VR I to VR IX.
  • a skilled artisan may determine which amino acids within the variable region correspond to amino acid sequence of AAV that can accommodate the insertion of, e.g., a targeting ligand as described herein, a first member of a binding pair and/or detectable label.
  • the targeting ligand, first member of a binding pair, and/or detectable label may be inserted into a variable region or variable loop of an AAV capsid protein, a GH loop of an AAV capsid protein, etc.
  • the targeting ligand, first member of a binding pair, and/or detectable label may be inserted into a variable region or variable loop VRI of an AAV capsid protein.
  • the targeting ligand, first member of a binding pair, and/or detectable label may be inserted into a variable region or variable loop VRII of an AAV capsid protein.
  • the targeting ligand, first member of a binding pair, and/or detectable label may be inserted into a variable region or variable loop VRIII of an AAV capsid protein. In some embodiments, the targeting ligand, first member of a binding pair, and/or detectable label may be inserted into a variable region or variable loop VRIV of an AAV capsid protein. In some embodiments, the targeting ligand, first member of a binding pair, and/or detectable label may be inserted into a variable region or variable loop VRV of an AAV capsid protein. In some embodiments, the targeting ligand, first member of a binding pair, and/or detectable label may be inserted into a variable region or variable loop VRV of an AAV capsid protein.
  • the targeting ligand, first member of a binding pair, and/or detectable label may be inserted into a variable region or variable loop VRVI of an AAV capsid protein. In some embodiments, the targeting ligand, first member of a binding pair, and/or detectable label may be inserted into a variable region or variable loop VRVII of an AAV capsid protein. In some embodiments, the targeting ligand, first member of a binding pair, and/or detectable label may be inserted into a variable region or variable loop VRIII of an AAV capsid protein. In some embodiments, the targeting ligand, first member of a binding pair, and/or detectable label may be inserted into a variable region or variable loop VRIX of an AAV capsid protein.
  • the first member of a binding pair and/or detectable label is inserted in a VP 1 capsid protein of a non-primate animal AAV after an amino acid position corresponding with an amino acid position selected from the group consisting of G453 of AAV2 capsid protein VP1, N587 of AAV2 capsid protein VP1, G453 of AAV9 capsid protein VP1, and A589 of AAV9 capsid protein VP1.
  • the first member of a binding pair and/or detectable label is inserted in a VP 1 capsid protein of a non-primate animal AAV between amino acids that correspond with N587 and R588 of an AAV2 VP1 capsid.
  • the nomenclature I-###, I# or the like herein refers to the insertion site (I) with ### naming the amino acid number relative to the VP I protein of an AAV capsid protein, however such the insertion may be located directly N- or C-terminal, preferably C-terminal of one amino acid in the sequence of 5 amino acids N- or C-terminal of the given amino acid, preferably 3, more preferably 2, especially 1 amino acid(s) N- or C-terminal of the given amino acid.
  • positions referred to herein are relative to the VP1 protein encoded by an AAV capsid gene, and corresponding positions (and point mutations thereof) may be easily identified for the VP2 and VP3 capsid proteins encoding by the capsid gene by performing a sequence alignment of the VP 1, VP2 and VP3 proteins encoded by the appropriate AAV capsid gene.
  • Additional suitable insertion sites of a non-primate animal VP1 capsid protein include those corresponding to 1-1, 1-34, 1-138, 1-139, 1-161, 1-261, 1-266, 1-381, 1-447, 1-448, 1-
  • a modified virus capsid protein as described herein may be a non-primate animal capsid protein comprising a first member of a binding pair and/or detectable label inserted into a position corresponding with a position of an AAV2 capsid protein selected from the group consisting of 1-1, 1-34, 1-138, 1-139, 1-161, 1-261, 1-266, 1-381, 1-447, 1-448, 1-459, 1-471, 1-520, 1-534, 1-570, 1-573, 1-584, 1-587, 1-
  • a modified virus capsid protein as described herein may be a non-primate animal capsid protein comprising a targeting ligand, first member of a binding pair and/or detectable label inserted into a position corresponding with a position selected from the group consisting of 1-587 (AAV1), 1-589 (AAV1), 1-585 (AAV3), 1-585 (AAV4), 1-585 (AAV5), and a combination thereof.
  • AAV1 1-587
  • AAV1 1-589
  • AAV3 1-585
  • AAV4 1-585
  • AAV5 1-585
  • the first member of a binding pair and/or detectable label is inserted in a VP 1 capsid protein of a non-primate animal AAV after an amino acid position corresponding with an amino acid position selected from the group consisting of 1444 of an avian AAV capsid protein VP1, 1580 of an avian AAV capsid protein VP1, 1573 of a bearded dragon AAV capsid protein VP 1, 1436 of a bearded dragon AAV capsid protein VP1, 1429 of a sea lion AAV capsid protein VP1, 1430 of a sea lion AAV capsid protein VP1, 1431 of a sea lion AAV capsid protein VP1, 1432 of a sea lion AAV capsid protein VP1, 1433 of a sea lion AAV capsid protein VP1, 1434 of a sea lion AAV capsid protein VP1, 1436 of a sea lion AAV capsid protein VP1, 1437
  • insertion into the corresponding position of the coding nucleic acid of one of these sites of the cap gene leads to an insertion into VP1, VP2 and/or VP3, as the capsid proteins are encoded by overlapping reading frames of the same gene with staggered start codons. Therefore, for AAV2, for example, according to this nomenclature insertions between amino acids 1 and 138 are only inserted into VP1, insertions between 138 and 203 are inserted into VP1 and VP2, and insertions between 203 and the C-terminus are inserted into VP1, VP2 and VP3, which is of course also the case for the insertion site 1-587. Therefore, the present invention encompasses structural genes of AAV with corresponding insertions in the VP 1, VP2 and/or VP3 proteins.
  • a viral capsid comprising the modified viral capsid protein comprising the first and second members of a binding pair is able to infect a specific cell, e.g., has an enhanced capacity to target and bind a specific cell compared to that of a control viral capsid that is identical to the modified viral capsid protein except that it lacks either or both the first and second members of a binding pair, e.g., comprises a control capsid protein.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to the first and second members of a binding pair linked to a targeting ligand exhibits a detectable transduction efficiency compared to the undetectable transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 10% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 20% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 30% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 40% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 50% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 60% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 70% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 75% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 80% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 85% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 90% greater than the transduction efficiency of a control capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 95% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 99% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising the modified viral capsid protein comprising the first and second members of a binding pair is able to infect a specific cell, e.g., has an enhanced capacity to target and bind a specific cell compared to that of a control viral capsid that is identical to the modified viral capsid protein except that it lacks either or both the first and second members of a binding pair, e.g., comprises a control capsid protein.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to the first and second members of a binding pair linked to a targeting ligand exhibits a detectable transduction efficiency compared to the undetectable transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 10% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 20% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 30% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 40% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 50% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 60% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 70% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 75% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 80% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 85% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 90% greater than the transduction efficiency of a control capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 95% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is 99% greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at leastl.5-fold greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at least 2-fold greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at least 3-fold greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at least 4-fold greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at least 5-fold greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at least 6-fold greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at least 7-fold greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at least 8-fold greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at least 9-fold greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at least 10-fold greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at least 20-fold greater than the transduction efficiency of a control capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to an appropriate the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at least 30-fold greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at least 40-fold greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at least 50-fold greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at least 60-fold greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at least 70-fold greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at least 80-fold greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at least 90-fold greater than the transduction efficiency of a control viral capsid.
  • a viral capsid comprising a modified viral capsid protein as described herein bound to the first and second members of a binding pair linked to a targeting ligand exhibits a transduction efficiency that is at least 100-fold greater than the transduction efficiency of a control viral capsid
  • a viral particle of the invention comprising a viral capsid protein comprising an amino acid sequence of a capsid protein of a non-primate animal AAV, a remote AAV, or a combination thereof, and optionally comprising a first and second members of a binding pair (e.g., wherein the second member is operably linked to a targeting ligand, comprises a multispecific binding protein, etc.) is better able to evade neutralization by pre-existing antibodies in serum isolated from a human patient compared to an appropriate control viral particle (e.g, comprising a viral capsid of an AAV serotype from which a portion is included in the viral capsid of the invention, e.g, as
  • a viral particle of the invention comprising a viral capsid protein comprising an amino acid sequence of a capsid protein of a non-primate animal AAV, a remote AAV, or a combination thereof requires at least 2-fold more total IVIG or IgG for neutralization (e.g., 50% or more infection inhibition) compared to an appropriate control viral particle, e. , (e.g, a viral particle of the invention has an IC50 value that is at least 2-fold that of a control virus particle).
  • compositions comprising the antigenbinding molecules as described herein.
  • pharmaceutical compositions may be formulated with suitable carriers, excipients, and other agents that provide improved transfer, delivery, tolerance, and the like.
  • suitable carriers, excipients, and other agents that provide improved transfer, delivery, tolerance, and the like.
  • a multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington’s Pharmaceutical Sciences, Mack Publishing Company, Easton, PA.
  • formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTINTM, Life Technologies, Carlsbad, CA), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax.
  • vesicles such as LIPOFECTINTM, Life Technologies, Carlsbad, CA
  • DNA conjugates such as LIPOFECTINTM, Life Technologies, Carlsbad, CA
  • DNA conjugates such as LIPOFECTINTM, Life Technologies, Carlsbad, CA
  • DNA conjugates such as LIPOFECTINTM, Life Technologies, Carlsbad, CA
  • DNA conjugates such as LIPOFECTINTM, Life Technologies, Carlsbad, CA
  • the dose of antigen-binding molecule administered to a patient may vary depending upon the age and the size of the patient, target disease, conditions, route of administration, and the like.
  • the preferred dose is typically calculated according to body weight or body surface area.
  • intravenously administer the antigen-binding molecule as described herein normally at a single dose of about 0.01 to about 20 mg/kg body weight, more preferably about 0.02 to about 7, about 0.03 to about 5, or about 0.05 to about 3 mg/kg body weight.
  • Effective dosages and schedules for administering a bispecific antigen-binding molecule may be determined empirically; for example, patient progress can be monitored by periodic assessment, and the dose adjusted accordingly.
  • interspecies scaling of dosages can be performed using well-known methods in the art (e.g., Mordenti ei ctL, 1991, Pharmaceut. Res. 5:1351).
  • Various delivery systems are known and can be used to administer the pharmaceutical composition as described herein, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the mutant viruses, receptor mediated endocytosis (see, e.g., Wu et al., 1987, J. Biol. Chem. 262:4429-4432).
  • Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes.
  • composition may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local.
  • epithelial or mucocutaneous linings e.g., oral mucosa, rectal and intestinal mucosa, etc.
  • Administration can be systemic or local.
  • a pharmaceutical composition as described herein can be delivered subcutaneously or intravenously with a standard needle and syringe.
  • a pen delivery device readily has applications in delivering a pharmaceutical composition as described herein.
  • Such a pen delivery device can be reusable or disposable.
  • a reusable pen delivery device generally utilizes a replaceable cartridge that contains a pharmaceutical composition. Once all of the pharmaceutical composition within the cartridge has been administered and the cartridge is empty, the empty cartridge can readily be discarded and replaced with a new cartridge that contains the pharmaceutical composition. The pen delivery device can then be reused.
  • a disposable pen delivery device there is no replaceable cartridge. Rather, the disposable pen delivery device comes prefilled with the pharmaceutical composition held in a reservoir within the device. Once the reservoir is emptied of the pharmaceutical composition, the entire device is discarded.
  • Numerous reusable pen and autoinjector delivery devices have applications in the subcutaneous delivery of a pharmaceutical composition as described herein. Examples include, but are not limited to AUTOPENTM (Owen Mumford, Inc., Woodstock, UK), DISETRONICTM pen (Disetronic Medical Systems, Bergdorf, Switzerland), HUMALOG MIX 75/25TM pen, HUMALOGTM pen, HUMALIN 70/30TM pen (Eli Lilly and Co., Indianapolis, IN), NOVOPENTM I, II and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIORTM (Novo Nordisk, Copenhagen, Denmark), BDTM pen (Becton Dickinson, Franklin Lakes, NJ), OPTIPENTM, OPTIPEN PROTM, OPTIPEN STARLETTM, and OPTICLIKTM (sanofi-aventis, Frankfurt, Germany), to name only a few.
  • Examples of disposable pen delivery devices having applications in subcutaneous delivery of a pharmaceutical composition as described herein include, but are not limited to the SOLOSTARTM pen (sanofi-aventis), the FLEXPENTM (Novo Nordisk), and the KWIKPENTM (Eli Lilly), the SURECLICKTM Autoinjector (Amgen, Thousand Oaks, CA), the PENLETTM (Haselmeier, Stuttgart, Germany), the EPIPEN (Dey, L.P.), and the HUMIRATM Pen (Abbott Labs, Abbott Park IL), to name only a few.
  • the pharmaceutical composition can be delivered in a controlled release system.
  • a pump may be used (see Langer, supra; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201).
  • polymeric materials can be used in another embodiment.
  • a controlled release system can be placed in proximity of the composition’s target, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, 1984, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138). Other controlled release systems are discussed in the review by Langer, 1990, Science 249: 1527- 1533.
  • the injectable preparations may include dosage forms for intravenous, subcutaneous, intracutaneous and intramuscular injections, drip infusions, etc. These injectable preparations may be prepared by methods publicly known. For example, the injectable preparations may be prepared, e.g., by dissolving, suspending or emulsifying the antibody or its salt described above in a sterile aqueous medium or an oily medium conventionally used for injections.
  • aqueous medium for injections there are, for example, physiological saline, an isotonic solution containing glucose and other auxiliary agents, etc., which may be used in combination with an appropriate solubilizing agent such as an alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol, polyethylene glycol), a nonionic surfactant [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], etc.
  • an alcohol e.g., ethanol
  • a polyalcohol e.g., propylene glycol, polyethylene glycol
  • a nonionic surfactant e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil
  • oily medium there are employed, e.g., sesame oil, soybean oil, etc., which may be used in combination with a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc.
  • a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc.
  • the pharmaceutical compositions for oral or parenteral use described above are prepared into dosage forms in a unit dose suited to fit a dose of the active ingredients.
  • dosage forms in a unit dose include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc.
  • the amount of the aforesaid antibody contained is generally about 5 to about 500 mg per dosage form in a unit dose; especially in the form of injection, it is preferred that the aforesaid antibody is contained in about 5 to about 100 mg and in about 10 to about 250 mg for the other dosage forms.
  • a further embodiment provides a medicament comprising at least one modified viral capsid protein and appropriate targeting ligand according to this invention and/or a nucleic acid according to this invention.
  • a medicament is useful as a gene transfer particle.
  • compositions comprising the viral particles described herein and a pharmaceutically acceptable carrier and/or excipient.
  • pharmaceutical dosage forms comprising the viral particle described herein.
  • the viral particles described herein can be used for various therapeutic applications (in vivo and ex vivo) and as research tools.
  • compositions based on the viral particles disclosed herein can be formulated in any conventional manner using one or more physiologically acceptable carriers and/or excipients.
  • the viral particles may be formulated for administration by, for example, injection, inhalation or insulation (either through the mouth or the nose) or by oral, buccal, parenteral or rectal administration, or by administration directly to a tumor.
  • the pharmaceutical compositions can be formulated for a variety of modes of administration, including systemic, topical or localized administration. Techniques and formulations can be found in, for example, Remington’s Pharmaceutical Sciences, Meade Publishing Co., Easton, Pa. For systemic administration, injection is preferred, including intramuscular, intravenous, intraperitoneal, and subcutaneous.
  • the pharmaceutical compositions can be formulated in liquid solutions, preferably in physiologically compatible buffers, such as Hank's solution or Ringer's solution.
  • the pharmaceutical compositions may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms of the pharmaceutical composition are also suitable.
  • the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycolate); or wetting agents (e.g. sodium lauryl sulfate).
  • binding agents e.g. pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate
  • lubricants e.g. magnesium stearate, talc or silica
  • disintegrants e.g. potato starch or sodium starch glycolate
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid).
  • the preparations can also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
  • the pharmaceutical compositions can be formulated for parenteral administration by injection, e.g. by bolus injection or continuous infusion.
  • Formulations for injection can be presented in a unit dosage form, e.g. in ampoules or in multi -dose containers, with an optionally added preservative.
  • the pharmaceutical compositions can further be formulated as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain other agents including suspending, stabilizing and/or dispersing agents.
  • the pharmaceutical compositions can also be formulated as a depot preparation. These long acting formulations can be administered by implantation (e.g. subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds may be formulated with suitable polymeric or hydrophobic materials (e.g. as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • suitable delivery systems include microspheres, which offer the possibility of local noninvasive delivery of drugs over an extended period of time. This technology can include microspheres having a precapillary size, which can be injected via a coronary catheter into any selected part of an organ without causing inflammation or ischemia. The administered therapeutic is men slowly released from the microspheres and absorbed by the surrounding cells present in the selected tissue.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, bile salts, and fusidic acid derivatives.
  • detergents may be used to facilitate permeation.
  • Transmucosal administration can occur using nasal sprays or suppositories.
  • the viral particles described herein can be formulated into ointments, salves, gels, or creams as generally known in the art.
  • a wash solution can also be used locally to treat an injury or inflammation in order to accelerate healing.
  • Pharmaceutical forms suitable for injectable use can include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid. It must be stable under the conditions of manufacture and certain storage parameters (e.g. refrigeration and freezing) and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • a therapeutic agent can be formulated into a composition in a neutral or salt form.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
  • a carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents known in the art. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compounds or constructs in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • solutions can be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
  • the formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but slow release capsules or microparticles and microspheres and the like can also be employed.
  • aqueous solutions for parenteral administration in an aqueous solution
  • the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intratumorally, intramuscular, subcutaneous and intraperitoneal administration.
  • sterile aqueous media that can be employed will be known to those of skill in the art in light of the present disclosure.
  • one dosage could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion.
  • a subject may be administered viral particles described herein on a daily or weekly basis for a time period or on a monthly, bi-yearly or yearly basis depending on need or exposure to a pathogenic organism or to a condition in the subject (e.g., cancer).
  • parenteral administration such as intravenous, intratumorally, intradermal or intramuscular injection
  • other pharmaceutically acceptable forms include, e.g., tablets or other solids for oral administration; liposomal formulations; time release capsules; biodegradable and any other form currently used.
  • Nasal solutions can be aqueous solutions designed to be administered to the nasal passages in drops or sprays.
  • Nasal solutions can be prepared so that they are similar in many respects to nasal secretions.
  • the aqueous nasal solutions usually are isotonic and slightly buffered to maintain a pH of 5.5 to 7.5.
  • antimicrobial preservatives similar to those used in ophthalmic preparations, and appropriate drug stabilizers, if required, may be included in the formulation.
  • Various commercial nasal preparations are known and can include, for example, antibiotics and antihistamines and are used for asthma prophylaxis.
  • Oral formulations can include excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders.
  • oral pharmaceutical compositions will include an inert diluent or assimilable edible carrier, or they may be enclosed in hard or soft shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
  • the active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • the tablets, troches, pills, capsules and the like may also contain the following: a binder, as gum tragacanth, acacia, cornstarch, or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, such as com starch, potato starch, alginic acid and the like; a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose or saccharin may be added or a flavoring agent, such as peppermint, oil of wintergreen, or cherry flavoring.
  • a binder as gum tragacanth, acacia, cornstarch, or gelatin
  • excipients such as dicalcium phosphate
  • a disintegrating agent such as com starch, potato starch, alginic acid and the like
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, lactose or saccharin may be added or
  • tablets, pills, or capsules may be coated with shellac, sugar or both.
  • a syrup of elixir may contain the active compounds sucrose as a sweetening agent methyl and propylparabens as preservatives, a dye and flavoring, such as cherry or orange flavor.
  • Kits can also include a suitable container, for example, vials, tubes, mini- or microfuge tubes, test tube, flask, bottle, syringe or other container. Where an additional component or agent is provided, the kit can contain one or more additional containers into which this agent or component may be placed. Kits herein will also typically include a means for containing the viral particles and any other reagent containers in close confinement for commercial sale. Such containers may include injection or blow-molded plastic containers into which the desired vials are retained.
  • one or more additional active agents such as, e.g, anti-inflammatory agents, anti-viral agents, anti-fungal or anti-bacterial agents or anti -tumor agents may be needed for compositions described.
  • compositions disclosed herein may be administered by any means known in the art.
  • compositions may include administration to a subject intravenously, intratumorally, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostaticaly, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, intramuscularly, intrathecally, subcutaneously, subconjunctival, intravesicularlly, mucosally, intrapericardially, intraumbilically, intraocularly, orally, locally, by inhalation, by injection, by infusion, by continuous infusion, by localized perfusion, via a catheter, via a lavage, in a cream, or in a lipid composition.
  • any method known to one skilled in the art maybe used for large scale production of viral particles, packaging cells and particle constructs described herein.
  • master and working seed stocks may be prepared under GMP conditions in qualified primary CEFs or by other methods.
  • Packaging cells may be plated on large surface area flasks, grown to near confluence and viral particles purified. Cells may be harvested and viral particles released into the culture media isolated and purified, or intracellular viral particles released by mechanical disruption (cell debris can be removed by large-pore depth filtration and host cell DNA digested with endonuclease). Virus particles may be subsequently purified and concentrated by tangential- flow filtration, followed by diafiltration.
  • the resulting concentrated bulk maybe formulated by dilution with a buffer containing stabilizers, filled into vials, and lyophilized. Compositions and formulations may be stored for later use. For use, lyophilized viral particles may be reconstituted by addition of diluent.
  • compositions as disclosed herein can also include adjuvants such as aluminum salts and other mineral adjuvants, tensoactive agents, bacterial derivatives, vehicles and cytokines.
  • adjuvants can also have antagonizing immunomodulating properties.
  • adjuvants can stimulate Thl or Th2 immunity.
  • Compositions and methods as disclosed herein can also include adjuvant therapy.
  • the method may comprise contacting the cell expressing CDH15 (e.g., in vitro, ex vivo, or in vivo) with an anti-hCDH15 antibody, antigen-binding fragment thereof, or pharmaceutical composition thereof of the present disclosure.
  • the activity of CDH15 includes, but is not limited to, inhibiting muscle regeneration e.g., by inhibiting activation of CDH15-expressing muscle stem cells.
  • the cell expressing CDH15 is a muscle cell.
  • the cell is a mammalian muscle cell.
  • the cell is a mammalian skeletal muscle cell.
  • the cell is a mammalian skeletal muscle cell that is not terminally differentiated. In some embodiments, the cell is a mammalian skeletal muscle cell that is terminally differentiated. In some embodiments, the cell is a muscle stem cell , a myoblast, or a myocyte. In some embodiments, the cell is a human rhabdomyosarcoma cell. [00305] Disclosed herein are also methods of accelerating the transition from quiescence to activation in a muscle stem cell, comprising contacting the muscle stem cell (e.g., in vitro, ex vivo, or in vivo) with an anti-hCDH15 antibody, antigen-binding fragment thereof, or pharmaceutical composition thereof of the present disclosure.
  • an anti-hCDH15 antibody, antigen-binding fragment thereof, or pharmaceutical composition thereof of the present disclosure comprising contacting the muscle stem cell (e.g., in vitro, ex vivo, or in vivo) with an anti-hCDH15 antibody, antigen-binding fragment
  • “Quiescence”, as used herein, refers to an inactive, non-proliferating state of a cell. For example, quiescent muscle stem cells do not proliferate or differentiate into myofibers. “Activation” as used herein in reference to muscle stem cells, refers to the ability of the muscle stem cells to proliferate and differentiate into myofibers e.g., to promote regrowth and/or repair of damaged muscle.
  • compositions comprising administering to a subject in need thereof a composition (e.g., a therapeutic composition) comprising an anti-hCDH15 antibody, antigen-binding fragment thereof or an antibody-drug conjugate comprising an anti-hCDH15 antibody (e.g., an anti-hCDH15 antibody, or ADC comprising any of the HCVR/LCVR or CDR sequences as set forth in Table 1 herein).
  • a composition e.g., a therapeutic composition
  • the therapeutic composition can comprise any of the anti-hCDH15 antibodies, antigen-binding fragments thereof, or ADCs disclosed herein, and a pharmaceutically acceptable carrier or diluent.
  • compositions e.g. , a therapeutic composition
  • a composition comprising an anti-hCDH15 antibody, antigen-binding fragment thereof, or an antibody-drug conjugate comprising an anti-hCDH15 antibody for the treatment of one or more condition as disclosed herein.
  • compositions comprising an anti-hCDH15 antibody, antigen-binding fragment thereof, or an antibody-drug conjugate comprising an anti-hCDH15 antibody for use as a therapy e.g., for use in the treatment of one or more condition as disclosed herein.
  • compositions e.g., a therapeutic compositions
  • an anti-hCDH15 antibody, antigen-binding fragment thereof, or an antibody-drug conjugate comprising an anti-hCDH15 antibody for use as a therapy e.g., for use in the treatment of one or more condition as disclosed herein.
  • the antibodies, antigen-binding fragment thereof, or an antibody-drug conjugate comprising an anti-hCDH15 antibody as described herein may be useful, inter alia, for the treatment, prevention and/or amelioration of one or more condition e.g., any disease or disorder associated with skeletal muscle tissue.
  • the antibodies and ADCs as described herein may be useful for the treatment of muscle wasting disorders (e.g., cachexia, glucocorticoid-induced muscle loss, heart failure induced muscle loss, HIV wasting, disuse, aging, etc ), muscular dystrophies/myopathies, and/or muscle-related cancers (e.g., rhabdomyosarcoma).
  • a method of treatment of a disease such as a muscle wasting disorder.
  • the method may include the step of providing an antibody or CDH15 antigen-binding fragment thereof, as described above, to a subject requiring said treatment.
  • a method of treatment of a muscle-related cancer may include the step of providing an antibody or CDH15 antigen-binding fragment thereof, as described above, to a subject requiring said treatment.
  • muscle-specific cancers include rhabdomyosarcomas, e.g, embryonal, alveolar, pleomorphic, botryoid and spindle/ sclerosing rhabdomyosarcomas.
  • a method of treatment of muscle injury may include the step of providing an antibody or CDH15 antigen-binding fragment thereof, as described above, to a subject requiring said treatment e.g., a subject that has experienced muscle injury and/or anticipates experiencing muscle injury. Accordingly, the antibody or CDH15 antigen-binding fragment thereof may be administered prior to injury e.g., prior to a muscle damaging surgery or after injury e.g., an unanticipated muscle injury.
  • a method of improving muscle regeneration in a subject following injury may include the step of providing an antibody or CDH15 antigen-binding fragment thereof, as described above, to a subject requiring said treatment.
  • “improved” in reference to muscle regeneration refers to any measurable increase in muscle repair.
  • muscle regeneration may be considered “improved” in a subject if it occurs at accelerated rate and/or to a greater degree as compared to a control subject e.g., a subject that has not been administered the anti-CDH15 antibody or antigen-binding fragment thereof.
  • “Improved” muscle regeneration may be an increase in rate or degree of at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 200%, at least 300%, at least 400%, or at least 500%.
  • a method of restoring the muscle regenerative capacity of an aged subject may include the step of providing an antibody or CDH15 antigen-binding fragment thereof, as described above, to a subject requiring said treatment.
  • “restore” refers the ability to revert to a prior functional state.
  • the muscle regenerative capacity of an aged subject may be considered “restored” if it can be reverted to a muscle regenerative capacity at or near that of a control subject e.g, the same subject at a younger age and/or a separate subject that is representative of the aged subject at a younger age.
  • the functional state may be considered “restored” if it is comparable to (e.g., not statistically different from) the prior functional state or the functional state of a subject or subjects that is representative of the prior functional state.
  • the functional state may also be considered “restored” if it is no more than 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 45%, 50%, 60%, 70%, 80%, or 90% different from the prior functional state or the functional state of a subject or subjects that is representative of the prior functional state.
  • anti-hCDH15 antibodies as described herein have various utilities.
  • anti-hCDH15 antibodies as described herein may be used in diagnostic assays for CDH15, e.g., detecting its expression in specific cells, tissues, etc., e.g., as a reagent to identify /label skeletal muscle fibers and/or muscle stem cells.
  • diagnostic assays for CDH15 e.g., detecting its expression in specific cells, tissues, etc.
  • diagnostic and prognostic assay techniques known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either heterogeneous or homogeneous phases (Zola (1987) Monoclonal Antibodies: A Manual of Techniques, CRC Press, Inc. pp. 147-1581).
  • the antibodies used in the assays can be labeled with a detectable moiety.
  • the detectable moiety should be capable of producing, either directly or indirectly, a detectable signal. Any method known in the art for conjugating the antibody to the detectable moiety may be employed. Methods of Use and Making Viral Particles
  • a further embodiment of the modified viral capsids described herein is the use of the modified viral capsids for delivering a nucleotide of interest, e.g., a reporter gene or a therapeutic gene, to a target cell (e.g., a muscle stem cell, myoblast, myocyte, any combination thereof, etc.).
  • a nucleotide of interest e.g., a reporter gene or a therapeutic gene
  • a target cell e.g., a muscle stem cell, myoblast, myocyte, any combination thereof, etc.
  • packaging of a nucleotide of interest comprises replacing an AAV genome between AAV ITR sequences with a gene of interest to create a transfer plasmid, which is then encapsulated in an AAV capsid according to well-known methods
  • a modified viral capsid as described herein may encapsulate a transfer plasmid and/or a nucleotide of interest, which may generally comprise 5' and 3' inverted terminal repeat (ITR) sequences flanking a gene of interest, e.g., reporter gene(s) or therapeutic gene(s), or a portion of the gene of interest (which may be under the control of a viral or non-viral promoter).
  • ITR inverted terminal repeat
  • a transfer plasmid and/or nucleotide of interest comprises from 5’ to 3’: a 5’ ITR, a promoter, a gene (e.g., a reporter and/or therapeutic gene) and a 3TTR.
  • a consideration for AAV transfer plasmid design is that a wildtype AAV genome is ⁇ 4.7kb.
  • strategies that provide for packaging nucleotides of interest that exceed the packaging capacity of an individual AAV.
  • Such strategies include, but are not limited to, dual-vector strategies that exploit ITR-mediated recombination to express genes of interest that are larger than a wildtype AAV genome by way of transcript splicing across intermolecularly recombined ITRs from two complementary vector genomes, vector recombination by homology, RNA trans-splicing, and/or protein “transsplicing” via split intein designs. See, e.g., Nakai, H. et al.
  • a trans-splicing approach takes advantage of the ability of AAV ITR sequences to concatemerized to reconstitute full-length genomes, wherein each of two or more viral capsids, respectively, encapsulate one of two or more transfer plasmids, each of which transfer plasmid comprises a portion of the gene of interest.
  • the two transfer plasmids may be designed as follows: the 5’-transfer plasmid comprises the promoter, the 5’ portion of the coding sequence of the gene of interest, and a splicing donor (SD) signal; the 3 ’-transfer plasmid comprises a splicing acceptor (SA) signal, the 3’ portion of the gene of interest, and the polyA signal.
  • SD splicing donor
  • SA splicing acceptor
  • a large gene of interest is also split when taking an overlapping region approach.
  • the 5’ and 3’ portions (and thus the 5’ transfer plasmid and 3’ transfer plasmid) share a recombinogenic sequence, e.g, region of homology, e.g., each portion comprises an overlapping sequence.
  • the gene of interest is made whole in a targeted cell via homologous recombination mediated by the recombinogenic sequence, e.g., homology/overlapping region.
  • the 5 ’-transfer plasmid and 3 ’-transfer plasmid each comprise a highly recombinogenic sequence, wherein the recombinogenic sequence is placed downstream of an SD signal of a 5’ portion of the coding sequence of the gene of interest and upstream of an SA signal of a 3’ portion of the coding sequence of the gene of interest.
  • the gene of interest may be made whole either via ITR-mediated concatemerization and splicing and/or by homologous recombination.
  • Trans-splicing at the RNA or protein levels may also be utilized.
  • two transfer plasmids may respectively encode for 5’ and 3’ fragments of the pre-mRNA of a large gene and share an intronic hybridization domain that can favor trans-splicing, leading to joining of the two half-transcripts into an intact full-length mRNA.
  • split-inteins Protein trans-splicing occurs post-translationally and is catalyzed by intervening proteins called split-inteins.
  • Split-inteins are expressed as two independent polypeptides (N- intein and C-intein) at the extremities of two host proteins.
  • the N-intein and C-intein polypeptides remain catalytically inactive until they encounter each other.
  • each intein precisely excises itself from the host protein while mediating ligation of the N- and C- host polypeptides via a peptide bond.
  • Split-intein use has been used in AAV- based delivery of therapeutic genes of interest in muscle, liver, and retinal diseases.
  • a modified viral capsid described herein encapsulates a nucleotide of interest, wherein the nucleotide of interest comprises a portion of a gene of interest.
  • a nucleotide of interest comprising a portion of a gene of interest further comprises a splicing donor signal or a splicing acceptor signal and/or a recombinogenic sequence.
  • a nucleotide of interest comprising a portion of a gene of interest comprises an intronic hybridization domain encoding sequence. In some embodiments, a nucleotide of interest comprising a portion of a gene of interest comprises a N-intein or C-intein encoding sequence.
  • Design of the transfer plasmid/nucleotide of interest includes including one or more regulatory elements, e.g., promoter and/or enhancer elements, that will control expression of the gene of interest.
  • useful promoters include, e.g., cytomegalovirus (CMV)-promoter, the spleen focus forming virus (SFFV)-promoter, the elongation factor 1 alpha (EFla)-promoter (the 1.2 kb EFla-promoter or the 0.2 kb EFla- promoter), the chimeric EF 1 a/IF4-promoter, and the phospho-glycerate kinase (PGK)- promoter.
  • CMV cytomegalovirus
  • SFFV spleen focus forming virus
  • EFla elongation factor 1 alpha
  • PGK phospho-glycerate kinase
  • An internal enhancer may also be present in the viral construct to increase expression of the gene of interest.
  • the CMV enhancer Karasuyama et al. 1989. J. Exp. Med. 169: 13, which is incorporated herein by reference in its entirety
  • the CMV enhancer can be used in combination with the chicken [3-actin promoter.
  • tissue specific regulatory elements e.g., a muscle specific promoter and/or regulatory element may be used to drive the expression of the gene of interest.
  • a transfer plasmid and/or nucleotide of interest herein comprises an enhancer and/or promoter of muscle creatine kinase (MCK), wherein the enhancer and/or promoter of MCK drives expression of the gene of interest.
  • MCK muscle creatine kinase
  • a transfer plasmid and/or nucleotide of interest herein comprises an enhancer and/or promoter element that recruits RNA Polymerase II, wherein the enhancer and/or promoter of MCK drives expression of the gene of interest.
  • a transfer plasmid and/or nucleotide of interest herein comprises an enhancer and/or promoter element that recruits RNA Polymerase III, wherein the enhancer and/or promoter of MCK drives expression of the gene of interest.
  • bidirectional promoter vectors have also been employed for delivery of dual therapeutic gene cassettes.
  • An example of this is the bidirectional chicken 0- actin ubiquitous promoter that drives the simultaneous expression of the hexosaminidase a- and 0-subunits of the HexA enzyme, the two respective genes involved in Tay-Sachs and Sandhoff diseases.
  • a transfer plasmid and/or nucleotide of interest herein comprises a bidirectional promoter, wherein the bidirectional promoter drives the expression of two different genes of interest.
  • reporter genes can be encapsidated in a multimeric structure comprising the modified viral capsid proteins described herein.
  • exemplary reporter genes include, for example, 0-galactosidase (encoded lacZ gene), Green Fluorescent Protein (GFP), enhanced Green Fluorescent Protein (eGFP), MmGFP, blue fluorescent protein (BFP), enhanced blue fluorescent protein (eBFP), mPlum, mCherry, tdTomato, mStrawberry, J- Red, DsRed, mOrange, mKO, mCitrine, Venus, YPet, yellow fluorescent protein (YFP), enhanced yellow fluorescent protein (eYFP), Emerald, CyPet, cyan fluorescent protein (CFP), Cerulean, T-Sapphire, luciferase, alkaline phosphatase, or a combination thereof.
  • GFP Green Fluorescent Protein
  • eGFP enhanced Green Fluorescent Protein
  • MmGFP blue fluorescent protein
  • BFP enhanced
  • a variety of therapeutic genes can also be encapsidated in a multimeric structure comprising the modified viral capsid proteins described herein, e.g, as part of a transfer particle.
  • Non-limiting examples of a therapeutic gene include those that encode a toxin (e.g., a suicide gene), a therapeutic antibody or fragment thereof, a CRISPR/Cas system or portion(s) thereof, antisense RNA, siRNA, shRNA, etc.
  • a further embodiment of the present invention is a process for the preparation of a modified capsid protein, the method comprising the steps of: a) expressing a nucleic acid encoding the modified capsid protein under suitable conditions, and b) isolating the expressed capsid protein of step a).
  • a viral particle as described herein comprises a mosaic capsid, e.g., a capsid comprising capsid proteins genetically modified as described herein (in the absence or presence of a covalent bond with a targeting ligand) in a certain ratio with reference capsid proteins.
  • a method for making such a mosaic viral particle comprises: a) expressing a nucleic acid encoding the modified capsid protein and a nucleotide encoding a reference capsid protein at a ratio (wt/wt) of at least about 60: 1 to about 1 :60, e.g, 2: 1, 1 : 1, 3:5 ,1 :2, 1:3, 1 :8, etc. under suitable conditions, and b) isolating the expressed capsid protein of step a).
  • a composition described herein comprises, or a method described herein combines, a modified cap gene: reference cap gene (or combination of reference cap genes) at a ratio that ranges from at least about 1 :60 to about 60: 1, e.g., 2: 1, 1 :1, 3:5, 1 :2, 1 :3, 1 :8, etc.
  • the ratio is at least about 1 :2.
  • the ratio is at least about 1 :3.
  • the ratio is at least about 1 :4.
  • the ratio is at least about 1 :5.
  • the ratio is at least about 1 :6.
  • the ratio is at least about 1 :7.
  • the ratio is at least about 1 :8. In some embodiments, the ratio is at least about 1:9. In some embodiments, the ratio is at least about 1 : 10. In some embodiments, the ratio is at least about 1 : 11. In some embodiments, the ratio is at least about 1 : 12. In some embodiments, the ratio is at least about 1: 13. In some embodiments, the ratio is at least about 1 :14. In some embodiments, the ratio is at least about 1: 15. In some embodiments, the ratio is at least about 1 : 16. In some embodiments, the ratio is at least about 1 :17. In some embodiments, the ratio is at least about 1 : 18. In some embodiments, the ratio is at least about 1 : 19.
  • the ratio is at least about 1:20. In some embodiments, the ratio is at least about 1 :25. In some embodiments, the ratio is at least about 1:30. In some embodiments, the ratio is at least about 1 :35. In some embodiments, the ratio is at least about 1 :40. In some embodiments, the ratio is at least about 1 :45. In some embodiments, the ratio is at least about 1 :50. In some embodiments, the ratio is at least about 1:55. In some embodiments, the ratio is at least about 1 :60. In some embodiments, the ratio is at least about 2: 1. In some embodiments, the ratio is at least about 3 : 1. In some embodiments, the ratio is at least about 4:1.
  • the ratio is at least about 5: 1. In some embodiments, the ratio is at least about 6:1. In some embodiments, the ratio is at least about 7:1. In some embodiments, the ratio is at least about 8:1. In some embodiments, the ratio is at least about 9: 1. In some embodiments, the ratio is at least about 10: 1. In some embodiments, the ratio is at least about 11 :1. i some embodiments, the ratio is at least about 12: 1. In some embodiments, the ratio is at least about 13 : 1. In some embodiments, the ratio is at least about 14:1. In some embodiments, the ratio is at least about 15: 1. In some embodiments, the ratio is at least about 16: 1. In some embodiments, the ratio is at least about 17:1.
  • the ratio is at least about 18: 1. In some embodiments, the ratio is at least about 19: 1. In some embodiments, the ratio is at least about 20: 1. In some embodiments, the ratio is at least about 25:1. In some embodiments, the ratio is at least about 30: 1. In some embodiments, the ratio is at least about 35: 1. In some embodiments, the ratio is at least about 40:1. In some embodiments, the ratio is at least about 45 : 1. In some embodiments, the ratio is at least about 50: 1. In some embodiments, the ratio is at least about 55: 1. In some embodiments, the ratio is at least about 60:1.
  • VP protein subunit ratios in the mosaic viral particle may, but do not necessarily, stoichiometrically reflect the ratios of modified cap gene reference cap gene.
  • a mosaic capsid formed according to the method may be considered to, but does not necessarily, have a modified capsid proteimreference capsid protein ratio similar to the ratio (wt:wt) of nucleic acids encoding same used to produce the mosaic capsid.
  • a mosaic capsid comprises a protein subunit ratio of about 1 :59 to about 59:1.
  • a further embodiment of the present invention is a method for altering the tropism of a virus, the method comprising the steps of: (a) inserting a nucleic acid encoding an amino acid sequence into a nucleic acid sequence encoding an viral capsid protein to form a nucleotide sequence encoding a genetically modified capsid protein comprising the amino acid sequence and/or (b) culturing a packaging cell in conditions sufficient for the production of viral particles, wherein the packaging cell comprises the nucleic acid.
  • a further embodiment of the present invention is a method for displaying a targeting ligand on the surface of a capsid protein, the method comprising the steps of: (a) expressing a nucleic acid encoding a modified viral capsid protein as described herein (and optionally with a nucleotide encoding a reference capsid protein) under suitable conditions, wherein the nucleic acid encodes a capsid protein comprising a first member of a specific binding pair, (b) isolating the expressed capsid protein comprising a first member of a specific binding pair of step (a) or capsid comprising same, and (c) incubating the capsid protein or capsid with a second cognate member of the specific binding pair under conditions suitable for allowing the formation of an isopeptide bond between the first and second member, wherein the second cognate member of the specific binding pair is fused with a targeting ligand.
  • the packaging cell further comprises a helper plasmid and/or a transfer plasmid comprising a nucleotide of interest.
  • the methods further comprise isolating self-complementary adeno-associated viral particles from culture supernatant.
  • the methods further comprise lysing the packaging cell and isolating single-stranded adeno-associated viral particles from the cell lysate.
  • the methods further comprise (a) clearing cell debris, (b) treating the supernatant containing viral particles with nucleases, e.g, DNase I and MgCh, (c) concentrating viral particles, (d) purifying the viral particles, and (e) any combination of (a)-(d).
  • nucleases e.g, DNase I and MgCh
  • Packaging cells useful for production of the viral particles described herein include, e.g., animal cells permissive for the virus, or cells modified to be permissive for the virus; or the packaging cell construct, for example, with the use of a transformation agent such as calcium phosphate.
  • Non-limiting examples of packaging cell lines useful for producing viral particles described herein include, e.g., human embryonic kidney 293 (HEK-293) cells (e.g., American Type Culture Collection [ATCC] No.
  • HEK-293 cells that contain the SV40 Large T-antigen HEK-293 T or 293 T
  • HEK293T/17 cells human sarcoma cell line HT- 1080 (CCL-121), lymphoblast-like cell line Raji (CCL-86), glioblastoma-astrocytoma epithelial- like cell line U87-MG (HTB-14), T-lymphoma cell line HuT78 (TIB-161), NIH/3T3 cells, Chinese Hamster Ovary cells (CHO) (e.g, ATCC Nos. CRL9618, CCL61, CRL9096), HeLa cells (e.g, ATCC No.
  • Vero cells NIH 3T3 cells (e.g, ATCC No. CRL-1658), Huh-7 cells, BHK cells (e.g, ATCC No. CCL10), PC12 cells (ATCC No. CRL1721), COS cells, COS- 7 cells (ATCC No. CRL1651), RATI cells, mouse L cells (ATCC No. CCLI.3), HLHepG2 cells, CAP cells, CAP-T cells, and the like.
  • human amniocytic cells e.g, CAP, CAP-T
  • yeast cells including, but not limited to, S. cerevisiae, Pichia pastoris
  • plant cells including, but not limited to, Tobacco NT1 , BY-2
  • insect cells including but not limited to SF9, S2, SF21, Tni (e.g. High 5)
  • bacterial cells including, but not limited to, E. coli
  • packaging techniques and particles for packaging the nucleic acid genome into the pseudotyped viral particle see, for example, Polo, et al, Proc Natl Acad Sci USA, (1999) 96:4598-4603.
  • Methods of packaging include using packaging cells that permanently express the viral components, or by transiently transfecting cells with plasmids.
  • Further embodiments include methods comprising contacting a modified Cap protein as described herein with the targeting vector in conditions sufficient to operably link the modified Cap protein with the targeting vector, e.g., in conditions sufficient to promote association of the targeting vector to the modified Cap protein, e.g., via chemical linkage and/or association of first and second members of a specific binding pair, wherein the first member is inserted into the modified Cap protein the first member and the targeting vector is fused to the second member of the specific binding pair.
  • a wide variety of cells may be targeted in order to deliver a nucleotide of interest using a modified viral particle as disclosed herein.
  • the target cells will generally be chosen based upon the nucleotide of interest and the desired effect.
  • a nucleotide of interest may be delivered to a target cell (e.g., a muscle stem cell, myoblast, myocyte, any combination thereof, etc.) such that the target cell produces a protein that makes up for a deficiency in an organism, such as an enzymatic deficiency, or immune deficiency, such as X-linked severe combined immunodeficiency.
  • a target cell e.g., a muscle stem cell, myoblast, myocyte, any combination thereof, etc.
  • a nucleotide of interest such as a gene encoding an siRNA, may inhibit expression of a particular gene in a target cell (e.g., a muscle stem cell, myoblast, myocyte, any combination thereof, etc.).
  • the nucleotide of interest may, for example, inhibit expression of a gene involved in a pathogen life cycle.
  • a nucleotide of interest may inhibit expression of a gene that is responsible for production of a toxin in a target cell.
  • a nucleotide of interest may encode a toxic protein that kills cells in which it is expressed. In this case, tumor cells or other unwanted cells may be targeted.
  • a nucleotide of interest that encodes a therapeutic protein.
  • a nucleotide of interest encodes a therapeutic protein comprising an antigen binding protein, or an antigen binding portion thereof.
  • a nucleotide of interest encodes a therapeutic protein comprising a human or humanized antibody or antigen binding fragment thereof, a monovalent Fab’, a divalent Fab2, a F(ab)’3 fragment, a single-chain fragment variable (scFv), a bis-scFv, a (scFv)2, a diabody, a minibody, a nanobody, a triabody, a tetrabody, a disulfide stabilized Fv protein (dsFv), a single-domain antibody (sdAb), an Ig NAR, a bispecific antibody or binding fragment thereof, a bi-specific T-cell engager (BiTE), a trispecific antibody, or a chemical
  • the scFv comprises variable regions arranged in the following orientation from N- terminus to C-terminus: HCVR-LCVR. In some embodiments, the scFv comprises variable regions arranged in the following orientation from N-terminus to C-terminus: LCVR-HCVR. In some embodiments, the scFv variable regions are connected by a linker. In some embodiments, the linker is a peptide linker. In some embodiments, the peptide linker is -(GGGGS)n- (SEQ ID NO: 789), wherein n is 1-10.
  • a target is selected that is specifically expressed on that population of target cells.
  • the target may be expressed exclusively on that population of cells or to a greater extent on that population of cells than on other populations of cells.
  • the more specific the expression the more specifically delivery can be directed to the target cells.
  • the desired amount of specificity of the marker may vary. For example, for introduction of a toxic gene, a high specificity is most preferred to avoid killing non-targeted cells. For expression of a protein for harvest, or expression of a secreted product where a global impact is desired, less marker specificity may be needed.
  • the target may be any cell-surface moiety e.g, a protein, for which a targeting ligand can be identified or created.
  • the target is a peptide or polypeptide, such as a receptor.
  • the target may be a carbohydrate or other molecule that can be recognized by a binding partner. If a binding partner, e.g., ligand, for the target is already known, it may be used as the affinity molecule. However, if a binding molecule is not known, antibodies to the target may be generated using standard procedures. The antibodies can then be used as a targeting ligand.
  • target cells may be chosen based on a variety of factors, including, for example, (1) the application (e.g., therapy, expression of a protein to be collected, and conferring disease resistance) and (2) expression of a marker with the desired amount of specificity.
  • Target cells are not limited in any way and include both germline cells and cell lines and somatic cells and cell lines.
  • the target cells are germline cells, the target cells are preferably selected from the group consisting of single-cell embryos and embryonic stem cells (ES).
  • the target cell is a cell that expresses a non-terminally differentiated muscle cell surface protein. In some embodiments, the target cell is a cell that expresses a mammalian non-terminally differentiated muscle cell surface protein. In some embodiments, the target cell is a cell that expresses a human non-terminally differentiated muscle cell surface protein. In some embodiments, the target cell is a cell that expresses CDH15, e.g., mammalian CDH15, e.g., human CDH15.
  • CDH15 e.g., mammalian CDH15, e.g., human CDH15.
  • the target cell is a muscle cell. In some embodiments, the target cell is a mammalian muscle cell. In some embodiments, the target cell is a mammalian muscle cell. In some embodiments, the target cell is a mammalian muscle cell that is not terminally differentiated. In some embodiments, the target cell is a mammalian muscle cell that is terminally differentiated. In some embodiments, the target cell is a muscle stem cell (also known as a satellite cell), a myoblast, a myocyte, or a non-differentiated myofiber. In some embodiments, the target cell is a mammalian rhabdomyosarcoma cell.
  • a skeletal muscle related disorder e.g., a muscle wasting disease and/or a genetic muscle disease, e.g., X-linked myotubular myopathy (XLMTM), Duchenne muscular dystrophy (DMD), myotonic dystrophy (DM1), Facioscapulohumeral muscular dystrophy Type 1 (FSHD), congenital muscular dystrophy type 1A (MDC1A), Limb girdle muscular dystrophy, dystroglycanopathy, muscle atrophy conditions, metabolic diseases, etc.
  • XLMTM X-linked myotubular myopathy
  • DMD Duchenne muscular dystrophy
  • DM1 myotonic dystrophy
  • FSHD Facioscapulohumeral muscular dystrophy Type 1
  • MDC1A congenital muscular dystrophy type 1A
  • such methods comprise administering to a patient suffering from or at risk for such skeletal related disorder a viral particle or pharmaceutical composition as described herein, wherein the viral particle comprises:
  • a second member of the protein: protein binding pair wherein the second member of the proteimprotein binding pair comprises a targeting ligand that binds a non-terminally differentiated muscle cell surface protein that is expressed on the surface of a muscle cell (e.g., CDH15), wherein the first member of the protein: protein binding pair and the second member of the protein: protein binding pair are associated to direct the tropism of the viral capsid to the muscle cell in the patient thereof, and
  • nucleotide of interest encodes a therapeutic protein, a suicide gene, an antibody or a fragment thereof, a CRISPR/Cas system or a portion(s) thereof, an antisense oligonucleotide, a ribozyme, an RNAi molecule, or a shRNA molecule.
  • the nucleotide of interest may encode a growth factor, neurotrophic factor, a disease modifying muscle protein, a metabolic protein, e.g, for muscle atrophy conditions or metabolic diseases.
  • muscle-related cancer e.g., a cancer expressing a non-terminally differentiated muscle cell protein, e.g, CDH15.
  • muscle-specific cancers include rhabdomyosarcomas, e.g., embryonal, alveolar, pleomorphic, botryoid and spindle/ sclerosing rhabdomyosarcomas.
  • such methods comprise administering to a patient suffering from or at risk for such muscle-related cancer a viral particle or pharmaceutical composition as described herein, wherein the viral particle comprises:
  • a viral capsid modified to comprise the targeting ligand inserted directly into the viral capsid or via, e.g., a first member of a protein: protein binding pair and its cognate second member of the protein: protein binding pair, wherein the second member of the protein: protein binding pair comprises a targeting ligand that binds a muscle-specific surface protein that is expressed on the surface of a non-terminally differentiated muscle cell e.g., CDH15), wherein the first member of the protein: protein binding pair and the second member of the protein: protein binding pair are associated to direct the tropism of the viral capsid to the muscle cell in the patient thereof, and
  • the nucleotide of interest comprises or encodes a therapeutic protein, a suicide gene, an antibody or a fragment thereof, a CRISPR/Cas system or a portion(s) thereof, an antisense oligonucleotide, a ribozyme, an RNAi molecule, or a shRNA molecule capable of treating the muscle-related cancer cell e.g., slowing and/or arresting the growth of and/or destroying the muscle-related cancer cell.
  • Example non-limiting embodiments of said nucleotides of interest include a therapeutic protein that targets and inhibits an oncogenic intracellular signaling pathway, a suicide gene that directs the cell to undergo apoptosis, and an RNAi molecule that targets and inhibits an oncogenic transcript.
  • Table 2 Example sequences of non-primate adeno-associated viruses. [00358] Table 2 - continued [00359] Table 2 - continued [00360] Table 2 - continued [00361] Table 2 - continued
  • Muscle stem cells are mitotically quiescent and non-proliferative under steady-state conditions in adult muscle tissue. In response to injury, however, MuSCs begin to actively divide, producing daughter cells. While some daughter cells become quiescent once more to replenish the pool of MuSCs, others continue to proliferate as myoblasts, which align and fuse together during differentiation into mature myotubes/myofibers that make up muscle fibers.
  • Quiescent muscle stem cells can be characterized by Pax7 expression
  • proliferating myoblasts can be characterized by Pax7 and myogenic differentiation factor 1 (MyoD) expression
  • myoblasts committing to terminal differentiation z.e., myocytes
  • myotubes can be characterized by myosin heavy chain (MyHC) expression.
  • MyoD myogenic differentiation factor 1
  • MyHC myosin heavy chain
  • Cadherin 15 (CDH15) mRNA is highly expressed in MuSCs and expression increases following muscular injury.
  • CDH15 homozygous CDH15 knockout mice
  • CDH I 5 ' mice demonstrated accelerated muscle regeneration following injury.
  • CDH15" ' mice exhibited increased myofiber size 5- and 15-days post-injury via injection with cardiotoxin (CTX) into the tibialis anterior muscle, and an increased number of central myonuclei in myofibers 15-days post-injury.
  • CX cardiotoxin
  • CDH15 ' mice demonstrated improved functional recovery following CTX injury, as evidenced by normal tetanic force measurements in ex vivo isolated extensor digitorum longus muscles 15 days following CTX injury (see Figure 3B).
  • WT mice exhibited a tetanic force loss of approximately 40% in ex vivo isolated muscle 15-days post-injury.
  • MuSCs derived from WT or CDH15' ' mice were cultured ex vivo with their associated myofibers for 48 hours. As demonstrated in Figures 4A-4B, a greater percentage of multi-cell clusters and a greater number of Pax7 + cells per cluster was observed for cultured CDH15 /_ MuSCs, as compared to WT MuSCs. This result suggests that abolishing CDH15 expression in MuSCs accelerates the transition from quiescence to activation.
  • RNA-seq was performed on FACS- isolated MuSCs from uninjured, healthy mice. As shown in Figure 5A, 132 genes were downregulated and 270 genes were upregulated in CDH15 ’’ MuSCs as compared to WT MuSCs. Of those upregulated genes, a cluster of genes was identified that contain serum response factor (SRF) binding motifs (see Figure 5B), indicating that accelerated activation of MuSCs in the absence of CDH15 may be due to altered SRF signaling.
  • SRF serum response factor
  • Muscle stem cells (MuSCs) in aging subjects display delayed activation and reduced motility in vitro), which translates to impaired MuSC mediated repair in vivo. Accordingly, it was hypothesized that CDH15 may be involved in reduction of the muscle regenerative capacity for aged subjects. To test this, homozygous CDH15 knockout mice (CDH15 z ) were generated, aged to 23 months, and injected intramuscularly in the tibialis anterior muscle with cardiotoxin to induce muscular damage (day 0).
  • Anti-human CDH15 antibodies are obtained by immunizing a mouse (e.g., an engineered mouse comprising DNA encoding human immunoglobulin heavy and human kappa light chain variable regions, see, e.g., in US Patent No. 7,105,348; US Patent No. 8,642,835; and US 9,622,459, each of which is incorporated herein by reference), with human CDH15.
  • a mouse e.g., an engineered mouse comprising DNA encoding human immunoglobulin heavy and human kappa light chain variable regions
  • splenocytes are harvested from each mouse and either (1) fused with mouse myeloma cells to preserve their viability and form hybridoma cells and screened for human CDH15 specificity, or (2) B-cell sorted (as described in US 2007/0280945A1) using a either a human CDH15 fragment as the sorting reagent that binds and identifies reactive antibodies (antigen-positive B cells).
  • Chimeric antibodies to human CDH15 were initially isolated having a human variable region and a mouse constant region using, e.g., VELOCIMMUNE technology as described in US Patent No. 7,105,348; US Patent No. 8,642,835; and US 9,622,459, each of which is incorporated herein by reference.
  • mouse constant regions were replaced with a desired human constant region, for example wild-type human CH or modified human CH e.g., IgGl, IgG2 or IgG4 isotypes), and light chain constant region (CL), to generate a fully human anti-hCDH15 antibody, or antigen binding portion thereof.
  • a desired human constant region for example wild-type human CH or modified human CH e.g., IgGl, IgG2 or IgG4 isotypes
  • CL light chain constant region
  • Table 1 sets forth sequence identifiers of a nucleic acid (NA) sequence encoding, and in parentheses an amino acid (AA) sequence of, a heavy or light chain variable region
  • HCVR HCVR or LCVR, respectively
  • HCDR and LCDR heavy or light chain CDR

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des anticorps anti-cadhérine (15), ainsi que des parties et des conjugués médicamenteux de ceux-ci. L'invention concerne également des séquences d'acides nucléiques codant pour ceux-ci, des particules virales les contenant, p. ex., pour recibler les particules virales vers les cellules musculaires, des compositions les contenant et des méthodes d'utilisation de celles-ci, p. ex.. pour traiter un sujet ayant besoin d'un tel traitement, p. ex., un sujet ayant un trouble musculaire squelettique (p. ex., la myopathie myotubulaire liée à X (XLMTM), la dystrophie musculaire de Duchenne (DMD), la dystrophie myotonique (DM1), la dystrophie musculaire facio-scapulo-humérale de type 1 (FSHD), la dystrophie musculaire congénitale de type 1A (MDC1A), la dystrophie musculaire des ceintures, la dystroglycanopathie, etc.) ou un rhabdomyosarcome.
EP24728805.3A 2023-05-02 2024-05-01 Anticorps anti-m-cadhérine humaine (cdh15), conjugués et leurs utilisations pour l'administration de charges utiles génétiques à des cellules musculaires Pending EP4705343A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363499527P 2023-05-02 2023-05-02
US202363499531P 2023-05-02 2023-05-02
PCT/US2024/027232 WO2024229105A1 (fr) 2023-05-02 2024-05-01 Anticorps anti-m-cadhérine humaine (cdh15), conjugués et leurs utilisations pour l'administration de charges utiles génétiques à des cellules musculaires

Publications (1)

Publication Number Publication Date
EP4705343A1 true EP4705343A1 (fr) 2026-03-11

Family

ID=91274889

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24728805.3A Pending EP4705343A1 (fr) 2023-05-02 2024-05-01 Anticorps anti-m-cadhérine humaine (cdh15), conjugués et leurs utilisations pour l'administration de charges utiles génétiques à des cellules musculaires

Country Status (6)

Country Link
EP (1) EP4705343A1 (fr)
KR (1) KR20260007578A (fr)
CN (1) CN121039163A (fr)
AU (1) AU2024265507A1 (fr)
MX (1) MX2025013007A (fr)
WO (1) WO2024229105A1 (fr)

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
JPH11510050A (ja) 1995-07-25 1999-09-07 イントロヘーネ ベスローテン フェンノートシャップ 標的遺伝子送達のための方法および手段
CA2265460A1 (fr) 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Vecteur de vaa4 et ses utilisations
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
EP1082413B1 (fr) 1998-05-28 2008-07-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Vecteurs d'aav5 et leurs utilisation
CA2349838C (fr) 1998-11-05 2011-06-07 The Trustees Of The University Of Pennsylvania Sequences d'acide nucleique du serotype i du virus associe aux adenovirus, vecteurs et cellules hotes contenant ces derniers
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
EP1718667B1 (fr) 2004-02-23 2013-01-09 Genentech, Inc. Liants et conjugues heterocycliques auto-immolateurs
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
WO2008122039A2 (fr) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molécules d'anticorps hybrides médiées par la sélénocystéine
JP2010528285A (ja) 2007-05-23 2010-08-19 ベンタナ・メデイカル・システムズ・インコーポレーテツド 免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
EP2276506A4 (fr) 2008-04-30 2014-05-07 Immunogen Inc Conjugués puissants et coupleurs hydrophiles
US8236557B2 (en) 2008-05-28 2012-08-07 University Of Missouri-Columbia Hybrid-AAV vectors to deliver large gene expression cassette
EP2374481B1 (fr) 2008-07-21 2015-11-04 Polytherics Limited Nouveaux réactifs et procédé pour conjuguer des molécules biologiques
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
JP5954789B2 (ja) 2009-08-10 2016-07-20 ユーシーエル ビジネス パブリック リミテッド カンパニー 機能的分子の可逆的共有結合
US8754287B2 (en) 2009-12-10 2014-06-17 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
SI2501817T2 (sl) 2010-02-08 2021-09-30 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
DK2528625T3 (da) 2010-04-15 2013-10-14 Spirogen Sarl Pyrrolobenzodiazepiner og konjugater deraf
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
RU2722373C2 (ru) 2011-02-25 2020-05-29 Редженерон Фармасьютикалс, Инк. Мыши adam6
KR20140037105A (ko) 2011-05-27 2014-03-26 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2013055993A1 (fr) 2011-10-14 2013-04-18 Seattle Genetics, Inc. Pyrrolobenzodiazépines et conjugués ciblés
CA2850096C (fr) 2011-10-14 2018-07-03 Spirogen Sarl Procede de synthese et intermediaires pouvant servir a preparer des pyrrolobenzodiazepines
CA2850103C (fr) 2011-10-14 2019-09-10 Spirogen Sarl Pyrrolobenzodiazepines
ES2945932T3 (es) 2011-10-14 2023-07-10 Seagen Inc Pirrolobenzodiazepinas y conjugados dirigidos
WO2013068874A1 (fr) 2011-11-11 2013-05-16 Pfizer Inc. Conjugués anticorps-médicament
CN104244718A (zh) 2011-12-05 2014-12-24 伊格尼卡生物治疗公司 抗体-药物缀合物以及相关化合物、组合物和方法
RU2664181C2 (ru) 2011-12-20 2018-08-15 Регенерон Фармасьютикалз, Инк. Мыши с гуманизированной легкой цепью
FI2911699T4 (fi) 2012-10-23 2025-12-09 Synaffix Bv Muokattu vasta-aine, vasta-ainekonjugaatti ja menetelmä niiden valmistamiseksi
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
GB201312010D0 (en) * 2013-07-04 2013-08-21 Univ Birmingham Receptor Agonists
KR102276752B1 (ko) 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
WO2015191508A1 (fr) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Capsides chimériques
PL3645553T3 (pl) 2017-06-27 2023-07-17 Regeneron Pharmaceuticals, Inc. Zrekombinowane cząstki wirusowe o zmodyfikowanym tropizmie i ich zastosowania do celowanego wprowadzania materiału genetycznego do komórek ludzkich
MX2020000244A (es) 2017-06-27 2020-09-28 Regeneron Pharma Vectores virales recombinantes con tropismo modificado y usos de estos para la introduccion dirigida de material genetico a celulas humanas.
US11851671B2 (en) 2017-10-23 2023-12-26 Regents Of The University Of Minnesota Programmable assembly of virus composites for receptor-targeted gene delivery
US20220028234A1 (en) 2020-02-27 2022-01-27 Mirza Faizan Active security system and a method to detect and neutralize armed intruders

Also Published As

Publication number Publication date
AU2024265507A1 (en) 2025-10-30
CN121039163A (zh) 2025-11-28
MX2025013007A (es) 2025-12-01
KR20260007578A (ko) 2026-01-14
WO2024229105A1 (fr) 2024-11-07

Similar Documents

Publication Publication Date Title
JP7410522B2 (ja) 抗ｆａｍ１９ａ５抗体のアデノ関連ウイルス（ａａｖ）伝達
CN117051045A (zh) 向性修饰的重组病毒载体及其用于将遗传材料靶向引入人细胞内的用途
JP2017524339A (ja) 中東呼吸器症候群−コロナウイルススパイクタンパク質に対するヒト抗体
US20250304918A1 (en) Viral particles retargeted to skeletal muscle
AU2023395983A1 (en) Antigen-binding molecules that bind to aav particles and uses
JP2026505440A (ja) 抗ヒトｃａｃｎｇ１抗体を用いた筋肉関連障害の治療
WO2024229105A1 (fr) Anticorps anti-m-cadhérine humaine (cdh15), conjugués et leurs utilisations pour l'administration de charges utiles génétiques à des cellules musculaires
WO2026039325A2 (fr) Gènes mtm1 modifiés et utilisations associées
US20250277048A1 (en) The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
US20250242018A1 (en) Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025255452A2 (fr) Molécules de liaison à l'antigène qui se lient à des particules d'aav et leurs utilisations
WO2026025058A1 (fr) Particules virales d'aav reciblées sur des cellules cancéreuses exprimant le r-egf
EA047634B1 (ru) Доставка антител к fam19a5 с помощью аденоассоциированного вируса (aav)

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR